P2X3 modulators
By providing P2X3 modulator compounds with specific structures, the problem of lack of effective treatment of P2X3 receptor-related diseases in the prior art is solved, and effective treatment of pain, urinary tract conditions, cough, pruritus and endometriosis is achieved. .
Patent Information
- Application Number
- CN202411099037.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2020-02-14
- Filing Date
- 2021-02-12
- Publication Date
- 2024-11-29
AI Technical Summary
The prior art lacks effective P2X3 receptor modulators for the treatment of various conditions associated with P2X3 receptors, such as pain, urinary tract conditions, cough, pruritus, and endometriosis.
A P2X3 modulator compound is provided, including compounds having a specific structure and a pharmaceutically acceptable salt or solvate, for modulating P2X3 receptors in mammals as medicines for the treatment of pain, urinary tract conditions, cough , pruritus and endometriosis. These compounds are administered intravenously, subcutaneously, orally, inhaled, topically or ocularly, in the form of tablets, pills, capsules, liquids, etc.
Effectively regulates the P2X3 receptor, providing a drug solution for the treatment of pain, urinary tract conditions, cough, pruritus and endometriosis, improving related symptoms and pathological status.
Smart Images

Figure BDA0004988855260000021 
Figure BDA0004988855260000031 
Figure BDA0004988855260000041
Abstract
Description
[0001] This application is a divisional application of Chinese invention patent application (application date: February 12, 2021; application number: 202180028882.0 (international application number: PCT / IB2021 / 000091); invention title: P2X3 regulator).
[0002] Cross-references
[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 977,008, filed on February 14, 2020, the entire contents of which are incorporated herein by reference. Background Technology
[0004] P2X purine receptors are a family of ion channels activated by extracellular adenosine triphosphate (ATP). Purine receptors are involved in a variety of biological functions. The P2X3 receptor subunit is a member of this family. It was originally cloned from the rat dorsal root ganglion. Chen et al., Nature, vol. 377, pp. 428-431 (1995). The nucleotide and amino acid sequences of rat and human P2X3 are now known. Lewis et al., Nature, vol. 377, pp. 432-435 (1995); and Garcia-Guzman et al., Brain Res. Mol. Brain Res., vol. 47, pp. 59-66 (1997).
[0005] In light of the foregoing, new P2X3 receptor modulators are needed to treat various conditions related to the P2X3 receptor. Summary of the Invention
[0006] This disclosure provides, for example, compounds and compositions as P2X3 modulators, their use as pharmaceutical agents, methods for their preparation, and pharmaceutical compositions comprising the disclosed compounds as at least one active ingredient. This disclosure also provides the use of the disclosed compounds as pharmaceuticals and / or in the preparation of pharmaceuticals for P2X3 regulation in warm-blooded animals such as humans. In some embodiments, the P2X3 modulator is a P2X3 antagonist.
[0007] On the one hand, P2X3 modulator compounds of formula (I) or pharmaceutically acceptable salts or solvates thereof are provided:
[0008]
[0009] in:
[0010] X is C(R) 2 ) or N;
[0011] Y is C(R) 2 ) or N;
[0012] Z represents a bond, CH2, or O;
[0013] R 1 Selected from hydrogen, deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0014] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0015] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0016] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9-S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0017] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0018] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0019] R 8 Each is independently selected from C1-C6 alkyl groups;
[0020] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0021] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0022] R 14 It is a C1-C6 alkyl group;
[0023] R 15 It is a C1-C6 alkyl group;
[0024] n is 0, 1, 2, or 3;
[0025] p is 1, 2, or 3; and
[0026] q can be 0, 1, 2, 3 or 4.
[0027] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 The halogen is provided. In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R... 3 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.
[0028] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia):
[0029]
[0030] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia'):
[0031]
[0032] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia):
[0033]
[0034] On the other hand, a P2X3 modifier compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is provided.
[0035]
[0036] in:
[0037] X is C(R) 2 ) or N;
[0038] Y is C(R) 2 ) or N;
[0039] Z represents a bond, CH2, or O;
[0040] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0041] R 3 Selected from deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -N(R7)2, -CN, -C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0042] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0043] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0044] R 6 Selected from -C(=O)OR 11 -C(=O)R11 and -C(=O)N(R) 12 (R) 13 );
[0045] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0046] R 8 Each is independently selected from C1-C6 alkyl groups;
[0047] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0048] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0049] R 14 It is a C1-C6 alkyl group;
[0050] R 15 It is a C1-C6 alkyl group;
[0051] n is 0, 1, 2, or 3;
[0052] p is 1, 2, or 3; and
[0053] q can be 0, 1, 2, 3 or 4.
[0054] In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa):
[0055]
[0056] In some embodiments, a compound of formula (IIa) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa'):
[0057]
[0058] In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa):
[0059]
[0060] On the other hand, a P2X3 modifier compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided.
[0061]
[0062] in:
[0063] X is C(R) 2 ) or N;
[0064] Y is C(R) 2 ) or N;
[0065] Z is CH2 or O;
[0066] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0067] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R4 They combine to form bridged heterocyclic alkyl rings;
[0068] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0069] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0070] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0071] R 8 Each is independently selected from C1-C6 alkyl groups;
[0072] R 9 and R 10 Independently selected from C1-C6 alkyl groups; or R 9 and R 10 They combine to form a 5- or 6-membered heterocyclic alkyl ring, which may be optionally substituted with 1, 2, 3 or 4 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy and C1-C6 alkoxy groups;
[0073] R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0074] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0075] R 14 It is a C1-C6 alkyl group;
[0076] R 15 It is a C1-C6 alkyl group;
[0077] n is 0, 1, 2, or 3;
[0078] p is 1, 2, or 3; and
[0079] q can be 0, 1, 2, 3 or 4.
[0080] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa):
[0081]
[0082] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa'):
[0083]
[0084] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa):
[0085]
[0086] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(O)N(R) 9 (R) 10 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 9 and R 10 Independently selected from C1-C6 alkyl groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 9 and R 10 The combination forms a 5- or 6-membered heterocyclic alkyl ring, which is optionally substituted with 1, 2, 3, or 4 groups selected from halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, hydroxyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3It is a C1-C6 alkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa"), (III), (IIIa), (IIIa') or (IIIa"), or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.
[0087] On the other hand, a P2X3 modulator compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided.
[0088]
[0089] in:
[0090] X is C(R) 2 ) or N;
[0091] Y is C(R) 2 ) or N;
[0092] Z is CH2 or O;
[0093] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0094] R 3 Selected from halogens, -CN, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R)7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0095] R 4 Each is independently selected from deuterium, -CN, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 Combined to form bridged heterocyclic alkyl rings; R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0096] R 6 Selected from -C(=O)R 11 ;
[0097] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0098] R 8 Each is independently selected from C1-C6 alkyl groups;
[0099] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0100] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0101] R 14 It is a C1-C6 alkyl group;
[0102] R15 It is a C1-C6 alkyl group;
[0103] n is 0, 1, 2, or 3;
[0104] p is 1, 2, or 3; and
[0105] q can be 0, 1, 2, 3 or 4.
[0106] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa):
[0107]
[0108] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa'):
[0109]
[0110]
[0111] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa):
[0112]
[0113] On the other hand, a P2X3 modifier compound having the chemical formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided.
[0114]
[0115] in:
[0116] X is C(R) 2 ) or N;
[0117] Y is C(R) 2 ) or N;
[0118] Z is CH2 or O;
[0119] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0120] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0121] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 ,
[0122] -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0123] R 6 Selected from -C(=O)OR 11 -C(=O)R11 and -C(=O)N(R) 12 (R) 13 );
[0124] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0125] R 8 Each is independently selected from C1-C6 alkyl groups;
[0126] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0127] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0128] R 14 It is a C1-C6 alkyl group;
[0129] R 15 It is a C1-C6 alkyl group;
[0130] n is 0, 1, 2, or 3;
[0131] p is 2 or 3; and
[0132] q can be 0, 1, 2, 3 or 4.
[0133] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va):
[0134]
[0135] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va'):
[0136]
[0137] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va):
[0138]
[0139] In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), or (IVa") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein Z is 0 and p is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is 0 and p is 2. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa) is provided. A compound of formula (IIIa'), (IIIa"), (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof, wherein Z is CH2 and p is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2 and p is 2. In some embodiments, a compound of formula (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 1It is a C1-C6 alkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is halogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein X is C(R) 2 And Y is N. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N and Y is C(R) 2 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein X is C(R) 2 And Y is C(R) 2 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 2Each is hydrogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, wherein n is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, wherein n is 2. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, wherein n is 0. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, wherein q is 0. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 5 -C(O)N(R) 9 (R) 10 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 10The form is hydrogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 5 -C(O)OR 9 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 9 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 9 The form is hydrogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 6 Selected from -C(O)OR 11 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 6 -C(O)R 11 In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") is provided, or a pharmaceutically acceptable salt or solvation thereof, wherein R 11It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 11 It is -CH3.
[0140] In another aspect, a pharmaceutical composition is provided comprising a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents, and excipients. In some embodiments, the pharmaceutical composition is formulated for administration to mammals via intravenous, subcutaneous, oral, inhalation, nasal, topical, or ocular administration. In some embodiments, the pharmaceutical composition is in the form of tablets, pills, capsules, liquids, suspensions, gels, dispersions, solutions, emulsions, ointments, or lotions.
[0141] On the other hand, a method is provided for treating a condition associated with P2X3 activity in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof.
[0142] On the other hand, a method for treating pain in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof.
[0143] On the other hand, a method is provided for treating a urinary tract condition in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the urinary tract condition includes neurogenic overactive bladder, non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostatodynia, and benign prostatic hyperplasia.
[0144] On the other hand, a method is provided for reducing or preventing uncontrolled urinary loss in mammals in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, uncontrolled urinary loss is associated with urge incontinence, cough incontinence, stress incontinence, overflow incontinence, functional incontinence, neurogenic incontinence, postprostatectomy incontinence, urinary urgency, nocturia, and enuresis.
[0145] On the other hand, a method for treating cough in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the cough is an acute cough or a chronic cough. In some embodiments, the cough is associated with a disease, symptom, or condition selected from: chronic obstructive pulmonary disease, asthma, tuberculosis, bronchitis, bronchiectasis, purulent lung disease, respiratory malignancies, allergic reactions, cystic fibrosis, pulmonary fibrosis, respiratory inflammation, emphysema, pneumonia, lung cancer, or lung tumor formation. (neoplasia), sore throat, common cold, influenza, respiratory infection, bronchoconstriction, sarcoidosis, viral or bacterial infection of the upper respiratory tract, angiotensin-converting enzyme (ACE) inhibitor therapy, smoker's cough, chronic nonproductive cough, tumor cough, cough due to gastroesophageal reflux and inhalation of irritants, smoke, haze, dust or air pollutants.
[0146] On the other hand, a method for treating pruritus in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the pruritus is associated with inflammatory skin diseases, infectious skin diseases, autoimmune skin diseases, or pregnancy-related skin diseases. In some embodiments, the pruritus is associated with inflammatory skin diseases selected from: atopic dermatitis, allergic, irritant contact dermatitis, xerotic dermatitis, nummular and dyshidrotic dermatitis, lichen planus, lichen sclerosus et al. Pruritus, polymorphic light psoriasis, Grover's disease, mucinous deposition syndrome, mastocytosis, and urticaria. In some embodiments, pruritus is associated with infectious skin diseases selected from: fungal infections, bacterial and viral infections, scabies, lice, insect bites, and folliculitis. In some embodiments, pruritus is associated with autoimmune skin diseases selected from: Duhring's disease, bullous pemphigoid; hereditary skin diseases, Darier's disease, and Hailey-Hailey's disease. In some embodiments, pruritus is associated with pregnancy-related skin diseases selected from: exanthema polymorpha gestationis (PEP), atopic dermatitis gestationis, and urticaria. Herpes zoster, gestational pemphigoid, tumor formation, and cutaneous T-cell lymphoma. In some embodiments, pruritus is associated with nodular prurigo. In some embodiments, pruritus is associated with kidney disease or a treatment procedure for kidney disease. In some embodiments, pruritus is associated with chronic kidney disease. In some embodiments, pruritus is associated with a treatment procedure for kidney disease, wherein the treatment procedure for kidney disease is selected from hemodialysis and peritoneal dialysis. In some embodiments, pruritus is associated with a medical procedure or treatment. In some embodiments, pruritus is associated with drug treatment using drugs selected from opioids, antimalarial drugs, anticancer therapies, and epidermal growth factor receptor inhibitors.
[0147] On the other hand, a method is provided for treating endometriosis, endometriosis-related pain, and endometriosis-related symptoms in mammals in need, comprising administering to the mammals in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically feasible compound thereof. Acceptable salts or solvates. In some embodiments, a method for treating endometriosis in mammals of need is provided, comprising administering to the mammal of need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvate thereof. In some embodiments, a method is provided for treating endometriosis-related pain in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In another aspect, a method is provided for treating endometriosis-related symptoms in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, endometriosis-related symptoms are selected from dysmenorrhea, dyspareunia, dysuria, and dysdefecation.
[0148] In some embodiments of the method described herein, the mammal is a human. In some embodiments of the method described herein, the method further includes administration of a second therapeutic agent. In some embodiments, the second therapeutic agent is an NK-1 antagonist. In some implementations, the NK-1 antagonist is selected from serlopitant, aprepitant, cassopitant, dapitant, ezlopitant, fosaprepitant, lanepitant, maropitant, netupitant, nolpitant, orvepitant, rolapitant, vestipitant, vorflupitant, AV-818, BIIF 1149CL, CP122,721, DNK-333, GSK-424887, L-733060, L-759274, LY-686017, M516102, and TA-5538. In some implementations, the second therapeutic agent is selected from hormonal contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandin E synthase (PTGES) inhibitors, interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors, prostaglandin EP4 receptor antagonists, aldehyde-ketone reductase 1C3 (AKR1C3) inhibitors, and prolactin receptor (PRLR) antagonists.
[0149] Incorporation
[0150] All publications, patents and patent applications mentioned in this specification are incorporated herein by reference to the same extent that each individual publication, patent or patent application is specifically and individually indicated to be incorporated by reference. Detailed Implementation
[0151] As used herein and in the appended claims, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” include plural indicators. Thus, for example, reference to “a reagent” includes multiple such reagents, reference to “the cell” includes reference to one or more cells (or multiple cells) and their equivalents, and so on. When the scope is used herein for physical properties (e.g., molecular weight) or chemical properties (e.g., chemical formula), it is intended to include all combinations and sub-combinations of the scope and specific embodiments thereof. When referring to a number or numerical range, the term “about” means that the number or numerical range mentioned is an approximation within experimental variability (or within statistical experimental error), and therefore the number or numerical range varies between 1% and 15% of that number or numerical range. The term “comprising” (and related terms such as “comprise,” “comprises,” “having,” or “including”) is not intended to exclude embodiments in which, for example, any embodiment of a composition, composition, method, or process described herein is “consistent with” or “substantially composed of” the described features.
[0152] definition
[0153] As used in the specification and appended claims, unless otherwise stated, the following terms have the meanings indicated below.
[0154] As used in this article, C1-C x Including C1-C2, C1-C3…C1-C x C1-C x It refers to the number of carbon atoms that make up its specified part (excluding optional substituents).
[0155] "Amino" refers to the -NH2 group.
[0156] "Cyano" refers to the -CN group.
[0157] "Nitro" refers to the -NO2 group.
[0158] "O-" refers to the -O- group.
[0159] "Oxo" refers to the =O group.
[0160] "Thio" refers to the =S group.
[0161] "Imine" refers to the =NH group.
[0162] "Oxime group" refers to the =N-OH group.
[0163] "Alkyl" or "alkylene" refers to a straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, without any degree of unsaturation, and having 1 to 15 carbon atoms (e.g., C1-C1). 15 Alkyl groups. In some embodiments, the alkyl group comprises 1 to 13 carbon atoms (e.g., C1-C1). 13 Alkyl group. In some embodiments, the alkyl group comprises 1 to 8 carbon atoms (e.g., C1-C8 alkyl). In other embodiments, the alkyl group comprises 1 to 6 carbon atoms (e.g., C1-C6 alkyl). In other embodiments, the alkyl group comprises 1 to 5 carbon atoms (e.g., C1-C5 alkyl). In other embodiments, the alkyl group comprises 1 to 4 carbon atoms (e.g., C1-C4 alkyl). In other embodiments, the alkyl group comprises 1 to 3 carbon atoms (e.g., C1-C3 alkyl). In other embodiments, the alkyl group comprises 1 to 2 carbon atoms (e.g., C1-C2 alkyl). In other embodiments, the alkyl group comprises 1 carbon atom (e.g., C1 alkyl). In other embodiments, the alkyl group comprises 5 to 15 carbon atoms (e.g., C5-C6 alkyl). 15 Alkyl group. In other embodiments, the alkyl group comprises 5 to 8 carbon atoms (e.g., C5-C8 alkyl). In other embodiments, the alkyl group comprises 2 to 5 carbon atoms (e.g., C2-C5 alkyl). In other embodiments, the alkyl group comprises 3 to 5 carbon atoms (e.g., C3-C5 alkyl). In other embodiments, the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1-dimethylethyl (tert-butyl), and 1-pentyl (n-pentyl). The alkyl group is linked to the rest of the molecule by a single bond. Unless otherwise specified in the specification, the alkyl group is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a -SR a -OC(O)R a -N(R) a )2、-C(O)R a -C(O)OR a -C(O)N(R) a )2、-N(R a )C(O)OR f -OC(O)-NR a R f -N(R) a )C(O)R f -N(R) a S(O) t R f (where t is 1 or 2), -S(O) tOR a (where t is 1 or 2), -S(O) t R f (where t is 1 or 2) and -S(O) t N(R a (where t is 1 or 2), where R a Each is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f Each can be independently alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl. "Alkoxy" refers to a group of the formula -O-alkyl bonded by an oxygen atom, wherein the alkyl is an alkyl chain as defined above.
[0164] "Alkenyl" refers to a straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon double bond and having 2 to 12 carbon atoms. In some embodiments, the alkenyl group contains 2 to 8 carbon atoms. In other embodiments, the alkenyl group contains 2 to 4 carbon atoms. The alkenyl group is connected to the rest of the molecule by a single bond, such as methinel (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, pent-1,4-dienyl, etc. Unless otherwise specifically stated in the specification, the alkenyl group may optionally be substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a -SR a -OC(O)R a -N(R) a )2、-C(O)R a -C(O)OR a -C(O)N(R) a )2、-N(R a )C(O)OR f -OC(O)-NR a R f -N(R) a )C(O)R f -N(R) a S(O) t R f (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R f (where t is 1 or 2) and -S(O) t N(R a (where t is 1 or 2), where R aEach is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f Each group is independently alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl. "Alynyl" refers to a straight-chain or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond and having 2 to 12 carbon atoms. In some embodiments, the alkynyl group contains 2 to 8 carbon atoms. In other embodiments, the alkynyl group has 2 to 4 carbon atoms. The alkynyl group is connected to the rest of the molecule by a single bond, such as ethynyl, propynyl, butynyl, pentyynyl, hexynyl, etc. Unless otherwise specifically stated in the specification, the alkynyl group is optionally substituted with one or more of the following substituents: halogen, cyano, nitro, oxo, thio, imino, oxime, trimethylsilyl, -OR a -SR a -OC(O)R a -N(R) a )2、-C(O)R a -C(O)OR a -C(O)N(R) a )2、-N(R a )C(O)OR f -OC(O)-NR a R f -N(R) a )C(O)R f -N(R) a S(O) t R f (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R f (where t is 1 or 2) and -S(O) t N(R a (where t is 1 or 2), where R a Each is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, and R f Each of them is independently an alkyl, fluoroalkyl, cycloalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl.
[0165] "Aryl" refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. An aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and 6 to 18 carbon atoms, wherein at least one ring in the ring system is fully unsaturated, i.e., according to Hückel theory, it contains a cyclic, delocalized (4n+2)π– electron system. Ring systems from which aryl groups are derived include, but are not limited to, groups such as benzene, fluorene, indene, indene, naphthalene, and naphthalene. Unless otherwise specifically stated in the specification, the term "aryl" or the prefix "ar-(ar-)" (as in "aralkyl") is intended to include an aryl group optionally substituted with one or more substituents independently selected from alkyl, alkenyl, ynyl, halogen, fluoroalkyl, cyano, nitro, aryl, aralkyl, areneyl, arynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroaralkyl, -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2) and -R b -S(O) t N(R a)2 (where t is 1 or 2), where R a Each of the following is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halogen groups), aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, R b Each is independently a direct bond or a straight-chain or branched alkylene or alkenylene chain, and R c Each is a straight-chain or branched alkylene or alkenylene chain.
[0166] "Aryloxy group" refers to a group of formula -O-aryl bonded by an oxygen atom, where the aryl group is as defined above. "Aryl group" refers to a group of formula -R c -aryl groups, where R c The alkylene chain is as defined above, such as methylene, ethylene, etc. The alkylene chain portion of the aralkyl group is optionally substituted with the alkylene chain as described above. The aryl portion of the aralkyl group is optionally substituted with the aryl group as described above.
[0167] "Araneoxy group" refers to a group of the formula -O-aranealkyl bonded by an oxygen atom, wherein the aranealkyl group is as defined above.
[0168] "Aryl" refers to the formula -R d -aryl groups, where R d It is an alkenyl chain as defined above. The aryl portion of the aryl group is optionally substituted with an aryl group as described above. The alkenyl chain portion of the aryl group is optionally substituted with an alkenyl group as described above.
[0169] "Arotyne group" refers to the formula -R e -aryl groups, where R e It is an ynyl chain as defined above. The aryl portion of the aryynyl group is optionally substituted with an aryl group as described above. The ynyl chain portion of the aryynyl group is optionally substituted with an ynyl chain as described above.
[0170] “Cycloalkyl” refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting only of carbon and hydrogen atoms, including fused ring or bridged ring systems, having 3 to 15 carbon atoms. In some embodiments, the cycloalkyl group contains 3 to 10 carbon atoms. In other embodiments, the cycloalkyl group contains 5 to 7 carbon atoms. The cycloalkyl group is connected to the rest of the molecule by a single bond. The cycloalkyl group is saturated (i.e., containing only a single C-C bond) or partially unsaturated (i.e., containing one or more double or triple bonds). Examples of monocyclic cycloalkyl groups include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. In some embodiments, the cycloalkyl group contains 3 to 8 carbon atoms (e.g., C3-C8 cycloalkyl). In other embodiments, the cycloalkyl group contains 3 to 7 carbon atoms (e.g., C3-C7 cycloalkyl). In other embodiments, the cycloalkyl group contains 3 to 6 carbon atoms (e.g., C3-C6 cycloalkyl). In other embodiments, the cycloalkyl group contains 3 to 5 carbon atoms (e.g., C3-C5 cycloalkyl). In other embodiments, the cycloalkyl group comprises 3 to 4 carbon atoms (e.g., C3-C4 cycloalkyl). Partially unsaturated cycloalkyl groups are also referred to as "cycloalkenyl". Examples of monocyclic cycloalkenyl groups include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic cycloalkyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptyl), norbornyl, decahydronaphthyl, 7,7-dimethyl-bicyclo[2.2.1]heptyl, etc. Unless otherwise specifically stated in the specification, the term "cycloalkyl" is intended to include cycloalkyl groups optionally substituted with one or more substituents independently selected from alkyl, alkenyl, ynyl, halogen, fluoroalkyl, cyano, nitro, aryl, aralkyl, arylenyl, aryynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroaryl, -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)ORa -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where R a Each of the following is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halogen groups), aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, R b Each is independently a direct bond or a straight-chain or branched alkylene or alkenylene chain, and R c Each is a straight-chain or branched alkylene or alkenylene chain.
[0171] "Halogen" or "halogenated" refers to a bromine, chlorine, fluorine, or iodine substituent.
[0172] "Halogenated alkyl" refers to an alkyl group as defined above that has been replaced by one or more halogenated groups as defined above.
[0173] "Fluoroalkyl" refers to an alkyl group as defined above, substituted with one or more halogen groups as defined above, such as trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl group may optionally be substituted with an alkyl group as defined above. "Haloalkoxy" refers to an alkoxy group as defined above, substituted with one or more halogen groups as defined above.
[0174] "Heterocyclic alkyl" refers to a stable 3- to 18-membered non-aromatic cyclic group comprising 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. Unless otherwise specified in the specification, heterocyclic alkyl groups are monocyclic, bicyclic, tricyclic, or tetracyclic cyclic systems, including fused-ring, spirocyclic, or bridged-ring systems. The heteroatoms in the heterocyclic alkyl group are optionally oxidized. If present, one or more nitrogen atoms are optionally quaternized. The heterocyclic alkyl group is partially or fully saturated. In some embodiments, the heterocyclic alkyl group is attached to the remainder of the molecule by any atom of the ring. Examples of such heterocyclic alkyl groups include, but are not limited to, dioxolanecycloyl, thienyl[1,3]dithiaalkyl, decahydroisoquinolinyl, imidazolinyl, imidazoalkyl, isothiazolyl, isoxazolyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopiperidinyl, oxazolyl, piperidinyl, piperazinyl, 4-piperidinoneyl, pyrrolyl, pyrazolyl, quininecycloyl, thiazoalkyl, tetrahydrofuranyl, trithiaalkyl, tetrahydropyranyl, thiomorpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless otherwise specified in the specification, the term "heterocyclic alkyl" is intended to include heterocyclic alkyl groups as defined above, optionally substituted with one or more substituents selected from alkyl, alkenyl, ynyl, halogen, fluoroalkyl, oxo, thio, cyano, nitro, aryl, aralkyl, aryl-alkenyl, arylynyl, cycloalkyl, heterocyclic alkyl, heteroaryl, heteroaryl, -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-R b -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O)t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where R a Each of the following is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl (optionally substituted with one or more halogen groups), aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, R b Each is independently a direct bond or a straight-chain or branched alkylene or alkenylene chain, and R c Each is a straight-chain or branched alkylene or alkenylene chain.
[0175] "Heteroaryl" refers to a group derived from a 5- to 18-membered aromatic ring group containing 1 to 17 carbon atoms and 1 to 6 heteroatoms selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryls are monocyclic, bicyclic, tricyclic, or tetracyclic systems in which at least one ring is fully unsaturated, i.e., according to Hückel's theory, it contains a cyclic, delocalized (4n+2)-electron system. Heteroaryls include fused-ring or bridged-ring systems. The heteroatoms in the heteroaryl group are optionally oxidized. If present, one or more nitrogen atoms are optionally quaternized. The heteroaryl group is connected to the rest of the molecule via any atom of the ring. Unless otherwise specified in the specification, the term "heteroaryl" is intended to include heteroaryl groups as defined above, optionally substituted with one or more substituents selected from the following: alkyl, alkenyl, ynyl, halogen, haloalkyl, oxo, thio, cyano, nitro, aryl, aralkyl, aryl-alkenyl, arylyynyl, cycloalkyl, heterocycloalkyl, heteroaryl, heteroaryl, -R b -OR a -R b -OC(O)-R a -R b -OC(O)-OR a -R b -OC(O)-N(R a )2、-R b -N(R a )2、-R b -C(O)R a -R b -C(O)OR a -R b -C(O)N(R a )2、-Rb -OR c -C(O)N(R a )2、-R b -N(R a )C(O)OR a -R b -N(R a )C(O)R a -R b -N(R a S(O) t R a (where t is 1 or 2), -R b -S(O) t OR a (where t is 1 or 2), -R b -S(O) t R a (where t is 1 or 2) and -R b -S(O) t N(R a )2 (where t is 1 or 2), where R a Each of the following is independently hydrogen, alkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocycloalkyl, heteroaryl, or heteroarylalkyl, R b Each is independently a direct bond or a straight chain or a branched alkylene or alkenylene chain, and R c It is a straight-chain or branched alkylene or alkenylene chain.
[0176] "N-Heteroaryl" refers to a heteroaryl group as defined above containing at least one nitrogen atom, wherein the connection point between the heteroaryl group and the rest of the molecule is through a nitrogen atom in the heteroaryl group. The N-heteroaryl group may optionally be substituted with a heteroaryl group as described above.
[0177] "C-heteroaryl" refers to a heteroaryl group as defined above, wherein the connection point between the heteroaryl group and the rest of the molecule is through a carbon atom in the heteroaryl group. The C-heteroaryl group may optionally be substituted with a heteroaryl group as described above.
[0178] "Heteroaryloxy group" refers to a group bonded by an oxygen atom of the formula -O-heteroaryl, where the heteroaryl group is as defined above.
[0179] "Heteroarylalkyl" refers to the formula -R c - A heteroaryl group, wherein R c It is an alkylene chain as defined above. If the heteroaryl group is a nitrogen-containing heteroaryl group, the heteroaryl group is optionally linked to an alkyl group at the nitrogen atom. The alkylene chain of the heteroaryl alkyl group is optionally substituted with an alkylene chain as defined above. The heteroaryl portion of the heteroaryl alkyl group is optionally substituted with a heteroaryl group as defined above.
[0180] "Heteroarylalkoxy" refers to the formula -OR, which is bonded by an oxygen atom. c - A heteroaryl group, wherein R c The alkylene chain is as defined above. If the heteroaryl group is a nitrogen-containing heteroaryl group, the heteroaryl group is optionally linked to an alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkoxy group is optionally substituted with an alkylene chain as defined above. The heteroaryl moiety of the heteroarylalkoxy group is optionally substituted with a heteroaryl group as defined above.
[0181] In some embodiments, the compounds disclosed herein contain one or more asymmetric centers, thus producing enantiomers, diastereomers, and other stereoisomers, defined by absolute stereochemistry as (R)- or (S)-. Unless otherwise stated, all stereoisomers of the compounds disclosed herein are considered in this disclosure. When the compounds described herein contain an alkene double bond, and unless otherwise specified, this disclosure is intended to include E and Z geometric isomers (e.g., cis or trans). Similarly, all possible isomers, as well as their racemic and optically pure forms and all tautomers, are included. The term "geometric isomer" refers to the E or Z geometric isomer of the alkene double bond (e.g., cis or trans). The term "positional isomer" refers to a structural isomer surrounding a central ring, such as ortho, meta, and para isomers surrounding a benzene ring.
[0182] A "tautomer" is a molecule in which a proton can move from one atom of the molecule to another atom of the same molecule. In some embodiments, the compounds provided herein exist as tautomers. Where tautomerization is possible, a chemical equilibrium of tautomers will exist. The exact proportions of tautomers depend on several factors, including physical state, temperature, solvent, and pH. Some examples of tautomeric equilibria include:
[0183]
[0184] "Optional" or "optionally" means that the event or situation described below may or may not occur, and the description includes both the possibility that the event or situation occurs and the possibility that it does not occur. For example, "optionally substituted aryl" means that the aryl group may or may not be substituted, and the description includes both substituted and unsubstituted aryl groups.
[0185] “Prodrug” includes compounds that are metabolized into pharmacologically active pharmaceutical ingredients after administration (RB Silverman, 1992, “The Organic Chemistry of Drug Design and Drug Action,” Academic Press, Chp. 8). Prodrugs can be used to improve how compounds are absorbed, distributed, metabolized, and excreted. “Pharmaceutically acceptable salt” includes both acid addition salts and base addition salts. The pharmaceutically acceptable salts of any compound described herein are intended to cover any and all pharmaceutically suitable salt forms. Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
[0186] "Pharmaceutically acceptable acid addition salts" refer to those salts that retain the biological effectiveness and properties of the free base, are not biologically or otherwise undesirable, and form with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, and phosphorous acid. This also includes salts formed with organic acids, such as aliphatic monocarboxylic acids and aliphatic dicarboxylic acids, phenyl-substituted alkanes, hydroxyalkanes, alkanedioic acids, aromatic acids, aliphatic sulfonic acids, and aromatic sulfonic acids, including, for example, acetic acid, trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Therefore, exemplary salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogen phosphates, dihydrogen phosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinates, caprylates, sebacic acid salts, fumarates, maleates, mandelates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, etc. Salts of amino acids, such as arginine salts, gluconates, and galacturons, are also considered (see, for example, Berge SM et al., "Pharmaceutical Salts," Journal of Pharmaceutical Science, 66:1-19 (1997)). Acid addition salts of basic compounds are prepared by contacting a free base with a sufficient amount of the desired acid to produce a salt.
[0187] "Pharmaceutically acceptable base addition salts" refer to those salts that retain the bioavailability and properties of the free acid, and are not biologically or otherwise undesirable. These salts are prepared by adding an inorganic or organic base to the free acid. In some embodiments, pharmaceutically acceptable base addition salts form with a metal or amine, such as alkali metals and alkaline earth metals or organic amines. Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum salts. Salts derived from organic bases include, but are not limited to, salts of the following substances: primary, secondary, and tertiary amines; substituted amines (including naturally occurring substituted amines); cyclic amines; and basic ion exchange resins, such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N-dibenzylethylenediamine, chloroprocaine, heptaamine, choline, betaine, ethylenediamine, ethylenediphenylamine, N-methylglucosamine, glucosamine, methylglucosamine, theobromine, purine, piperazine, piperidine, N-ethylpiperidine, polyamine resins, etc. See Berge et al., ibid.
[0188] The term "mammal" refers to humans, non-human primates, dogs, cats, cattle, sheep, pigs, rats, or other veterinary or laboratory mammals. Those skilled in the art recognize that a therapy that reduces the severity of a pathology in one mammal can predict the effect of that therapy in another mammal.
[0189] As used herein, the terms “treatment,” “palliating,” or “ameliorating” are used interchangeably. These terms refer to methods of achieving a beneficial or desired outcome, including but not limited to therapeutic and / or preventive benefits. A “therapeutic benefit” means the eradication or improvement of the underlying condition being treated. Furthermore, a therapeutic benefit is achieved by eradicating or improving one or more physical symptoms associated with the underlying condition, resulting in an observed improvement in the patient, even though the patient still has the underlying condition. For preventive benefits, the composition is administered to patients at risk of developing a specific disease, or to patients who report one or more physical symptoms of a disease, even if the disease has not yet been diagnosed.
[0190] compound
[0191] The compounds of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") described herein are P2X3 modifiers. In some embodiments, the compounds of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") described herein are P2X3 antagonists. In some embodiments, compounds of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") and compositions comprising these compounds may be used to treat pain, urinary tract symptoms, cough, pruritus, endometriosis, endometriosis-related pain, or endometriosis-related symptoms.
[0192] In some embodiments, a compound of formula (I) is provided:
[0193]
[0194] in:
[0195] X is C(R) 2 ) or N;
[0196] Y is C(R) 2 ) or N;
[0197] Z represents a bond, CH2, or O;
[0198] R 1 Selected from hydrogen, deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0199] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0200] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0201] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0202] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0203] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0204] R 8 Each is independently selected from C1-C6 alkyl groups;
[0205] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0206] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0207] R 14 It is a C1-C6 alkyl group;
[0208] R 15 It is a C1-C6 alkyl group;
[0209] n is 0, 1, 2, or 3;
[0210] p is 1, 2, or 3; and
[0211] q can be 0, 1, 2, 3, or 4;
[0212] Or its pharmaceutically acceptable salts or solvates.
[0213] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia):
[0214]
[0215] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia'):
[0216]
[0217] In some embodiments, a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Ia):
[0218]
[0219] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(R) 2In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(H). In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N.
[0220] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein Y is C(R 2 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is C(H). In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is N.
[0221] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is O. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is a bond.
[0222] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein each R 2 It is hydrogen.
[0223] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 0. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 2.
[0224] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 -C(=O)OR 11In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)OCH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)OCH2CH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)R 11 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)CH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)CH2CH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)N(R) 12 (R) 13 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 It is -C(=O)N(H)(CH3).
[0225] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)N(H)(CH3). In some embodiments, a compound of formula (I), (Ia), (Ia') or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)NH2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R5 The form is -C(=O)N(CH3)2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)OCH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 It is -C(=O)OCH2CH3.
[0226] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CF3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 -CHF2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is hydrogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R...1 For deuterium. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C3-C6 alkyl group.
[0227] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 Selected from hydrogen, deuterium, halogens, C1-C6 alkyl groups and -OR 7 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 -CH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 For -OR 7 In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 -OCH3. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 The form is hydrogen. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 3 It is deuterium.
[0228] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 0.
[0229] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is a halogen.
[0230] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is a halogen.
[0231] In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 1. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 2. In some embodiments, a compound of formula (I), (Ia), (Ia'), or (Ia") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 3.
[0232] In some embodiments, a compound of formula (II) is provided:
[0233]
[0234] in:
[0235] X is C(R) 2) or N;
[0236] Y is C(R) 2 ) or N;
[0237] Z represents a bond, CH2, or O;
[0238] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0239] R 3 Selected from deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -N(R7)2, -CN, -C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0240] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0241] R 5 -C(=O)N(R) 9 (R) 10-C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0242] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0243] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0244] R 8 Each is independently selected from C1-C6 alkyl groups;
[0245] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0246] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0247] R 14 It is a C1-C6 alkyl group;
[0248] R 15 It is a C1-C6 alkyl group;
[0249] n is 0, 1, 2, or 3;
[0250] p is 1, 2, or 3; and
[0251] q can be 0, 1, 2, 3, or 4;
[0252] Or its pharmaceutically acceptable salts or solvates.
[0253] In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa):
[0254]
[0255] In some embodiments, a compound of formula (IIa) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa'):
[0256]
[0257] In some embodiments, a compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIa):
[0258]
[0259] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein X is C(R 2 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(H). In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N.
[0260] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein Y is C(R 2 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is C(H). In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is N.
[0261] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is O. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is a bond.
[0262] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 2 Each is hydrogen.
[0263] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 0. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 1. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 2.
[0264] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 -C(=O)OR 11 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)OCH3. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)OCH2CH3. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 -C(=O)R 11 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 It is -C(=O)CH3. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)CH2CH3. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)N(R) 12 (R) 13In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 It is -C(=O)N(H)(CH3).
[0265] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)N(H)(CH3). In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 For -C(=O)NH2. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)N(CH3)2. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)OCH3. In some embodiments, a compound of formula (II), (IIa), (IIa') or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 It is -C(=O)OCH2CH3.
[0266] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1-CH3. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CF3. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 -CHF2. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is hydrogen. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 1 For deuterium. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C3-C6 alkyl group.
[0267] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 Selected from deuterium and C3-C6 alkyl groups. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R3 It is a C3-C6 alkyl group. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 It is deuterium.
[0268] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 2. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 0.
[0269] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is a halogen. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is a halogen.
[0270] In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 1. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 2. In some embodiments, a compound of formula (II), (IIa), (IIa'), or (IIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 3.
[0271] In some embodiments, a compound of formula (III) is provided:
[0272]
[0273] in:
[0274] X is C(R) 2 ) or N;
[0275] Y is C(R) 2 ) or N;
[0276] Z is CH2 or O;
[0277] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0278] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8-C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0279] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 ,
[0280] -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0281] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0282] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0283] R 8 Each is independently selected from C1-C6 alkyl groups;
[0284] R 9 and R 10 Independently selected from C1-C6 alkyl groups; or R 9 and R 10 They combine to form a 5- or 6-membered heterocyclic alkyl ring, which may be optionally substituted with 1, 2, 3 or 4 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy and C1-C6 alkoxy groups;
[0285] R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0286] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0287] R 14 It is a C1-C6 alkyl group;
[0288] R 15 It is a C1-C6 alkyl group;
[0289] n is 0, 1, 2, or 3;
[0290] p is 1, 2, or 3; and
[0291] q can be 0, 1, 2, 3, or 4;
[0292] Or its pharmaceutically acceptable salts or solvates.
[0293] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa):
[0294]
[0295] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa'):
[0296]
[0297] In some embodiments, a compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IIIa):
[0298]
[0299] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein X is C(R 2 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(H). In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N.
[0300] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein Y is C(R 2 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is C(H). In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is N.
[0301] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is O. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2.
[0302] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 2 Each is hydrogen.
[0303] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 0. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 1. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 2.
[0304] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 -C(=O)OR 11 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6The form is -C(=O)OCH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)OCH2CH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa') or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)R 11 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)CH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa') or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)CH2CH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa') or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)N(R) 12 (R) 13 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 It is -C(=O)N(H)(CH3).
[0305] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 And R 9 and R 10 Independently selected from C1-C6 alkyl groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5The form is -C(=O)N(CH3)2. In some embodiments, a compound of formula (III), (IIIa), (IIIa') or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 And R 9 and R 10 The combination forms a 5- or 6-membered heterocyclic alkyl ring, which is optionally substituted with 1, 2, 3, or 4 groups selected from halogens, C1-C6 alkyl groups, C1-C6 haloalkyl groups, hydroxyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)OCH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 It is -C(=O)OCH2CH3.
[0306] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a halogen. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1-CF3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 -CHF2. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is hydrogen. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 1 For deuterium. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C3-C6 alkyl group.
[0307] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 Selected from hydrogen, deuterium, halogens, C1-C6 alkyl groups and -OR 7 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3It is a C1-C6 alkyl group. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 -CH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 For -OR 7 In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 -OCH3. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 The form is hydrogen. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 3 The substance is deuterium. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 2. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 0.
[0308] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4Each is a halogen. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is a halogen.
[0309] In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 1. In some embodiments, a compound of formula (III), (IIIa), (IIIa'), or (IIIa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 2.
[0310] In some embodiments, a compound of formula (IV) is provided:
[0311]
[0312] in:
[0313] X is C(R) 2 ) or N;
[0314] Y is C(R) 2 ) or N;
[0315] Z is CH2 or O;
[0316] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0317] R 3 Selected from halogens, -CN, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0318] R 4 Each is independently selected from deuterium, -CN, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 Combined to form bridged heterocyclic alkyl rings; R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 ,
[0319] -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0320] R 6 Selected from -C(=O)R 11 ;
[0321] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0322] R 8 Each is independently selected from C1-C6 alkyl groups;
[0323] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0324] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0325] R 14 It is a C1-C6 alkyl group;
[0326] R 15 It is a C1-C6 alkyl group;
[0327] n is 0, 1, 2, or 3;
[0328] p is 1, 2, or 3; and
[0329] q can be 0, 1, 2, 3, or 4;
[0330] Or its pharmaceutically acceptable salts or solvates.
[0331] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa):
[0332]
[0333] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa'):
[0334]
[0335] In some embodiments, a compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (IVa):
[0336]
[0337] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein X is C(R) 2In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(H). In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N.
[0338] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein Y is C(R 2 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is C(H). In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is N.
[0339] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is O. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2.
[0340] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 2 Each is hydrogen.
[0341] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 0. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 1. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 2.
[0342] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6The form is -C(=O)CH3. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 It is -C(=O)CH2CH3.
[0343] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)N(H)(CH3). In some embodiments, a compound of formula (IV), (IVa), (IVa') or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)NH2. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)N(CH3)2. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)OCH3. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 It is -C(=O)OCH2CH3.
[0344] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1-CH3. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 It is a halogen. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CF3. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 -CHF2. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is hydrogen. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For deuterium. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C3-C6 alkyl group.
[0345] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R3 Selected from halogens and -OR 7 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 For -OR 7 In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 It is -OCH3.
[0346] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 2. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 0.
[0347] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from deuterium, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is a C1-C6 alkoxy group.
[0348] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from deuterium, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4Each is a C1-C6 alkoxy group. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is a C1-C6 haloalkyl group.
[0349] In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 1. In some embodiments, a compound of formula (IV), (IVa), (IVa'), or (IVa") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 2.
[0350] In some embodiments, a compound of formula (V) is provided:
[0351]
[0352] in:
[0353] X is C(R) 2 ) or N;
[0354] Y is C(R) 2 ) or N;
[0355] Z is CH2 or O;
[0356] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0357] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0358] R 3Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0359] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0360] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0361] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0362] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0363] R 8 Each is independently selected from C1-C6 alkyl groups;
[0364] R 9 R 10 R 12and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0365] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0366] R 14 It is a C1-C6 alkyl group;
[0367] R 15 It is a C1-C6 alkyl group;
[0368] n is 0, 1, 2, or 3;
[0369] p is 2 or 3; and
[0370] q can be 0, 1, 2, 3, or 4;
[0371] Or its pharmaceutically acceptable salts or solvates.
[0372] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va):
[0373]
[0374] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va'):
[0375]
[0376] In some embodiments, a compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof is provided, having the structure of formula (Va):
[0377]
[0378] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein X is C(R 2 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is C(H). In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein X is N.
[0379] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein Y is C(R 2 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is C(H). In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Y is N.
[0380] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is O. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein Z is CH2.
[0381] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 2 Each is hydrogen.
[0382] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 0. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 1. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein q is 2.
[0383] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 -C(=O)OR 11 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)OCH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6The form is -C(=O)OCH2CH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)R 11 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 The form is -C(=O)CH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 The form is -C(=O)CH2CH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 6 -C(=O)N(R) 12 (R) 13 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 6 It is -C(=O)N(H)(CH3).
[0384] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 -C(=O)N(R) 9 (R) 10 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)N(H)(CH3). In some embodiments, a compound of formula (V), (Va), (Va') or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)NH2. In some embodiments, a compound of formula (V), (Va), (Va') or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 The form is -C(=O)N(CH3)2. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 -C(=O)OR 9In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 5 The form is -C(=O)OCH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 5 It is -C(=O)OCH2CH3.
[0385] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a halogen. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CF3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 -CHF2. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 For -OR 7 And R 7 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 For -OR 7 And R 7It is a C1-C6 haloalkyl group. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 1 The form is hydrogen. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 1 For deuterium. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 1 It is a C3-C6 alkyl group.
[0386] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 Selected from hydrogen, deuterium, halogens, C1-C6 alkyl groups and -OR 7 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 It is a halogen. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 It is a C1-C6 alkyl group. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 3 -CH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 For -OR 7 In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 -OCH3. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 3 The form is hydrogen. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R... 3 It is deuterium.
[0387] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 2. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 0.
[0388] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein R 4 Each is a halogen.
[0389] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvate thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from deuterium, halogen, C1-C6 alkyl, C1-C6 haloalkyl, and C1-C6 alkoxy. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein n is 1 or 2 and R 4 Each is a halogen.
[0390] In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 2. In some embodiments, a compound of formula (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof is provided, wherein p is 3.
[0391] In some of the embodiments described herein, the P2X3 modifier is selected from:
[0392]
[0393]
[0394]
[0395]
[0396]
[0397]
[0398] Or its pharmaceutically acceptable salts or solvates.
[0399] In some embodiments, the disclosed compound used by one or more of the foregoing methods is one of the genus, subgenus, or specific compounds described herein, such as compounds of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va").
[0400] Preparation of Compounds The compounds used in the methods described herein are prepared according to the method disclosed in U.S. Patent No. 9,598,409, which is incorporated herein by reference in its entirety, or by known organic synthesis techniques, starting with commercially available chemicals and / or compounds described in chemical literature.Commercially available chemicals were obtained from standard commercial sources, including Acros Organics (Geel, Belgium), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Ark Pharm, Inc. (Libertyville, IL), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Combi-blocks (San Diego, CA), Crescent Chemical Co. (Hauppauge, NY), eMolecules (San Diego, CA), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc. (Costa Mesa, CA), Key Organics (Cornwall, U.K.), Lancaster Synthesis (Windham, NH), Matrix Scientific, (Columbia, SC), Maybridge Chemical Co. Ltd. (Cornwall, U.K.), Parish Chemical Co. (Orem, UT), Pfaltz & Bauer, Inc. (Waterbury, CN), Polyorganix (Houston, TX), Pierce Chemical Co. (Rockford, IL), Riedel de Haen AG (Hanover, Germany), Ryan Scientific, Inc. (Mount Pleasant, SC), Spectrum Chemicals (Gardena, CA), Sundia Meditech, (Shanghai, China), TCI America (Portland, OR), Trans World Chemicals, Inc. (Rockville, MD) and WuXi (Shanghai, China).
[0401] Suitable reference books and papers that detail the synthesis of reactants used to prepare the compounds described herein or provide reference to articles describing the preparation include, for example, "Synthetic Organic Chemistry", John Wiley & Sons, Inc., New York; SRSandler et al., "Organic Functional Group Preparations", 2nd ed., Academic Press, New York, 1983; HO House, "Modern Synthetic Reactions", 2nd ed., WABenjamin, Inc., Menlo Park, Calif., 1972; TL Gilchrist, "Heterocyclic Chemistry", 2nd ed., John Wiley & Sons, New York, 1992; J. March, "Advanced Organic Chemistry: Reactions, Mechanisms and Structure", 4th ed., Wiley-Interscience, New York, 1992. Other suitable references and papers that detail the synthesis of reactants used to prepare the compounds described herein or provide reference to articles describing the preparations include, for example, Fuhrhop, J. and Penzlin G., *Organic Synthesis: Concepts, Methods, Starting Materials*, Second Revised and Expanded Edition (1994), John Wiley & Sons, ISBN: 3-527-29074-5; Hoffman, RV., *Organic Chemistry, An Intermediate Text* (1996), Oxford University Press, ISBN 0-19-509618-5; Larock, RC., *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*, Second Edition (1999), Wiley-VCH, ISBN: 0-471-19031-4; March, J., *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Fourth Edition (1992), John Wiley & Sons, ISBN: 3-527-29074-5; Hoffman, RV., *Organic Chemistry: Concepts, Methods, Starting Materials*, Second Revised and Expanded Edition (1994), John Wiley & Sons, ISBN: 3-527-29074-5; Hoffman, RV., *Organic Chemistry: Concepts, Methods, Starting Materials* (1996), Oxford University Press, ISBN: 0-19-509618-5; Larock, RC., *Comprehensive Organic Transformations: A Guide to Functional Group Preparations*, Second Edition (1999), Wiley-VCH, ISBN: 0-471-19031-4; March, J., *Advanced Organic Chemistry: Reactions, Mechanisms, and Structure*, Fourth Edition (1992), John Wiley & Sons, ISBN: 3-527-29074-5; H Wiley & Sons, ISBN: 0-471-60180-2; Otera, J.(editor) "Modern Carbonyl Chemistry" (2000) Wiley-VCH, ISBN: 3-527-29871-1; Patai, S. "Patai's 1992Guide to the Chemistry of Functional Groups" (1992) Interscience ISBN: 0-471-93022-9; Solomons, TWG "Organic Chemistry" Seventh Edition (2000) John Wiley & Sons, ISBN: 0-471-19095-0; Stowell, JC, "Intermediate Organic Chemistry" Second Edition (1993) Wiley-Interscience, ISBN: 0-471-57456-2; "Industrial Organic Chemicals: Starting Materials and Intermediates: An Ullmann'sEncyclopedia"(1999)John Wiley & Sons, ISBN: 3-527-29645-X, in 8 volumes; "Organic Reactions" (1942–2000) by John Wiley & Sons, in over 55 volumes; and "Chemistry of Functional Groups" by John Wiley & Sons, in 73 volumes.
[0402] Specific and similar reactants are also identified by an index of known chemicals prepared by the Chemical Abstracts Service of the American Chemical Society, which is available in most public and university libraries as well as through online databases (contact the American Chemical Society in Washington, D.C. for more details). Chemicals known but not commercially available in the catalogue are optionally prepared by custom chemical synthesis facilities, many of which provide custom synthesis services to standard chemical suppliers (e.g., those listed above). References for the preparation and selection of pharmaceutical salts of the compounds described herein are PHStahl & C.G. Wermuth, "Handbook of Pharmaceutical Salts," Verlag Helvetica Chimica Acta, Zurich, 2002.
[0403] Other forms of the compounds disclosed herein
[0404] Isomers
[0405] Furthermore, in some embodiments, the compounds described herein exist as geometric isomers. In some embodiments, the compounds described herein have one or more double bonds. The compounds provided herein include all cis isomers, trans isomers, syn isomers, antiisomers, engegen isomers, and zusammen isomers, and mixtures thereof. In some cases, the compounds exist as tautomers. The compounds described herein include all possible tautomers within the formulas described herein. In some cases, the compounds described herein have one or more chiral centers, and each center exists in an R or S configuration. The compounds described herein include all diastereomers, enantiomers, and epimers, and mixtures thereof. In further embodiments of the compounds and methods provided herein, mixtures of enantiomers and / or diastereomers produced by a single preparation step, combination, or tautomerization can be used for the applications described herein. In some embodiments, the compound described herein is prepared as its individual stereoisomers by reacting a racemic mixture of the compound with an optically active resolving agent to form a pair of diastereomers, separating the diastereomers, and recovering the optically pure enantiomers. In some embodiments, dissociable complexes (e.g., crystalline diastereomer salts) are preferred. In some embodiments, the diastereomers have different physical properties (e.g., melting point, boiling point, solubility, reactivity, etc.) and are separated by utilizing these differences. In some embodiments, the diastereomers are separated by chiral chromatography or preferably by a separation / resolution technique based on solubility differences. In some embodiments, the optically pure enantiomers and the resolving agent are then recovered by any practical method that does not cause racemization.
[0406] Labeled compounds In some embodiments, the compounds described herein are present in their isotopically labeled form. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such isotopically labeled compounds. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such isotopically labeled compounds as pharmaceutical compositions. Thus, in some embodiments, the compounds disclosed herein include isotopically labeled compounds that are the same as those described herein, but in fact one or more atoms are replaced by atoms having atomic masses or mass numbers different from those normally found in nature. Examples of isotopes incorporated into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, for example, respectively. 2 H, 3 H,13 C 14 C l5 N、 16 O、 17 O、 31 P, 32 P, 35 S, 18 F and 36 Cl. Other isotopes containing the aforementioned isotopes and / or other atoms, as well as their pharmaceutically acceptable salts, esters, solvates, hydrates, or derivatives, are within the scope of this invention. Certain isotope-labeled compounds, such as those doped with radioactive isotopes, are also included. 3 H and 14 Those of type C can be used for drug and / or substrate tissue distribution determination. Tritium-based, i.e. 3 H and carbon-14 are particularly preferred due to their ease of preparation and detectability. 14 C isotopes. In addition, heavy isotopes such as deuterium (i.e., carbon) are used. 2 H) substitution produces certain therapeutic advantages due to increased metabolic stability, such as prolonged in vivo half-life or reduced dose requirement. In some embodiments, the isotopically labeled compound, its pharmaceutically acceptable salt, ester, solvate, hydrate, or derivative is prepared by any suitable method.
[0407] In some embodiments, the compounds described herein are labeled in other ways, including but not limited to using chromophores or fluorescent moieties, bioluminescent labeling, or chemiluminescent labeling.
[0408] Pharmaceutically acceptable salts
[0409] In some embodiments, the compounds described herein are present in the form of their pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts. In some embodiments, the methods disclosed herein include methods of treating a disease by administering such pharmaceutically acceptable salts as a pharmaceutical composition.
[0410] In some embodiments, the compounds described herein have acidic or basic groups and thus react with a variety of inorganic or organic bases and any of inorganic and organic acids to form pharmaceutically acceptable salts. In some embodiments, these salts are prepared in situ during the final isolation and purification of the compounds of the invention, or by reacting the purified free form of the compound alone with a suitable acid or base and isolating the resulting salt.
[0411] prodrug
[0412] In some embodiments, the compounds described herein are formulated as agents that are converted in vivo to their active form to alter the biodistribution or pharmacokinetics of a particular agent. For example, the carboxylic acid group can be esterified, for example, with methyl or ethyl groups to produce an ester. When the ester is administered to a subject, it is enzymatically or non-enzymatically, reducingly, oxidatively, or hydrolyzed to expose an anionic group. The anionic group can be partially esterified (e.g., with acyloxymethyl esters), and these moieties are cleaved to expose an intermediate reagent, which is subsequently decomposed to produce the active agent. The prodrug moiety can be metabolized in vivo to a carboxylic acid via esterases or other mechanisms. Alternatively, other functional groups can be modified into the prodrug form. For example, the amino group can be converted to a carbamate or amide that can be cleaved in vivo.
[0413] solvates
[0414] In some embodiments, the compounds described herein are present as solvates. The present invention provides a method for treating a disease by administering such a solvate. The present invention also provides a method for treating a disease by administering such a solvate in the form of a pharmaceutical composition.
[0415] The solvates contain stoichiometric or non-stoichiometric amounts of solvent and, in some embodiments, are formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. When the solvent is water, a hydrate is formed, or when the solvent is an alcohol, an alcohol is formed. The solvates of the compounds described herein are conveniently prepared or formed in the methods described herein. By way of example only, the hydrates of the compounds described herein are conveniently prepared by recrystallization from an aqueous / organic solvent mixture using organic solvents including, but not limited to, dioxane, tetrahydrofuran, or methanol. Furthermore, the compounds provided herein are present in both solvated and non-solvated forms. Generally, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the non-solvated form.
[0416] Pharmaceutical Composition
[0417] In some embodiments, the compounds described herein are administered as pure chemicals. In other embodiments, the compounds described herein are combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, a physiologically suitable (or acceptable) excipient, or a physiologically suitable (or acceptable) carrier) selected based on, for example, the route of administration and standard pharmaceutical practice described in Remington: The Science and Practice of Pharmacy (Gennaro, 21st edition. Mack Pub. Co., Easton, PA (2005)).
[0418] Therefore, this document provides a pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt described herein and one or more pharmaceutically acceptable carriers. A carrier (or excipient) is acceptable or suitable if it is compatible with the other components of the composition and is harmless to the recipient of the composition (i.e., the subject).
[0419] One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt thereof.
[0420] Another embodiment provides a pharmaceutical composition substantially consisting of a pharmaceutically acceptable carrier and a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va') or (Va"), or a pharmaceutically acceptable salt thereof.
[0421] In some embodiments, the compounds described herein are substantially pure because they contain less than about 5%, or less than about 1%, or less than about 0.1% of other small organic molecules, such as polluting intermediates or byproducts generated in one or more steps of the synthetic method.
[0422] These formulations include those suitable for oral, topical, sublingual, parenteral (e.g., subcutaneous, intramuscular, intradermal, or intravenous) or aerosol administration.
[0423] Exemplary pharmaceutical compositions are used in the form of pharmaceutical formulations, such as solid, semi-solid, or liquid forms, comprising one or more disclosed compounds as active ingredients, mixed with an organic or inorganic carrier or excipient suitable for external, enteral, or parenteral application. In some embodiments, the active ingredient is mixed with a generally non-toxic, pharmaceutically acceptable carrier, such as that used in tablets, pills, capsules, suppositories, solutions, emulsions, suspensions, and any other suitable form. The amount of the active target compound contained in the pharmaceutical composition is sufficient to produce the desired effect on the course or condition of a disease.
[0424] In some embodiments, compounds of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") are administered to a subject in a biocompatible form suitable for topical application to treat or prevent skin diseases, conditions, or illnesses. "Biocompatible form suitable for topical application" means the form of the compound to be administered, of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), wherein the inhibitor's therapeutic effect outweighs any toxic effects. The administration of compounds of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") as described herein may be in any pharmacological form, including therapeutically effective amounts of compounds of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), alone or in combination with a pharmaceutically acceptable carrier.
[0425] Topical application of compounds of formulas (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") can be in the form of aerosols, semi-solid pharmaceutical compositions, powders, or solutions. The term "semi-solid composition" refers to ointments, creams, ointments, gels, or other pharmaceutical compositions of substantially similar consistency suitable for the skin. Examples of semi-solid compositions are given in Chapter 17 of *The Theory and Practice of Industrial Pharmacy* by Lea and Febiger (1970) and Chapter 67 of *Remington's Pharmaceutical Sciences*, 15th edition (1975) by Mack Publishing.
[0426] Epidermal or skin patches are another method for transdermal delivery of the therapeutic or pharmaceutical compositions described herein. Patches may include absorption enhancers such as DMSO to increase compound absorption. Patches may include those that control the rate of drug delivery to the skin. Patches can provide various drug delivery systems, including reservoir systems or monolithic systems. A reservoir design may, for example, have four layers: an adhesive layer in direct contact with the skin, a control membrane to control drug molecule diffusion, a drug molecule reservoir, and a waterproof backing. This design delivers a uniform amount of drug over a specified time period, and the delivery rate must be less than the saturation limit for different skin types. For example, a monolithic design typically has only three layers: an adhesive layer, a polymer matrix containing the compound, and a waterproof backing. This design provides the skin with a saturated amount of drug. Therefore, delivery is controlled by the skin. As the amount of drug in the patch decreases below the saturation level, the delivery rate decreases. In one embodiment, the topical composition may take, for example, the form of a hydrogel based on polyacrylic acid or polyacrylamide; as an ointment, for example with polyethylene glycol (PEG) as a carrier, such as the standard ointment DAB8 (50% PEG 300, 50% PEG 1500); or as an emulsion, especially a microemulsion based on water-in-oil or oil-in-water, optionally with the addition of liposomes. Suitable penetration enhancers (entrainers) include sulfoxide derivatives, such as dimethyl sulfoxide (DMSO) or decyl methyl sulfoxide (decyl-MSO) and carbitol (diethylene glycol monoethyl ether) or cyclodextrin; and pyrrolidones, such as 2-pyrrolidone, N-methyl-2-pyrrolidone, 2-pyrrolidone-5-carboxylic acid or biodegradable N-(2-hydroxyethyl)-2-pyrrolidone and its fatty acid esters; urea derivatives, such as dodecylurea, 1,3-di(dodecyl)urea and 1,3-diphenylurea; and terpenes, such as D-limonene, menthone, α-terpineol, carvone, limonene oxide or 1,8-eudesmol.
[0427] Ointments, pastes, creams, and gels may also contain excipients such as starch, tragacanth gum, cellulose derivatives, polyethylene glycol, silicone, bentonite, silicic acid, and talc, or mixtures thereof. Powders and sprays may also contain excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicate, and polyamide powders, or mixtures thereof. Solutions of nanocrystalline antimicrobial metals can be converted into aerosols or sprays by any known method conventionally used for the preparation of aerosol pharmaceuticals. Typically, this method involves pressurization or providing a device for a pressurized solution container, usually using an inert carrier gas, and passing the pressurized gas through a small orifice. Sprays may additionally contain conventional propellants such as chlorofluorocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
[0428] In some embodiments for preparing solid compositions such as tablets, the major active ingredient is mixed with a pharmaceutical carrier, such as a conventional tableting component like corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gum, and other pharmaceutical diluents such as water to form a solid preformation composition containing a homogeneous mixture of the disclosed compound or a non-toxic, pharmaceutically acceptable salt thereof. When these preformed compositions are referred to as homogeneous, it means that the active ingredient is uniformly dispersed throughout the composition, making the composition easily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules.
[0429] In solid dosage forms (capsules, tablets, pills, sugar-coated pills, powders, granules, etc.) for oral administration, the subject composition is mixed with one or more pharmaceutically acceptable carriers such as sodium citrate or dicalcium phosphate and / or any of the following: (1) a filler or extender, such as starch, cellulose, microcrystalline cellulose, silicified microcrystalline cellulose, lactose, sucrose, glucose, mannitol and / or silicic acid; (2) a binder, such as carboxymethyl cellulose, hydroxypropyl methylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose and / or gum arabic; (3) a humectant, such as (3) Glycerin; (4) Disintegrants, such as crospovidone, croscarmellose sodium, glycolic acid starch sodium, agar, calcium carbonate, potato or cassava starch, alginate, certain silicates and sodium carbonate; (5) Solution blockers, such as paraffin; (6) Absorption enhancers, such as quaternary ammonium compounds; (7) Wetting agents, such as sodium docusate, cetyl alcohol and glyceryl monostearate; (8) Absorbents, such as kaolin and bentonite; (9) Lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate and mixtures thereof; and (10) Colorants. In the case of capsules, tablets and pills, in some embodiments, the composition contains a buffer. In some embodiments, similar type of solid compositions are also used as fillers in soft-filled and hard-filled gelatin capsules using excipients such as lactose or milk sugar and high molecular weight polyethylene glycol.
[0430] In some embodiments, tablets are prepared by compression or molding, optionally together with one or more excipients. In some embodiments, compressed tablets are prepared using binders (e.g., gelatin or hydroxypropyl methylcellulose), lubricants, inert diluents, preservatives, disintegrants (e.g., sodium hydroxyacetic acid starch or croscarmellose sodium), surfactants, or dispersants. In some embodiments, molded tablets are prepared by molding a mixture of the subject composition wetted with an inert liquid diluent in a suitable machine. In some embodiments, tablets and other solid dosage forms (e.g., sugar-coated pills, capsules, pellets, and granules) are scored or prepared with coatings and shells (e.g., enteric coatings and other coatings).
[0431] Compositions for inhalation or inhalation include solutions and suspensions, as well as powders, in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof. Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to the target composition, in some embodiments, the liquid dosage form contains inert diluents such as water or other solvents, solubilizers and emulsifiers such as ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butanediol, oils (especially cottonseed oil, peanut oil, corn oil, germ oil, olive oil, castor oil, and sesame oil), glycerin, tetrahydrofuranol, fatty acid esters of polyethylene glycol and sorbitol, cyclodextrins, and mixtures thereof.
[0432] In some embodiments, in addition to the subject composition, the suspension also contains suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum hydroxide, bentonite, agar and tragacanth gum and mixtures thereof.
[0433] In some embodiments, in addition to the subject composition, the powder and spray also contain excipients such as lactose, talc, silica, aluminum hydroxide, calcium silicate, and polyamide powders or mixtures of these substances. In some embodiments, the spray also contains conventional propellants such as chlorofluorocarbons and volatile unsubstituted hydrocarbons such as butane and propane.
[0434] The compositions and compounds disclosed herein may optionally be administered via aerosols. This is achieved by preparing aqueous aerosols, liposome formulations, or solid particles containing said compounds. In some embodiments, non-aqueous (e.g., fluorocarbon propellants) suspensions are used. In some embodiments, sonic aerosols are used because they minimize the agent's exposure to shear, which leads to degradation of the compounds contained in the subject composition. Typically, aqueous aerosols are prepared by formulating an aqueous solution or suspension of the subject composition with conventionally pharmaceutically acceptable carriers and stabilizers. Carriers and stabilizers vary depending on the requirements of the specific subject composition but typically include nonionic surfactants (Tween, Pluronic, or polyethylene glycol), harmless proteins such as serum albumin, sorbitol esters, oleic acid, lecithin, amino acids such as glycine, buffers, salts, sugars, or sugar alcohols. Aerosols are typically prepared from isotonic solutions.
[0435] Pharmaceutical compositions suitable for parenteral administration comprise a combination of a subject composition with one or more pharmaceutically acceptable sterile isotonic aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, or sterile powders reconstituted into sterile injectable solutions or dispersions prior to use, and in some embodiments contain antioxidants, buffers, antibacterial agents, solutes or suspending agents or thickeners that make the formulation isotonic with the blood of the intended recipient.
[0436] Examples of suitable aqueous and non-aqueous carriers for pharmaceutical compositions include water, ethanol, polyols (e.g., glycerol, propylene glycol, polyethylene glycol, etc.) and suitable mixtures thereof, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate and cyclodextrin). For example, by using coating materials such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using surfactants to maintain appropriate flowability.
[0437] The dosage of a composition comprising at least one of the compounds described herein varies depending on the patient's (e.g., human) condition, i.e., stage of disease, general health status, age, and other factors.
[0438] The pharmaceutical composition is administered in a manner suitable for treating (or preventing) the disease. The appropriate dosage and the appropriate duration and frequency of administration will be determined by factors such as the patient's condition, the type and severity of the patient's disease, the specific form of the active ingredient, and the method of administration. Generally, an appropriate dosage and treatment regimen provides an amount of composition sufficient to provide therapeutic and / or preventative benefits (e.g., improved clinical outcomes, such as more frequent complete or partial remissions, or longer disease-free and / or overall survival, or reduced symptom severity). The optimal dosage is typically determined using experimental models and / or clinical trials. In some embodiments, the optimal dosage depends on the patient's body mass, weight, or blood volume.
[0439] The oral dosage is usually from about 1.0 mg to about 1000 mg, once to four times or more daily.
[0440] method
[0441] pain
[0442] P2X3 is selectively expressed on nociceptive, small-diameter sensory neurons (i.e., neurons stimulated by pain or injury), consistent with its role in pain sensitivity. Furthermore, blocking P2X3 receptors has been reported to have analgesic effects in animal models of chronic inflammatory and neuropathic pain. (Jarvis et al., PNAS, 99, 17179-17184 (2002)). Therefore, it is suggested that methods to reduce P2X3 levels or activity could be used to modulate pain perception in pain-afflicted individuals.
[0443] In some embodiments, a method for treating pain in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the pain is inflammation and aches. In some embodiments, the pain is neuropathic pain. In some embodiments, the pain is chronic pain.
[0444] Urinary tract diseases
[0445] P2X3 has been reported to be involved in the afferent pathway controlling the bladder capacity reflex. Therefore, inhibiting P2X3 may have therapeutic potential for treating urine storage and excretion disorders such as overactive bladder. (Cockayne et al., Nature, vol. 407, pp. 1011-1015 (2000)). Recent studies have also shown that P2X2 / 3 is primarily expressed in bladder sensory neurons (more so than P2X3) and may play a role in the perception of bladder fullness and nociceptive sensation. (Zhong et al., Neuroscience, vol. 120, pp. 667-675 (2003)).
[0446] In some embodiments, a method for treating a urinary tract condition in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the urinary tract condition includes neurogenic overactive bladder, non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostatodynia, and benign prostatic hyperplasia.
[0447] In some embodiments, a method is provided for reducing or preventing uncontrolled urine loss in mammals in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (Iva"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, uncontrolled urine loss is associated with urge incontinence, cough incontinence, stress incontinence, overflow incontinence, functional incontinence, neurogenic incontinence, postprostatectomy incontinence, urinary urgency, nocturia, and enuresis.
[0448] cough Most stimuli that trigger coughing affect the upper respiratory tract (e.g., strong odors / smoke, cold air, postnasal drip, aspiration of gastroesophageal reflux, talking). Furthermore, the highest concentrations of cough receptors are found in the larynx, carina, and bifurcation of large and medium-sized bronchi. These observations suggest that the upper respiratory tract plays a major role in coughing. Therefore, given that the upper respiratory tract is innervated by jugular C-fibers that primarily express P2X3 channels, this suggests that P2X3 homotrimeric receptors are responsible for increased sensitivity of the cough reflex. In some embodiments, a method for treating cough in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, the cough is an acute cough or a chronic cough. In some implementation plans, cough is associated with diseases, symptoms, or conditions selected from the following: chronic obstructive pulmonary disease, asthma, tuberculosis, bronchitis, bronchiectasis, purulent lung disease, respiratory malignancies, allergic reactions, cystic fibrosis, pulmonary fibrosis, respiratory inflammation, emphysema, pneumonia, lung cancer, lung tumor formation, sore throat, common cold, influenza, respiratory infection, bronchoconstriction, sarcoidosis, viral or bacterial infection of the upper respiratory tract, angiotensin-converting enzyme (ACE) inhibitor therapy, cough in smokers, chronic nonproductive cough, neoplastic cough, cough due to gastroesophageal reflux, and cough caused by inhalation of irritants, smoke, haze, dust, or air pollutants.
[0449] Pruritus
[0450] Itching stimuli can be induced by mechanical, thermal, and chemical methods. These stimuli are sensed by afferent neurons innervating the skin and transmitted to the thalamus for processing and reflex initiation. Stimulation and afferent transmission operate through a variety of afferent neurons (pruritus-sensing neurons), a group that partially overlaps in molecular phenotype with pain-sensing neurons in the skin. Pruritus neurons can respond to a variety of stimuli, but pathological pruritus is primarily induced by endogenous chemical agents (e.g., histamine, substance P, gastrin-releasing peptide, interleukins, nerve growth factor) acting on the neuronal terminals in the skin. These pruritogens are released in conditions with excessive inflammation (e.g., atopic dermatitis, psoriasis), systemic diseases (e.g., chronic liver and kidney diseases), neurological conditions (e.g., postherpetic pruritus), or psychotic conditions (e.g., obsessive-compulsive disorder, substance abuse) (Yosipovitch et al., N. Engl. J. Med., 2013, 1625-1634). Pruritogenic afferent neurons are characterized by c- or aδ-fibers of the dorsal root ganglion, which innervate skin tissue and form synapses with the spinal cord. The terminals of c- and aδ-fibers in the skin express receptors that respond to pruritogenic chemicals to elicit action potentials transmitted to the CNS. These neurons also express P2X3 cation channels, which modulate the neuronal sensitivity to pruritogenic stimuli. Notably, P2X3 channels are co-expressed on the cell membrane of MgprA3+ neurons, which are the predominant pruritogenic neuronal phenotype innervating the skin, and the number of these neurons is increased in mouse models of chronic pruritus (Han et al., Nat. Neurosci., 2013, 174-182; Zhao et al., J. Clin. Invest., 2013, 4769-4780).
[0451] P2X3 channels are regulators of neuronal excitability, activated through the local release of ATP, neurotransmitters, and extracellular messengers with pro-inflammatory properties. ATP, an important chemical messenger, is excessively released by both neuronal and non-neuronal cell types under various pathological conditions (Burnstock, Front. Pharmacol., 2017, 661; Burnstock, Biochem. Pharmacol., 2017, doi:10.1016 / j.bcp.2017.07.016). Therefore, increased ATP release can lead to hyperexcitability of afferent pruritus neurons and increased sensitivity to any pruritogens pathologically released in the skin. In summary, P2X3 channels, acting through pathological ATP release, may be potential relevant targets for modulating the sensitivity of afferent neurons to pruritus sensations. Their inhibition could provide a mechanism for suppressing peripheral hypersensitivity to pruritus in various diseases, with a broad mechanism independent of pathological stimuli acting on pruritus receptors.
[0452] In some embodiments, a method for treating pruritus in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable thereof. Salts or solubilizers. In some embodiments, pruritus is associated with inflammatory skin diseases, infectious skin diseases, autoimmune skin diseases, or pregnancy-related skin diseases. In some embodiments, pruritus is associated with inflammatory skin diseases selected from: atopic dermatitis, allergic, irritant contact dermatitis, xeritis, nummular and dyshidrotic dermatitis, lichen planus, lichen sclerosus, polymorphic light eruption psoriasis, Grover's disease, mucinous deposits, mastocytosis, and urticaria. In some embodiments, pruritus is associated with infectious skin diseases selected from: Related to: fungal infections, bacterial and viral infections, scabies, lice, insect bites, and folliculitis. In some embodiments, pruritus is associated with autoimmune skin diseases selected from: Duhring's disease, bullous pemphigoid; hereditary skin diseases, Darier's disease, and Hailey-Hailey's disease. In some embodiments, pruritus is associated with pregnancy-related skin diseases selected from: eruption of pregnancy (PEP), atopic dermatitis of pregnancy, pemphigoid of pregnancy, tumor formation, and cutaneous T-cell lymphoma. In some embodiments... Pruritus is associated with nodular prurigo. In some embodiments, pruritus is associated with kidney disease or a treatment procedure for kidney disease. In some embodiments, pruritus is associated with chronic kidney disease. In some embodiments, pruritus is associated with a treatment procedure for kidney disease, wherein the treatment procedure for kidney disease is selected from hemodialysis and peritoneal dialysis. In some embodiments, pruritus is associated with a medical procedure or treatment. In some embodiments, pruritus is associated with drug treatment using drugs selected from opioids, antimalarial drugs, anticancer therapies, and epidermal growth factor receptor inhibitors.
[0453] Endometriosis
[0454] Pain associated with endometriosis is attributed to functional endometriotic lesions embedded with nerve fibers outside the uterine cavity. Afferent sensory fibers and pro-inflammatory mediators are associated with endometriosis-related pain. Specifically, women with endometriosis have elevated levels of pro-inflammatory cytokines, such as interleukin (IL)-1β, IL-6, prostaglandins (PG), tumor necrosis factor (TNF)-α, and nerve growth factor (NGF), in peritoneal fluid and endometriotic lesions. Inflammatory mediators in the inflammatory microenvironment of the endometriotic peritoneum activate nociceptive receptors on afferent neurons by stimulating sensory nerve fibers (including C- or Aδ-fibers) innervated within the endometriotic lesions, providing sensitization of sensory neurons and ultimately triggering a pain signal cascade. In some cases, anti-inflammatory agents provide pain relief. However, these drugs usually have little effect on relieving pain symptoms and may cause relapse and serious side effects (Ding et al., PloS one, 2017, 12(9), 1-17; Yuan et al., Int. J. Nanod., 2017, 8171-8183).
[0455] In extrauterine endometriotic lesions, afferent neurons are composed of C- or Aδ-fibers from the dorsal root ganglion and synapse with the spinal cord. The terminals of the C- or Aδ-fibers express receptors that respond to pro-inflammatory mediators to trigger action potentials transmitted to the CNS. A key transducer of this signaling pathway expressed by these neurons is the P2X3 cation channel. Notably, the P2X3 channel is co-expressed on the cell membranes of small and medium-diameter sensory neurons, which are key pain sensors for noxious stimuli. Furthermore, P2X3 expression is significantly higher in the endometriotic endometrium and in endometriotic lesions than in normal endometrial tissue, and both are positively correlated with endometriosis-related pain. (Han et al., Nat. Neurosci., 2013, 174-182; Vilotti et al., PLOS one, 2013, 8(11):e81138; Ding et al., PLOS one, 2017, 12(9), 1-17).
[0456] Under pathophysiological conditions, increased ATP release regulated by inflammatory mediators can lead to P2X3 activation, resulting in hyperexcitability of afferent neurons in the extrauterine endometrium and increased sensitivity to endometriosis-related pain. In summary, P2X3 channels, acting via pathological ATP release, may be potential targets for modulating the sensitivity of afferent neurons coupled with endometriosis-related pain. Their inhibition offers a pathway to alleviate pain caused by endometriosis and endometriosis-like symptoms (Yuan et al., Int. J. Nanod., 2017, 8171-8183).
[0457] In some embodiments, a method is provided for treating endometriosis, endometriosis-related pain, and endometriosis-related symptoms in mammals of need, comprising administering to the mammals of need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or pharmaceutically effective thereof. An acceptable salt or solvation. In some embodiments, a method for treating endometriosis in a mammal in need is provided, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, a method is provided for treating endometriosis-related pain in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In another aspect, a method is provided for treating endometriosis-related symptoms in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va") or a pharmaceutically acceptable salt or solvation thereof. In some embodiments, endometriosis-related symptoms are selected from dysmenorrhea, dyspareunia, dysuria, and dysdefecation.
[0458] Drug combination
[0459] This article also considers combination therapy, such as the co-administration of the disclosed compounds and additional active agents as part of a specific treatment regimen designed to provide a beneficial effect from the combined action of these therapeutic agents. The beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic synergies resulting from the combination of therapeutic agents. The combined administration of these therapeutic agents is typically carried out over a defined time period (typically weekly, monthly, or yearly, depending on the chosen combination). Combination therapy is intended to include the sequential administration of multiple therapeutic agents, i.e., each therapeutic agent is administered at different times and in a substantially simultaneous manner, or at least two therapeutic agents.
[0460] Substantial simultaneous administration is achieved, for example, by administering to the subject a single formulation or composition (e.g., tablets or capsules of each therapeutic agent in a fixed ratio) or multiple single formulations of each therapeutic agent (e.g., capsules). The therapeutic agents are administered sequentially or substantially simultaneously via any suitable route, including but not limited to oral, intravenous, intramuscular, and direct absorption through mucosal tissue. The therapeutic agents may be administered via the same or different routes. For example, the first therapeutic agent of a selected combination may be administered intravenously, while the other therapeutic agents in the combination may be administered orally. Alternatively, for example, all therapeutic agents may be administered orally or via intravenous injection.
[0461] In some embodiments, a method is provided for treating a condition associated with P2X3 activity in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (Iva"), (V), (Va), (Va'), or (Va"), further comprising administering to the mammal a One or more other agents. In some embodiments, a method for treating pain in a mammal in need is provided, the method comprising administering to the mammal a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further comprising administering to the mammal one or more other agents. In some embodiments, a method is provided for treating urinary tract conditions in mammals in need, the method comprising administering to the mammal a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further comprising administering to the mammal one or more additional agents. In some embodiments, a method is provided for treating or preventing urine loss in mammals in need, the method comprising administering to the mammal a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further comprising administering to the mammal one or more additional agents. In some embodiments, a method of treating cough in a mammal in need includes administering to the mammal a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further includes administering to the mammal one or more additional agents.In some embodiments, a method of treating pruritus in a mammal in need is provided, the method comprising administering to the mammal a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further comprising administering to the mammal one or more additional agents. In some embodiments, a method of treating pruritus in a mammal is provided. A method for treating endometriosis, endometriosis-related pain, and endometriosis-related symptoms in mammals in need, the method comprising administering to mammals a compound of formula (I), (Ia), (Ia'), (Ia"), (II), (IIa), (IIa'), (IIa"), (III), (IIIa), (IIIa'), (IIIa"), (IV), (IVa), (IVa'), (IVa"), (V), (Va), (Va'), or (Va"), and further comprising administering to mammals one or more additional agents.
[0462] In some embodiments, the additional agent is an NK-1 antagonist. In some embodiments, the NK-1 antagonist is selected from sloppitant, aprepitant, cassopitant, dappitant, epoppitant, fosapitant, raneppitant, maroppitant, netutoppitant, nolpitant, ostippitant, lorappitant, verteppitant, vorflupitant, AV-818, BIIF 1149CL, CP122,721, DNK-333, GSK-424887, L-733060, L-759274, LY-686017, M516102, and TA-5538. In some embodiments, one or more additional agents are selected from hormonal contraceptives, nonsteroidal anti-inflammatory drugs (NSAIDs), prostaglandin E synthase (PTGES) inhibitors, interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors, prostaglandin EP4 receptor antagonists, aldosterone reductase 1C3 (AKR1C3) inhibitors, and prolactin receptor (PRLR) antagonists. In some embodiments, the additional agent is a hormonal contraceptive. In some embodiments, the additional agent is a nonsteroidal anti-inflammatory drug (NSAID). In some embodiments, the additional agent is a prostaglandin E synthase (PTGES) inhibitor. In some embodiments, the additional agent is an interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor. In some embodiments, the additional agent is a prostaglandin EP4 receptor antagonist. In some embodiments, the additional agent is an aldosterone reductase 1C3 (AKR1C3) inhibitor. In some embodiments, the additional agent is a prolactin receptor (PRLR) antagonist.
[0463] Combination therapy also includes the further combined administration of the aforementioned therapeutic agents with other bioactive ingredients and non-pharmacological treatments. Where combination therapy further includes non-pharmacological treatments, these treatments may be administered at any appropriate time, provided that the combined effect of the therapeutic agents and non-pharmacological treatments is achieved. For example, where appropriate, beneficial effects may still be achieved even when non-pharmacological treatments are temporarily removed from the administration of the therapeutic agents, perhaps for several days or even weeks.
[0464] The combined components are administered to the patient simultaneously or sequentially. It should be understood that these components are present in the same pharmaceutically acceptable carrier and therefore administered simultaneously. Alternatively, the active ingredient is present in separate drug carriers, such as conventional oral dosage forms administered simultaneously or sequentially.
[0465] Example
[0466] These embodiments are provided for illustrative purposes only and are not intended to limit the scope of the claims provided herein.
[0467] List of abbreviations
[0468] As used above and throughout the description of this invention, unless otherwise specified, the following abbreviations shall be understood to have the following meanings:
[0469]
[0470]
[0471] I. Chemical Synthesis Unless otherwise specified, reagents and solvents were used as received from the commercial supplier. Hydrochloric and / or oxygen-sensitive synthetic transformations were performed using anhydrous solvents and dried glassware. Yields were not optimized. Reaction times were approximate and not optimized. Unless otherwise specified, column chromatography and thin-layer chromatography (TLC) were performed on silica gel. Spectra are expressed in ppm (δ), and coupling constants (J) are expressed in Hertz. For proton spectra, the solvent peak was used as a reference peak.
[0472] Example 1: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-fluoroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A1)
[0473]
[0474] Step 1: Cu(OTf)₂ (242 mg, 669 μmol) and CuCl (66 mg, 669 μmol) were added to a 2-Me-THF (10 mL) solution of N-Boc-(S)-2-ethynylmorpholine (989 mg, 4.68 mmol), methyl 3,5-difluoro-4-carboxymethylbenzoate (937 mg, 4.68 mmol), and 4-fluoro-2-aminopyridine (500 mg, 4.46 mmol). The mixture was stirred in N₂ at 80 °C for 16 h. The mixture was washed with saturated Na₂CO₃ and extracted with EA (10 mL × 2). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography and concentrated to give compound 1 (200 mg, 9%). LCMS (ESI, m / z): 506.0 [M+H] + . 1 H NMR (400MHz, CDCl3)8.34-8.32(m,1H),7.75-7.66(m,2H),7.24(d,J=2.4Hz,1H),6.73-6.71(m,1H),3.97(s,3H),3.78(s,2H ),3.62-3.53(m,1H),3.44-3.31(m,1H),3.01-2.95(m,2H),2.89-2.76(m,1H),2.54-2.50(m,1H),1.47(s,1H),1.42(s,9H).
[0475] Step 2: A solution of compound 1 (320 mg, 633 μmol) in 4 M HCl / dioxane (4.0 mL) was stirred at 20 °C for 0.5 h. The mixture was concentrated to obtain compound 2 (300 mg), which was a yellow oil and used in the next step without further purification. LCMS (ESI, m / z): 406.2 [M+H] + Step 3: Et3N (2.0 mmol, 285 μL) and methyl chloroformate (2.0 mmol, 160 μL) were added to a DCM (5.0 mL) solution of compound 2 (300 mg, 679 μmol) at 0 °C. The mixture was stirred at 20 °C for 0.5 h. The mixture was diluted with DCM (5 mL) and washed with H2O (30 mL). The organic layer was dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give compound 3 (140 mg, 44%). LCMS (ESI, m / z): 464.2 [M+H] + . 1H NMR(400MHz, CDCl3)8.34-8.31(m,1H),7.74-7.64(m,2H),7.26-7.21(m,1H),6.77-6.68(m,1H),3.97(s,3H) ,3.92-3.73(m,3H),3.68(s,3H),3.58-3.56(m,1H),3.38-3.37(m,1H),3.02-2.82(m,3H),2.64-2.58(m,1H).
[0476] Step 4: Add a solution of LiOH·H₂O (25 mg, 600 μmol) in H₂O (0.6 mL) to a MeOH (2.0 mL) solution of compound 3 (140 mg, 302 μmol). Stir the mixture at 20 °C for 0.5 h, adjust the pH to 2-3 by adding 1 M HCl aqueous solution, concentrate to remove MeOH, and extract the aqueous layer with CHCl₃ / IPA = 3 / 1 (2 × 2.0 mL). Dry the combined organic layers with Na₂SO₄, filter, and concentrate to obtain compound 4 (130 mg, 96%). The product can be used in the next step without further purification. LCMS (ESI, m / z): 450.1 [M+H] + .
[0477] Step 5: Add EDCI (166 mg, 868 μmol), HOBt (117 mg, 868 μmol), methylamine hydrochloride (98 mg, 1.45 mmol), and DIPEA (1.74 mmol, 300 μL) to a DCM (2.0 mL) solution of compound 4 (130 mg, 289 μmol). Stir the mixture at 20 °C for 16 h. Wash the mixture with H2O (4.0 mL), and extract the aqueous wash with DCM (2 × 2.0 mL). Dry the combined organic layers with Na2SO4, filter, and concentrate. Purify the crude product by preparative HPLC, and collect and lyophilize the fractions containing the product to give compound A1 (38 mg, 28%) as a white solid. LCMS (ESI, m / z): 463.3 [M+H] + . 1H NMR(400MHz, CDCl3)8.39-8.26(m,1H),7.49-7.36(m,2H),7.26-7.22(m,1H),7.15-6.94(m,1H),6.75-6.72(m,1H),4.00-3.7 3(m,3H),3.67(s,3H),3.56(d,J=2.6Hz,1H),3.37-3.36(m,1H),3.02(d,J=4.8Hz,3H),2.98-2.79(m,3H),2.63-2.60(m,1H).
[0478] Example 2: Synthesis of (S)-2-((7-chloro-2-(2,6-difluoro-4-(methyl-carbamoyl)-phenyl)-imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A2)
[0479]
[0480] Compound A2 was prepared from 4-chloro-2-aminopyridine by the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 479.2 [M+H] + . 1 H NMR(400MHz, CDCl3)8.29(d,J=7.6Hz,1H),7.61(d,J=1.6Hz,1H),7.46 -7.38(m,2H),6.91(s,1H),6.84-6.82(m,1H),3.98-3.72(m,3H),3.67(s,3H),3.63-3.5 1(m,1H),3.44-3.30(m,1H),3.03(d,J=4.8Hz,3H),2.98-2.81(m,3H),2.69-2.54(m,1H).
[0481] Example 3: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methoxyimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A3)
[0482]
[0483] Compound A3 was prepared from 4-methoxy-2-aminopyridine using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 475.1 [M+H] + . 1H NMR(400MHz, CDCl3)8.15(d,J=7.6Hz,1H),7.42(d,J=7.6Hz,2H),7.23-7.00(m,1H) ,6.87(d,J=2.4Hz,1H),6.58-6.55(m,1H),3.88-3.78(m,6H),3.67(s,3H),3.55(br d,J=2.0Hz,1H),3.40-3.35(m,1H),3.02(d,J=4.8Hz,3H),2.99-2.88(m,3H),2.61-2.58(m,1H).
[0484] Example 4: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A4)
[0485]
[0486] Compound A4 was prepared from 4-difluoromethyl-2-aminopyridine using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 495.3 [M+H] + . 1 H NMR (400MHz, CDCl3)8.45(br d,J=7.2Hz,1H),7.75(s,1H),7.44(d,J=7.6Hz,2H),7.00(br d,J=7.2Hz,1H),6.84-6.56(m,2H),3.86-3.79(m,3H),3.68(s,3H),3.58(br d,J=2.4Hz,1H),3.40-3.37(m,1H),3.04-3.00(m,5H),2.95-2.87(m,1H),2.65-2.62(m,1H).
[0487] Example 5: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-(trifluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A5)
[0488]
[0489] Compound A5 was prepared from 4-trifluoromethyl-2-aminopyridine using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 513.3 [M+H] + . 1H NMR (400MHz, CDCl3)8.49(d,J=7.2Hz,1H),7.94(s,1H),7.46-7.44(m,2H),7.03-7.01(m,2H),3.86-3.78(m,3H),3.68(s,3H),3.59(br d,J=2.6Hz,1H),3.40-3.34(m,1H),3.04-2.95(m,5H),2.95-2.82(m,1H),2.65-2.60(m,1H).
[0490] Example 6: Synthesis of (S)-2-((7-methyl-2-(2,3,6-trifluoro-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A6)
[0491]
[0492] Step 1: 2M LDA (13.0 mL) was added dropwise to a THF (70 mL) solution of 2,3,5-trifluorobromobenzene (5.00 g, 23.7 mmol, 2.8 mL) in N2 at -78 °C. The mixture was stirred at -78 °C for 0.5 h. Then, a THF (5 mL) solution of DMF (26.1 mmol, 2.0 mL) was added to the above reaction mixture. The resulting reaction mixture was stirred at -78 °C for 15 min, then heated to 20 °C and stirred for 1 h. The mixture was quenched by adding saturated NH4Cl (200 mL) aqueous solution and extracted with EA (100 mL × 2). The combined extracts were washed with brine (150 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give 2,3,5-trifluoro-4-formyl-bromobenzene (4.50 g, 79%). 1 H NMR (400MHz, CDCl3) 10.29 (d, J = 0.8 Hz, 1H), 7.29 (td, J = 2.3, 4.6 Hz, 1H), 7.26 (d, J = 2.4 Hz, 1H).
[0493] Step 2: N-Boc-(S)-2-ethynylmorpholine (2.05 g, 9.71 mmol), 2,3,5-trifluoro-4-carboxyloyl-bromobenzene (2.32 g, 9.71 mmol), and 4-methyl-2-aminopyridine (1.00 g, 9.25 mmol) were reacted as described in Step 1 of Example 1 to give (S)-2-((2-(4-bromo-2,3,6-trifluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid tert-butyl ester (5) (440 mg, 8%). LCMS (ESI, m / z): 542.0 [M+H]+ . 1 H NMR (400MHz, CDCl3)8.19(d,J=7.1Hz,1H),7.38(s,1H),7.24(dt,J=2.5,5.4Hz,1H),6.69(br d,J=6.8Hz,1H),3.99-3.71(m,3H),3.60-3.49(m,1H),3.44-3.29(m,1H),3.06-2.91(m,2H),2.83(br d, J=6.7Hz, 1H), 2.54 (dd, J=10.7, 13.0Hz, 1H), 2.42 (s, 3H), 1.43 (s, 9H).
[0494] Step 3: To a solution of (S)-2-((2-(4-bromo-2,3,6-trifluorophenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid tert-butyl ester (5) (110 mg, 0.20 mmol) in MeOH (2.0 mL) and DMSO (2.0 mL), Pd(OAc)₂ (5 mg, 0.02 mmol), DPPF (23 mg, 0.04 mol), and TEA (0.61 mmol, 85 μL) were added. The mixture was then stirred at 60 °C under CO₂ (50 psi) for 16 h. The mixture was diluted with water (30 mL) and extracted with EA (15 mL × 2). The combined extracts were washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography to yield (S)-2-((7-methyl-2-(2,3,6-trifluoro-4-(methoxycarbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid tert-butyl ester (6) (80 mg, 66%). LCMS (ESI, m / z): 520.3 [M+H] + . 1H NMR(400MHz,CDCl3)8.19(br d,J=7.1Hz,1H),7.57(ddd,J=2.1,5.2,9.2Hz,1H),7.39(s,1H),6.75-6.64(m,1H),4.00(s,3H),3.91-3.66(m,3H),3.61-3. 50(m,1H),3.45-3.31(m,1H),3.09-2.92(m,2H),2.89-2.77(m,1H),2.54(dd,J=10.8,13.0Hz,1H),2.43(s,3H),1.43(s,9H). Steps 4-7: Compound A6 was prepared from (S)-2-((7-methyl-2-(2,3,6-trifluoro-4-(methoxycarbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid tert-butyl ester (6) by the method described in steps 2-5 of Example 1. LCMS (ESI, m / z): 477.3 [M+H] + . 1 HNMR(400MHz, CDCl3)8.18(d,J=7.0Hz,1H),7.73(ddd,J=2.1,5.6,9.6Hz,1H),7.39(s,1H),6.78-6.66(m,2H),4.03-3.72(m,3H),3.68(s,3H),3.56(br dd,J=3.7,6.9Hz,1H),3.44-3.32(m,1H),3.09(d,J=4.4Hz,3H),3.06-2. 96(m,2H),2.95-2.83(m,1H),2.61(dd,J=11.0,12.6Hz,1H),2.43(s,3H).
[0495] Example 7: Synthesis of methyl (S)-2-((7-chloro-2-(2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A7)
[0496]
[0497] Step 1: SOCl2 (0.8 mL, 11.0 mmol) was added dropwise to a MeOH (10 mL) solution of 4-formyl-3-methylbenzoic acid (900 mg, 5.48 mmol) at 0 °C. The mixture was stirred at 30 °C for 10 h. The mixture was concentrated, and the residue was purified by column chromatography to give methyl 4-formyl-3-methylbenzoate (510 mg, 52%) as a white solid. 1H NMR (400MHz, CDCl3) 10.35 (s, 1H), 8.00 (d, J = 7.9Hz, 1H), 7.95 (s, 1H), 7.87 (d, J = 7.9Hz, 1H), 3.96 (s, 3H), 2.72 (s, 3H).
[0498] Steps 2-6: Compound A7 was prepared by means of the methods described in steps 1-5 of Example 1, starting with N-Boc-(S)-2-ethynylmorpholine, methyl 4-formyl-3-methylbenzoate, and 4-chloro-2-aminopyridine. LCMS (ESI, m / z): 457.1 [M+H] + . 1 H NMR (400MHz, CDCl3)8.20(br d,J=7.3Hz,1H),7.71(d,J=0.7Hz,1H),7.66-7.57(m,2H),7.31(d,J=7.9Hz,1H),6.82(dd,J=2.1,7.3Hz,1H),6.46(br d,J=3.9Hz,1H),4.03-3.70(m,3H),3.66(s,3H),3.48(br d,J=3.5Hz,1H),3.36(br t,J=11.6Hz,1H),3.03(d,J=4.9Hz,3H),2.99-2.92(m,2H),2.92-2.80(m,1H),2.52(br t,J=11.6Hz,1H),2.29(s,3H).
[0499] Example 8: Synthesis of methyl (S)-2-((2-(2-chloro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A8)
[0500]
[0501] Compound A8 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 4-formyl-3-chlorobenzoate, and 4-methyl-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 457.3 [M+H] + . 1H NMR(400MHz,CDCl3)8.12(br d,J=7.1Hz,1H),7.91(d,J=1.7Hz,1H),7.70(dd,J=1.7,7.9Hz,1H),7.55(d,J=7.9Hz,1H),7.38(s,1H),6.69(dd,J=1.4,7.0Hz,1H),6.41(br s,1H),3.96-3.70(m,3H),3.66(s,3H),3.51(br dd,J=2.1,5.7Hz,1H),3.42-3.31(m,1H),3.05(d,J=4.9Hz,3H),3.03-2.99(m,2H),2.93-2.81(m,1H),2.52(br t,J=11.9Hz,1H),2.43(s,3H).
[0502] Example 9: Synthesis of methyl (S)-2-((2-(2-chloro-4-(methylcarbamoyl)phenyl)-7-chloroimidazolo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A9)
[0503]
[0504] Compound A9 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 4-formyl-3-chlorobenzoate, and 4-chloro-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 477.2 [M+H] + . 1 H NMR(400MHz,CDCl3)8.24(br d,J=7.4Hz,1H),7.92(d,J=1.5Hz,1H),7.71(dd,J=1.6,7.9Hz,1H),7.62(d,J=2.0Hz,1H),7.52(d,J=8.0Hz,1H),6.84(dd,J=2.0,7.4Hz,1H),6.39(br d,J=3.8Hz,1H),3.97-3.72(m,3H),3.67(s,3H),3.58-3.47(m,1H),3.44-3.30(m,1H),3.05(d,J=4.8Hz,3H),3.00(br d,J=5.8Hz,2H),2.88(br s, 1H), 2.63-2.49 (m, 1H).
[0505] Example 10: Synthesis of methyl (S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A10)
[0506]
[0507] Step 1: TEA (11.9 mmol, 1.7 mL, 5.0 equivalence) and EDCI (684 mg, 3.57 mmol) were added to an 8 mL solution of 3-fluoro-4-formylbenzoic acid (400 mg, 2.38 mmol), methylamine hydrochloride (321 mg, 4.76 mmol), and HOBt (482 mg, 3.57 mmol) in DMF at 0 °C. The mixture was heated to 20 °C and stirred for 16 h. The mixture was filtered, and the filter cake was washed with EA (20 mL). The combined filtrates were washed with brine (30 mL), and the organic layer was dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography to give 3-fluoro-4-formyl-N-methylbenzamide (400 mg, 93%) as a white solid. 1 HNMR (400MHz, DMSO-d6) 10.24 (s, 1H), 8.72 (d, J = 3.6Hz, 1H), 7.92 (d, J = 7.4Hz, 1H), 7.83-7.75 (m, 2H), 2.81 (d, J = 4.6Hz, 3H).
[0508] Steps 2-4: Compound A10 was prepared by means of the methods described in steps 1-3 of Example 1, starting with N-Boc-(S)-2-ethynylmorpholine, 3-fluoro-4-formyl-N-methylbenzamide, and 4-methyl-2-aminopyridine. LCMS (ESI, m / z): 441.2 [M+H] + . 1 H NMR(400MHz, CDCl3)8.26(s,1H),7.74-7.57(m,3H),7.44(s,1H),6.78-6.64(m,2H),4.01-3.76(m,3H),3.68(s,3H ),3.65-3.57(m,1H),3.37-3.34(m,1H),3.03(d,J=4.8Hz,5H),2.97-2.83(m,1H),2.64-2.59(m,1H),2.44(s,3H).
[0509] Example 11: Synthesis of methyl (S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-chloroimidazolo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A11)
[0510]
[0511] Compound A11 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 4-formyl-3-fluorobenzoate, and 4-chloro-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 461.1 [M+H] + . 1 H NMR(400MHz, CDCl3)8.33(d,J=7.2Hz,1H),7.77-7.73(m,1H),7.69-7.59(m,3H),6.84-6.82(m,1H),6.45(d,J=4.6Hz,1H),4 .06-3.78(m,3H),3.71(s,3H),3.66(d,J=2.8Hz,1H),3.41-3.40(m,1H),3.13-3.03(m,5H),2.99-2.87(m,1H),2.67(s,1H).
[0512] Example 12: Synthesis of (S)-2-((2-(5-fluoro-2-methyl-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A12)
[0513]
[0514] Compound A12 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 2-fluoro-4-formyl-5-methylbenzoate, and 4-methyl-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 454.9 [M+H] + . 1 HNMR(400MHz,CDCl3)8.07(br d,J=6.8Hz,1H),8.02(d,J=8.0Hz,1H),7.36(s,1H),7.12(d,J=12.4Hz,1H),6.87-6.75(m,1 H),6.70(dd,J=1.4,7.0Hz,1H),4.00-3.73(m,3H),3.67(s,3H),3.56-3.45(m,1H),3.37(br t,J=9.8Hz,1H),3.11-3.04(m,3H),3.04-2.83(m,3H),2.51(dd,J=10.6,13.1Hz,1H),2.43(s,3H),2.28(s,3H).
[0515] Example 13: Synthesis of (S)-2-((7-chloro-2-(5-fluoro-2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A13)
[0516]
[0517] Compound A13 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 2-fluoro-4-formyl-5-methylbenzoate, and 4-chloro-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 475.2 [M+H] + . 1 HNMR (400MHz, CDCl3)8.18(br d,J=7.2Hz,1H),8.03(d,J=8.1Hz,1H),7.61(d,J=1.5Hz,1H),7.10(d,J=12.2Hz,1H),6.85(dd,J=2.1,7.3Hz,1H),6.78(br dd,J=4.5,12.0Hz,1H),6.24(s,1H),3.97-3.77(m,3H),3.68(s,3H),3.55-3.45(m,1H),3.38(br t,J=10.9Hz,1H),3.07(d,J=4.2Hz,3H),3.03-2.94(m,2H),2.93-2.83(m,1H),2.60-2.51(m,1H),2.27(s,3H).
[0518] Example 14: Synthesis of methyl 2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-1,4-oxazacycloheptan-4-carboxylate (A14)
[0519]
[0520] Step 1: A solution of NaHCO3 (6.0 g, 71.6 mmol) in H2O (20 mL) was added to a THF (80 mL) solution of (1,4-oxazacycloheptan-2-yl)methanol (4.0 g, 23.9 mmol) and Boc2O (7.8 g, 35.8 mmol). The mixture was stirred at 20 °C for 16 h, then diluted with H2O (40 mL) and extracted with EA (40 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography and concentrated to give compound 17 (5 g, 90%). LCMS (ESI, m / z): 132.3 [M-100] + .1 H NMR(400MHz,DMSO-d6)4.69-4.66(m,1H),3.94-3.93(m,1H),3.70-3.69(m,1H),3.59 -3.35(m,4H),3.31-3.20(m,2H),3.08-2.89(m,1H),1.81-1.69(m,2H),1.40(s,9H).
[0521] Step 2: Add 2-iodobenzoic acid (3.6 g, 13 mmol) to a 20 mL solution of compound 17 (1.5 g, 6.49 mmol). Stir the mixture at 80 °C for 1 h. Filter the mixture and concentrate the filtrate to obtain compound 18 (1.4 g, 94%), a colorless oil, which is used in the next step without further purification. 1 H NMR(400MHz, CDCl3)9.64(d,J=13.4Hz,1H),4.16-4.03(m,2H),4.00-3.90(m ,1H),3.67-3.55(m,2H),3.47-3.41(m,2H),2.00-1.85(m,2H),1.44(s,9H).
[0522] Step 3: Add K₂CO₃ (2.1 g, 15.3 mmol) to a MeOH (10 mL) solution of compound 18 (1.4 g, 6.1 mmol) and stir the mixture at 20 °C for 10 min. Then, add a MeOH (5 mL) solution of 1-diazo-1-dimethoxyphosphoryl-prop-2-one (1.2 g, 6.11 mmol). Stir the mixture at 20 °C for 1 h. Dilute the mixture with H₂O until the solid dissolves, and extract with EA (5 mL × 2). Dry the combined organic extracts with Na₂SO₄, filter and concentrate, and purify the residue by silica gel chromatography to give compound 19 (500 mg, 36%). 1 HNMR(400MHz, CDCl3)4.40-4.39(m,1H),4.14-3.77(m,3H),3.60-3.58(m,1H ),3.33-3.03(m,2H),2.48(d,J=3.0Hz,1H),2.01-1.78(m,2H),1.45(s,9H).
[0523] Steps 4-8: Compound A14 was prepared by means of the method described in steps 1-5 of Example 1, starting with N-Boc-2-ethynyl-1,4-oxazacycloheptane (14), methyl 3,5-difluoro-4-carboxymethylbenzoate, and 4-methylpyridin-2-amine. LCMS (ESI, m / z): 473.0 [M+H]+ . 1 H NMR(400MHz, CDCl3)8.29-8.16(m,1H),7.44-7.26(m,4H),6.69-6.66(m,1H),3.91-3.80(m,1H),3.69-3.57( m,5H),3.35-3.14(m,2H),3.01(d,J=4.6Hz,3H),2.98-2.82(m,3H),2.42(d,J=2.4Hz,3H),1.91-1.79(m,3H).
[0524] Step 9: Compound A14 was separated into R- and S-isomers by supercritical fluid chromatography (SFC). Racemic A14 (40 mg) was separated by chiral SFC on a Daicel Chiralpak AD-H column (250 × 30 mm, 5 μm particle size) and eluted with 30% IPA (containing 0.1% NH3 aqueous solution) in supercritical CO2 at a flow rate of 60 g / min, yielding two enantiomers, A14 (PEAK 1) and A14. The sample was dissolved in MeCN (1.0 mL) and H2O (5.0 mL) and lyophilized (15 mg each). Individual A14 enantiomers were isolated, but absolute stereochemistry was not determined. LCMS (SFC peak 1): M + H = 473.0.
[0525] LCMS (SFC peak 2): M+H=473.2.
[0526] 1 H NMR (400MHz, CDCl3) (SFC peak 1): 8.22-8.20(m,1H),7.48-7.33(m,3H),7.23-6.98(m,1H),6.68-6.65(m,1H),3.97-3 .57(m,7H),3.34-3.14(m,2H),3.02(d,J=4.6Hz,3H),2.99-2.83(m,3H),2.42(d,J=1.6Hz,3H),1.88-1.77(m,2H).
[0527] 1 H NMR (400MHz, CDCl3) (SFC peak 2): 8.29-8.17(m,1H),7.69-7.30(m,4H),6.69-6.66(m,1H),3.97- 3.53(m,7H),3.36-3.16(m,2H),3.08-2.82(m,6H),2.42(d,J=1.6Hz,3H),1.80-1.67(m,2H).
[0528] Example 15: Synthesis of methyl 6-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)-1,4-oxazacycloheptan-4-carboxylate (A16)
[0529] EDCI (50.5 g, 264 mmol) was added to a solution of 4-bromo-2,6-difluorobenzoic acid (50 g, 211 mol), N,O-dimethylhydroxylamine hydrochloride (22.6 g, 232.1 mmol), DMAP (2.6 g, 21.1 mmol), and DIEA (316 mmol, 55 mL) in 600 mL of DCM at 0 °C. The mixture was stirred at 20 °C for 16 h and concentrated to remove DCM. The solution was washed with H2O (400 mL) and extracted with EA (150 mL × 2). The combined organic layers were dried over Na2SO4, filtered, concentrated, and the residue was purified by column chromatography to give 4-bromo-2,6-difluoro-N-methoxy-N-methylbenzamide (39 g, 66%) as a white solid. 1 H NMR (400MHz, CDCl3) 7.14 (d, J = 6.6Hz, 2H), 3.54 (s, 3H), 3.38 (s, 3H).
[0530] At 0 °C, magnesium methyl bromide (3 M, 54 mL) was added dropwise to a THF (100 mL) solution of 35 g (125 mmol) of 4-bromo-2,6-difluoro-N-methoxy-N-methylbenzamide in N2. The mixture was stirred for 0.5 minutes at 25 °C, then poured into a saturated NH4Cl solution (300 mL) and extracted with EA (40 mL × 2). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography. The eluent was concentrated to give 28 g of 1-(4-bromo-2,6-difluorophenyl)ethyl-1-one as a colorless oil. 1 H NMR (400MHz, CDCl3)7.22-7.08(m,2H),2.65-2.50(m,3H).
[0531] Tetrabutylammonium tribromide (63.2 g, 131.1 mmol) was added to a MeCN (350 mL) solution of 1-(4-bromo-2,6-difluorophenyl)ethyl-1-one (28 g, 119 mmol). The mixture was stirred at 25 °C for 2 h. The mixture was diluted with brine (500 mL) and extracted with EA (200 mL × 2). The combined organic layers were dried over Na₂SO₄, filtered, concentrated, and the residue was purified by column chromatography to give 2-bromo-1-(4-bromo-2,6-difluorophenyl)ethyl-1-one (35 g, 94%) as a colorless oil.1 H NMR (400MHz, CDCl3) 7.71-7.67 (m, 2H), 4.73 (d, J = 1.0Hz, 2H).
[0532] To a solution of 2-bromo-1-(4-bromo-2,6-difluorophenyl)ethyl-1-one (24 g, 76.5 mmol) and 4-methyl-2-aminopyridine (9.9 g, 91.7 mmol) in EtOH (250 mL), Na₂CO₃ (16.2 g, 153 mmol) was added. The mixture was heated to 120 °C in N₂ for 2 h. The mixture was combined with a second reaction batch and concentrated to remove EtOH. The residue was washed with H₂O (200 mL) and extracted with EA (100 mL × 2). The combined organic layers were dried over Na₂SO₄, filtered, concentrated, and the residue was purified by column chromatography to give 2-(4-bromo-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridine (20 g) as a brown solid. LCMS (ESI, m / z): 322.9 [M+H] + . 1 ¹H NMR (400 MHz, CDCl₃) 8.01 (d, J = 7.0 Hz, 1H), 7.83 (s, 1H), 7.43 (s, 1H), 7.24–7.09 (m, 2H), 6.64 (d, J = 6.8 Hz, 1H), 2.39 (s, 3H). In N₂, Pd(OAc)₂ (1.4 g, 6.2 mmol) was added to a solution of 2-(4-bromo-2,6-difluorophenyl)-7-methylimidazo[1,2-a]pyridine (20 g, 61.9 mmol), TEA (187 mmol, 26 mL), DPPF (6.9 g, 12.4 mmol) in MeOH (300 mL) and DMSO (300 mL). The suspension was degassed under vacuum and purged several times with CO. The mixture was stirred at 80 °C for 6 h under CO (50 psi). The mixture was filtered, and the filtrate was concentrated to remove MeOH. The residue was then washed with H₂O (2.0 L) and extracted with EA (300 mL × 3). The combined organic layers were dried over Na₂SO₄, filtered, and concentrated to remove EA. The precipitated solid was then filtered and concentrated. The concentrated filtrate was purified by silica gel chromatography, and the product was combined with the precipitated solid to give methyl 3,5-difluoro-4-(7-methylimidazo[1,2-a]pyridin-2-yl)benzoate (15 g, 80%) as a yellow solid. LCMS (ESI, m / z): 303.1 [M+H] + . 1H NMR (400MHz, CDCl3) 8.03 (d, J = 6.8 Hz, 1H), 7.94 (s, 1H), 7.73-7.62 (m, 2H), 7.45 (s, 1H), 6.67-6.65 (m, 1H), 3.94 (s, 3H), 2.40 (s, 3H).
[0533] Br2 (69.5 mmol, 3.6 mL) was added to a stirred suspension of methyl 3,5-difluoro-4-(7-methylimidazo[1,2-a]pyridin-2-yl)benzoate (14 g, 46.3 mmol) in EtOH (280 mL) at 0 °C. The mixture was stirred at 20 °C for 0.5 h and then concentrated to give methyl 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzoate (25 g) as a yellow solid, which was used directly in the next step without further purification. LCMS (ESI, m / z): 383.2 [M+H] + . 1 HNMR (400MHz, CDCl3) 8.73 (d, J = 6.6 Hz, 1H), 7.99-7.76 (m, 3H), 7.56 (d, J = 5.4 Hz, 1H), 4.00 (s, 3H), 2.68 (s, 3H).
[0534] A solution of methyl 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzoate (19 g, 49.9 mmol) in MeOH (240 mL) was added to a solution of LiOH·H₂O (8.4 g, 200 mmol) in H₂O (80 mL). The mixture was stirred at 20 °C for 0.5 h, then concentrated to remove MeOH, and the residue was adjusted to pH 2 with HCl (1 M) aqueous solution. A white solid precipitate was filtered to give 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzoic acid (14 g). LCMS (ESI, m / z): 369.0 [M+H] + . 1 H NMR (400MHz, CDCl3) 14.55-12.79 (m, 1H), 8.33 (d, J = 7.0Hz, 1H), 7.73 (d, J = 7.8Hz, 2H), 7.50 (s, 1H), 7.03-7.01 (m, 1H), 2.42 (s, 3H).
[0535] To a DMF (150 mL) solution of 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluorobenzoic acid (14 g, 38.1 mmol), DIEA (190.7 mmol, 33.2 mL) and HATU (43.5 g, 114.4 mmol) were added, followed by methylamine hydrochloride (7.7 g, 114.40 mmol). The mixture was stirred at 25 °C for 1 h. The mixture was added to H₂O (1 L), and the solid precipitate was filtered off. The solid was ground with EA (30 mL) at 25 °C for 10 min and filtered off. The filter cake was concentrated to give 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (10 g, 69%) as a yellow solid. LCMS(ESI,m / z):380.2[M+H] + . 1 H NMR(400MHz, CDCl3)8.73(d,J=4.4Hz,1H),8.32(d,J=7.0Hz,1H),7.69(d,J=8 .3Hz,2H),7.49(s,1H),7.02-7.00(m,1H),2.83(d,J=4.6Hz,3H),2.42(s,3H).
[0536]
[0537] Step 1: A solution of t-BuOH OsO4 [11.92 mg, 2.5% wt (prepared by dissolving 0.25 g of OsO4 in 9.75 g of t-BuOH)] was added to a mixture of tert-butyl 6-methylene-1,4-oxazacycloheptan-4-carboxylate (1.30 g, 6.10 mmol) in THF (13 mL) and H2O (13 mL). The mixture was stirred at 25 °C for 0.5 h, then NaIO4 (3.91 g, 18.29 mmol) was added and the mixture was stirred at 25 °C for 16 h. The mixture was diluted with H2O (50 mL) and extracted with EA (20 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography and the eluent was concentrated to give compound 24 (830 mg, 61%) as a colorless oil. LCMS(ESI, m / z): 160.2 [M-56] + .
[0538] Step 2: The flask containing (bromomethyl)triphenylphosphine bromide (3.36 g, 7.71 mmol) was degassed under vacuum and then cooled to -40 °C in N2. THF (8 mL) was added, followed by KHMDS (1 M, 7.7 mL) in N2. The resulting yellow suspension was stirred at -40 °C for 0.5 h. Then, a THF (2 mL) solution of compound 24 (830 mg, 3.86 mmol) was added. The resulting brown suspension was warmed to 25 °C and stirred at 25 °C for 0.5 h. The mixture was quenched with saturated NH4Cl and extracted with EA (30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography to give compound 25 (1 g, 88%). LCMS (ESI, m / z): 192.0 [M-100] + .
[0539] Step 3: A mixture of P(Cy)3 (0.21 mmol, 67 μL) and Pd(dppf)Cl2 (75 mg, 0.10 mmol) in DMSO (10.0 mL) was stirred in N2 for 10 min at 25 °C. Then, a solution of bis(pinacol)diboron (1.74 g, 6.85 mmol) in DMSO (30 mL), KOAc (1.01 g, 10.3 mmol), and compound 25 (1.00 g, 3.42 mmol) were added sequentially. The mixture was heated in N2 to 80 °C for 12 h. It was then cooled, diluted with H2O (100 mL), and extracted with EA (30 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography to give compound 26 (820 mg, 61%). LCMS (ESI, m / z): 284.1 [M+H] + . 1 H NMR(400MHz, CDCl3)5.48-5.25(m,1H),4.64-4.32(m,2H),4.18-4.08(m,2H), 3.80-3.67(m,2H),3.59-3.47(m,2H),1.52-1.42(m,9H),1.32-1.21(m,24H).
[0540] Step 4: Pd(PPh3)4 (182 mg, 0.16 mmol) was added to a mixture of 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (600 mg, 1.58 mmol), compound 26 (803 mg, 2.37 mmol), and K2CO3 (436 mg, 3.16 mmol) in N2 with H2O (3 mL) and dioxane (15 mL). The mixture was stirred at 90 °C for 12 h. The mixture was diluted with H2O (30 mL) and extracted with EA (25 mL × 3). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography to give compound 27 (450 mg, 50%). LCMS (ESI, m / z): 513.3 [M+H] + .
[0541] Step 5: 10% Pd / C (680 mg) and ammonium formate (418 mg, 6.6 mmol) were added to a solution of compound 27 (340 mg, 663 μmol) in EtOH (70 mL). The mixture was then stirred at 20 °C for 16 h. The mixture was filtered and concentrated, and the residue was purified by preparative HPLC. The eluent was extracted with EA (20 mL × 2), dried over Na₂SO₄, filtered, and concentrated to give compound 28 (270 mg, 77%). LCMS (ESI, m / z): 515.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.03-7.89(m,1H),7.40(br d,J=4.0Hz,3H),7.04-6.92(m,1H),6.74(br s,1H),3.77-3.46(m,5H),3.42-3.15(m,3H),3.03(d,J=4.8Hz,3H),2.99 -2.70(m,3H),2.44(s,3H),2.33-2.15(m,1H),1.44(s,5H),1.32(s,5H).
[0542] Steps 6 and 7: Starting with compound 28, compound A16 was prepared by the methods described in steps 2 and 3 of Example 1. LCMS (ESI, m / z): 473.2 [M+H] + . 1H NMR(400MHz, DMSO-d6)8.70(br d,J=4.5Hz,1H),8.36(brt,J=6.4Hz,1H),7.66(br d,J=7.7Hz,2H),7.37(s,1H),6.87(d,J=7.0Hz,1H),3.62-3.44(m,6H),3.44-3. 36(m,2H),3.26-3.08(m,2H),3.01-2.87(m,1H),2.82(d,J=4.5Hz,3H),2.80(br d,J=4.6Hz,2H),2.39(s,3H),2.10(br s,1H).
[0543] Step 8: As described in Step 9 of Example 14, compound A16 was resolved into R-isomers and S-isomers by supercritical fluid chromatography, yielding two enantiomers, A16(peak 1) and A16(peak 2). Individual A16 enantiomers were isolated, but their absolute stereochemistry was not determined. LCMS (SFC peak 1): M+H = 473.2.
[0544] LCMS (SFC peak 2): M+H=473.2.
[0545] 1 H NMR (400MHz, DMSO-d6) (SFC peak 1): 8.69 (br d, J = 4.5Hz, 1H), 8.37 (br t, J = 6.2Hz, 1H), 7.66 (br d, J = 7.6Hz, 2H), 7.38 (s, 1H), 6.87 (br d,J=6.8Hz,1H),3.60-3.46(m,6H),3.37(s,2H),3.25-3.10(m,2H),2.99-2.88(m,1H),2.84-2.71(m,5H),2.39(s,3H),2.16-2.04(m,1H)
[0546] 1 H NMR (400MHz, DMSO-d6) (SFC peak 2): 8.70 (br d, J=4.6Hz, 1H), 8.37 (br t, J=6.5Hz, 1H), 7.66 (br d, J=7.9Hz, 2H), 7.38 (br s, 1H), 6.87 (br d,J=7.0Hz,1H),3.62-3.43(m,6H),3.37(br s,2H),3.26-3.08(m,2H),3.01-2.87(m,1H),2.86-2.69(m,5H),2.39(s,3H),2.18-2.02(m,1H).
[0547] Example 16: Synthesis of methyl 3-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)azacycloheptane-1-carboxylate (A17)
[0548]
[0549] Steps 1 and 2: Compound 30 was prepared from tert-butyl 3-oxazacycloheptan-1-carboxylate (4.60 g, 10.6 mmol) in 33% yield using the method described in step 2 of Example 15, and further converted to compound 31 (410 mg, 41%) using the method described in step 3 of Example 15, isolated as a yellow oil. LCMS (ESI, m / z): 338.3 [M+H] + .
[0550] Step 3: Using the method described in Step 4 of Example 15, compound 31 (404 mg, 1.20 mmol, 1.30 equivalents) was coupled with 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (350 mg, 921 μmol, 1.00 equivalents) to obtain compound 32 (300 mg, 48%). LCMS (ESI, m / z): 511.2 [M+H] + .
[0551] Step 4: Compound 32 (280 mg, 548 μmol) was reduced using the method described in Step 5 of Example 15 to obtain compound 33 (250 mg, 84%). LCMS (ESI, m / z): 513.3 [M+H] + . 1 H NMR(400MHz,DMSO-d6)8.04-7.81(m,1H),7.42(br d,J=7.0Hz,3H),7.11-6.90(m,1H),6.75(dd,J=1.3,7.1Hz,1H),3.79-3.60(m,1H),3.57-3.42(m,1H) ,3.05-2.87(m,5H),2.79-2.58(m,2H),2.56-2.46(m,1H),2.44(d,J=2.4Hz,3H),1.51-1.14(m,16H).
[0552] Steps 5 and 6: Compound A17 was prepared from compound 33 using the methods described in steps 2 and 3 of Example 1. LCMS (ESI, m / z): 471.2 [M+H] + . 1H NMR (400MHz, DMSO-d6)8.69(br d,J=4.5Hz,1H),8.33(br t,J=6.5Hz,1H),7.66(br d,J=7.8Hz,2H),7.37(br s,1H),6.86(br d,J=7.0Hz,1H),3.58-3.46(m,2H),3.30(s,3H),3.13-2.97(m,1H),2.82(d,J=4.5Hz,3H) ,2.79-2.64(m,3H),2.38(s,3H),1.98-1.78(m,1H),1.68-1.32(m,5H),1.11-0.89(m,3H).
[0553] Step 7: As described in Step 9 of Example 14, Compound 17 (100 mg) was resolved into R- and S-isomers by chiral SFC on a Daicel Chiralpak AD-H column (250 × 30 mm, 5 μm particle size). The fractions were eluted with 40% MeOH (0.1% NH3 aqueous solution) in supercritical CO2 to give two enantiomers: A17 (peak 1) (28 mg) and (S)-A17 (peak 2) (39 mg). Individual A17 enantiomers were isolated, but absolute stereochemistry was not determined.
[0554] LCMS (SFC peak 1): M+H=471.2.
[0555] LCMS (SFC peak 2): M+H=471.2.
[0556] 1 H NMR (400MHz, DMSO-d6) (SFC peak 1): 8.69 (q, J = 4.2Hz, 1H), 8.33 (t, J = 6.9Hz, 1H), 7.66 (br d, J = 7.9Hz, 2H), 7.37 (br s,1H),6.91-6.82(m,1H),3.51(s,2H),3.45-3.37(m,1H),3.30(br s,3H),3.11-2.96(m,1H),2.82(d,J=4.5Hz,3H),2.79-2.65(m,3H),2.39(s,3H),2.01-1.79(m,2H),1.70-1.32(m,5H),1.02-0.91(m,2H).
[0557] 1H NMR (400MHz, DMSO-d6) (SFC peak 2): 8.69 (br d, J=4.6Hz, 1H), 8.33 (br t, J=6.6Hz, 1H), 7.66 (br d, J=7.7Hz, 2H), 7.37 (br s, 1H), 6.86 (br d,J=7.0Hz,1H),3.62-3.48(m,2H),3.30(br s,2H),3.11-2.96(m,1H),2.82(d,J=4.4Hz,3H),2.79(br s,3H),2.39(s,3H),2.06-1.79(m,2H),1.72-1.31(m,5H),1.06-0.89(m,2H).
[0558] Example 17: Synthesis of methyl 4-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)azacycloheptane-1-carboxylate (A18)
[0559]
[0560] Steps 1-6: Compound A18 was prepared from tert-butyl 4-oxozylidene-1-carboxylate via the method described in steps 1-6 of Example 16. LCMS (ESI, m / z): 471.2 [M+H] + . 1 H NMR(400MHz, CDCl3)7.85(d,J=7.1Hz,1H),7.46-7.35(m,3H),6.81-6.69(m,2H),3.65(s,3H),3.61-3.18(m,3H) ,3.04(d,J=4.8Hz,4H),2.86-2.68(m,2H),2.44(s,3H),1.62-1.53(m,2H),1.44-1.14(m,4H),1.10-0.93(m,1H).
[0561] Step 7: Compound A18 (35 mg) was separated by chiral HPLC on a Daicel Chiralpak IG column (250 × 30 mm, 5 μm particle size), eluted with 30% EtOH (0.1% NH3 aqueous solution) in heptane at a flow rate of 70 g / min, yielding two enantiomers, A18(peak 1) (11 mg) and A18(peak 2) (9 mg). Individual A18 enantiomers were isolated, but their absolute stereochemistry was not determined.
[0562] LCMS (SFC peak 1): M+H=471.2.
[0563] LCMS (SFC peak 2): M+H=471.2.
[0564] 1 H NMR (400MHz, MeOD) (SFC peak 1): 8.47 (dd, J=3.7, 7.0Hz, 1H), 7.71-7.61 (m, 2H), 7.53 (br s, 1H), 7.15 (br t,J=5.3Hz,1H),3.61(d,J=2.6Hz,3H),3.55-3.44(m,1H),3.42-3.34(m,2H),3.17-3.06(m,1H),2.96(s,3H),2.9 2(dd,J=1.8,7.5Hz,2H),2.54(s,3H),1.87-1.57(m,4H),1.51-1.35(m,1H),1.30-1.16(m,1H),1.14-0.99(m,1H).
[0565] 1 H NMR (400MHz, MeOD) (SFC peak 2): 8.53 (dd, J = 3.5, 7.2Hz, 1H), 7.71-7.64 (m, 2H), 7.58 (s, 1H), 7.22 (br t,J=5.3Hz,1H),3.61(d,J=2.2Hz,3H),3.56-3.44(m,1H),3.42-3.32(m,2H),3.18-3.06(m,1H),2.96(s,3H),2.95-2 .92(m,2H),2.57(s,3H),1.91-1.56(m,4H),1.50-1.35(m,1H),1.25(ddd,J=3.6,6.7,14.1Hz,1H),1.15-1.00(m,1H).
[0566] Example 18: Synthesis of methyl (S)-3-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)piperidine-1-carboxylate ((S)-A19)
[0567] Step 1: Add 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (50 mg, 0.13 mmol), (S)-3-(bromomethyl)piperidin-1-carboxylic acid tert-butyl ester (48 mg, 0.17 mmol), Ir[dF(CF3)ppy]2(dtbpy)(PF6) (2 mg, 1.32 μmol), NiCl2·dtbbpy (0.3 mg, 0.66 μmol), TTMSS (0.13 mmol, 40 μL), LiOH (32 mg, 1.32 mmol) in DMA (0.75 mL), and toluene (0.75 mL) to an 8 mL vial equipped with a stir bar. Seal the vial under N2, stir, and irradiate with a 34 W blue LED lamp (7 cm away). Maintain the reaction temperature at 25 °C for 16 h using a cooling fan. The crude product was purified by preparative HPLC to obtain compound 40 (15 mg, 30%) as a white solid.
[0568] Steps 2 and 3: Starting with compound 40, compound (S)-A19 was prepared by the methods described in steps 2 and 3 of Example 1. LCMS (ESI, m / z): 457.2 [M+H] + . 1 H NMR(400MHz, DMSO-d6)7.86(d,J=7.0Hz,1H),7.40(d,J=7.4Hz,3H),7.11-6.84(m,1H),6.73-6.71(m,1H),3.88(d,J=12.8Hz,1H),3.62(s,3H), 3.02(d,J=4.8Hz,3H),2.91-2.75(m,1H),2.72-2.59(m,2H),2.43(s,3H ),1.73(s,2H),1.61-1.43(m,3H),1.31-1.17(m,1H),0.92-0.74(m,1H).
[0569] Example 19: Synthesis of methyl (R)-3-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)piperidine-1-carboxylate ((R)-A19)
[0570]
[0571] Compound (R)-A19 was prepared from 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide and (R)-3-(bromomethyl)piperidine-1-carboxylic acid tert-butyl ester by the method described in steps 1-3 of Example 18. LCMS (ESI, m / z): 457.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.27-7.79(m,2H),7.66-7.47(m,3H),6.89(d,J=6.8Hz,1H),4.09-3.73(m,2H),3.62(s,3H),3.00(d,J=4.6Hz,3H),2.94(d,J =4.2Hz,1H),2.85-2.76(m,1H),2.72-2.61(m,2H),2.48(s,3H),2.42-2. 36(m,1H),1.50(d,J=14.2Hz,2H),1.35-1.15(m,1H),1.01-0.75(m,1H).
[0572] Example 20: Synthesis of methyl 4-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)piperidine-1-carboxylate (A20)
[0573]
[0574] Compound A20 was prepared from N-Boc-4-ethynylpiperidine, methyl 4-formyl-3,5-difluorobenzoate, and 4-methyl-2-aminopyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 457.3 [M+H] + . 1 H NMR(400MHz, CDCl3)7.98(d,J=7.0Hz,1H),7.68-7.49(m,4H),6.91(d,J=6.6Hz,1H),4.17-3.91(m,2H),3.63(s,3H) ,3.01(d,J=4.8Hz,3H),2.79(d,J=7.2Hz,2H),2.67-2.51(m,3H),2.49(s,3H),1.56-1.42(m,2H),1.10-0.89(m,2H).
[0575] Example 21: Synthesis of 4-(3-((4-acetamidocyclohexyl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (A21)
[0576]
[0577] Steps 1 and 2: As described above, according to steps 2 and 3 in Example 15, tert-butyl 4-((4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)methylene)cyclohexyl)carbamate (1.4 g) was prepared from (4-oxocyclohexyl)carbamate (2.0 g). LCMS (ESI, m / z): 238.1 [M-100] + .
[0578] Step 3: Pd(PPh3)4 (304 mg, 263 μmol) was added to a mixture of 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (1.00 g, 2.63 mmol), (4-((4,4,5,5-tetramethyl-1,3,2-dioxaborhexacyclopentan-2-yl)methylene)cyclohexyl)tert-butyl carbamate (1.33 g, 3.95 mmol), K2CO3 (727 mg, 5.26 mmol), H2O (4 mL), and dioxane (20 mL) in N2. The mixture was stirred at 90 °C for 12 h. The mixture was diluted with H2O (30 mL) and extracted with EA (25 mL × 3). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, concentrated, and the residue was purified by column chromatography to give compound 44 (1 g, 74%). LCMS (ESI, m / z): 511.2 [M+H] + Step 4: Compound 45 (410 mg) was prepared using the method described in Step 5 of Example 15, yielding compound 44 (500 mg). LCMS (ESI, m / z): 513.3 [M+H] + . 1 H NMR(400MHz, DMSO-d6)7.85(d,J=7.0Hz,1H),7.43-7.37(m,4H),6.75-6.68(m,1H),4.31(br s,1H),3.31-3.15(m,1H),3.02(d,J=4.6Hz,4H),2.71(d,J=7.3Hz,2H),2.43(s,4H),1.88(br d,J=9.0Hz,2H),1.58(br d,J=9.6Hz,2H),1.42(s,3H),1.40(s,9H),0.96-0.80(m,4H).
[0579] Step 5: Compound 46 was prepared from compound 45 (240 mg) using the method described in Step 2 of Example 1. LCMS (ESI, m / z): 413.1 [M+H]+ .
[0580] Step 6: Add Ac₂O (680 μmol, 64 μL) to a solution of compound 46 (140 mg, 339 μmol) in EtOH (3 mL). Stir the reaction mixture at 80 °C for 3 h. Dilute the mixture with water (30 mL) and adjust the pH to 8 with saturated NaHCO₃. Extract the mixture with EA (20 mL × 2). Wash the organic layer with brine (30 mL), dry with Na₂SO₄, filter, and concentrate. Combine the residue with the product of the second reaction and purify by preparative HPLC, then lyophilize to give compound A21 (120 mg, 77%) as a white solid. LCMS (ESI, m / z): 455.2 [M+H] + .
[0581] Step 7: Compound A21 (100 mg) was separated into cis and trans isomers by SFC on a Daicel Chiralpak AD-H column (250 × 30 mm, 5 μm particle size). The elution was performed in supercritical CO2 with 40% IPA (0.1% NH3 aqueous solution) at a flow rate of 70 g / min, yielding cis-A21 and trans-A21 (4.6 mg and 61 mg) as white solids.
[0582] Cis-A21
[0583] LCMS: 455.2 [M+H] + .
[0584] 1H NMR (400MHz, MeOD)8.23(d,J=7.0Hz,1H),7.63-7.53(m,2H),7.35(s,1H),6.90(d,J=7.1Hz,1H),3.76(br d,J=4.9Hz,1H),2.95(s,3H),2.89(d,J=7.4Hz,2H),2.46(s,3H),1.87(s,3H),1.81-1.70(m,1H),1.44(br s,6H),1.30-1.14(m,2H).
[0585] Trans-A21
[0586] LCMS: 455.2 [M+H] + .
[0587] 1H NMR (400MHz, MeOD)8.24(d,J=7.0Hz,1H),7.63-7.54(m,2H),7.34(s,1H),6.89(dd,J=1.5,7.0Hz,1H),3.44(tt,J=3.8,11.4Hz,1H),2. 95(s,3H),2.81(d,J=7.0Hz,2H),2.45(s,3H),1.85(s,3H),1.81-1.74(m,2H),1.66-1.48(m,3H),1.12-1.00(m,2H),0.99-0.85(m,2H).
[0588] Example 22: Synthesis of 4-(3-((3-acetamidocyclohexyl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (cis-A22)
[0589]
[0590] Step 1: CDI (2.00 g, 12.3 mmol) was added to a THF (20 mL) solution of (cis)-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid (2.00 g, 8.22 mmol). The mixture was stirred at 20 °C for 16 h. Then, the mixture was added to a NaBH4 (373 mg, 9.86 mmol) H2O (2 mL) solution at 0 °C. The resulting reaction mixture was stirred at 20 °C for 1 h. The mixture was quenched with an aqueous NH4Cl solution and extracted with EA (20 mL × 2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give tert-butyl ((cis)-3-(hydroxymethyl)cyclohexyl)carbamate (1.80 g, 95%) as a white solid. 1 H NMR(400MHz, CDCl3)4.42(br s,1H),3.47(br t,J=5.3Hz,3H),2.11-1.93(m,2H),1.85-1.78(m,1H),1.60(dtt,J=3.1,6.1,12.0Hz,1H),1.51(br s,1H),1.44(s,9H),1.39-1.25(m,1H),1.00(dq,J=3.8,12.4Hz,1H),0.93-0.82(m,1H),0.81-0.72(m,1H).
[0591] Step 2: CBr4 (1.74 g, 5.23 mmol) was added to a DCM (16 mL) solution of (cis)-3-(hydroxymethyl)cyclohexyl)carbamate (800 mg, 3.49 mmol) and PPh3 (1.37 g, 5.23 mmol) in N2 at 0 °C. The reaction mixture was then stirred at 20 °C for 1 h and concentrated. The residue was purified by silica gel chromatography to give (cis)-3-(bromomethyl)cyclohexyl)carbamate (800 mg, 78%) as a white solid. 1 H NMR (400MHz, CDCl3)4.40(br d,J=1.2Hz,1H),3.57-3.37(m,1H),3.31(d,J=5.9Hz,2H),2.14(br d,J=12.3Hz,1H),1.97(br d,J=11.4Hz,1H),1.87-1.68(m,4H),1.45(s,10H),1.41-1.32(m,1H),1.03-0.80(m,4H).
[0592] Step 3: Add 4-(3-bromo-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (400 mg, 1.05 mmol), ((cis)-3-(bromomethyl)cyclohexyl)carbamate tert-butyl ester (615 mg, 2.10 mmol), Ir[dF(CF3)ppy]2(dtbpy)(PF6) (12 mg, 10.5 μmol), NiCl2.dtbbpy (2 mg, 5.3 μmol), TTMSS (1.05 mmol, 325 μL), and LiOH (252 mg, 10.5 mmol) in DME (15 mL) to a 40 mL vial equipped with a stir bar. Seal the vial and place it under nitrogen atmosphere. Stir the reaction mixture and irradiate it with a 34W blue LED lamp (7 cm away). Maintain the reaction temperature at 25 °C for 14 h using a cooling fan. The mixture was diluted with water (50 mL), adjusted to pH 8 with 1 M HCl aqueous solution, and extracted with EA (20 mL × 2). The organic layer was washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by preparative HPLC. The combined fractions were adjusted to pH 8 with saturated NaHCO₃, and the mixture was extracted with EA (20 mL × 2). The organic layer was washed with brine (30 mL), dried over Na₂SO₄, filtered, and concentrated to give compound 47 (50 mg). LCMS (ESI, m / z): 513.3 [M + H] + . 1H NMR(400MHz, CDCl3)7.85(d,J=7.0Hz,1H),7.42-7.34(m,3H),6.93(br d,J=7.9Hz,1H),6.72(dd,J=1.6,7.1Hz,1H),4.38-4.24(m,1H),3.34-3.20(m,1H),3.04(d,J=4.8Hz,4H),2.44(s,3H),1.42(s,10H).
[0593] Step 4: Compound 48 (33 mg, 97%) was prepared from compound 47 (50 mg) using the method described in Step 2 of Example 1. LCMS (ESI, m / z): 413.1 [M+H] + .
[0594] Step 5: Add Ac₂O (87 μmol, 8 μL) to a solution of compound 48 (18.0 mg, 43.6 μmol) in EtOH (1.0 mL). Stir the reaction mixture at 80 °C for 2 h, then dilute with water (20 mL) and adjust the pH to 8 with saturated NaHCO₃. Extract the mixture with EA (10 mL × 2). Wash the combined organic layers with brine (20 mL), dry with Na₂SO₄, filter, and concentrate. Obtain compound cis-A₂₂ (19 mg) as a pale yellow solid. LCMS (ESI, m / z): 455.3 [M + H] + .
[0595] Step 6: The compound cis-A22 (35.0 mg, 77 μmol) was separated by a combination of preparative HPLC and SFC methods to obtain two pure cis stereoisomers—cis-A22 (peak 1) (7.9 mg) and cis-A22 (peak 2) (6.4 mg). A single cis-A22 stereoisomer was isolated, but its absolute stereochemistry was not determined.
[0596] Peak 1
[0597] LCMS: 455.3 [M+H] + .
[0598] 1H NMR (400MHz, CDCl3)7.87(d,J=6.9Hz,1H),7.41(br s,1H),7.39(d,J=7.6Hz,2H),6.95(br d,J=3.0Hz,1H),6.75(dd,J=1.5,7.0Hz,1H),5.25(br d,J=8.4Hz,1H),3.63(ttd,J=4.1,7.9,11.8Hz,1H),3.04(d,J=4.8Hz,3H) ,2.82-2.65(m,2H),2.45(s,3H),1.92(s,3H),1.90-1.82(m,2H),1.49(br d,J=11.6Hz,2H),1.28-1.11(m,2H),0.89(dq,J=2.9,12.2Hz,1H),0.71-0.52(m,2H).
[0599] Peak 2
[0600] LCMS: 455.1 [M+H] + .
[0601] 1H NMR (400MHz, CDCl3)7.86(d,J=7.0Hz,1H),7.39(d,J=7.5Hz,3H),6.85(brd,J=4.8Hz,1H),6.73(dd,J=1.5,7.0Hz,1H),5.24(br d,J=8.3Hz,1H),3.70-3.57(m,1H),3.04(d,J=4.8Hz,3H),2.81-2.66(m,2H),2.44(s,3H),1.92(s,3H),1.90-1.81(m,2H),1.49(br d,J=12.8Hz,2H),1.28-1.12(m,2H),0.95-0.83(m,1H),0.70-0.54(m,2H).
[0602] Example 23: Synthesis of 4-(3-((3-acetamidocyclohexyl)methyl)-7-methylimidazo[1,2-a]pyridin-2-yl)-3,5-difluoro-N-methylbenzamide (trans-A22)
[0603]
[0604] Starting with trans-3-((tert-butoxycarbonyl)amino)cyclohexane-1-carboxylic acid, two trans isomers of A22 were prepared as described above for the cis isomers of A22. The compound trans-A22 (35.0 mg, 77 μmol) was separated by a combination of preparative HPLC and SFC methods to obtain two pure trans stereoisomers—trans-A22 (peak 1) (7.8 mg) and trans-A22 (peak 2) (9.7 mg). A single trans-A22 stereoisomer was isolated, but its absolute stereochemistry was not determined.
[0605] Peak 1
[0606] LCMS: 455.2 [M+H] + .
[0607] 1H NMR (400MHz, MeOD)8.24(d,J=7.0Hz,1H),7.63-7.51(m,2H),7.34(s,1H),6.90(dd,J=1.4,7.1Hz,1H),3.82(br s,1H),2.95(s,3H),2.92-2.84(m,2H),2.45(s,3H),2.06-1.92(m,1H),1.87(s,3H),1.60-1.28(m,7H),1.07-0.93(m,1H).
[0608] Peak 2
[0609] LCMS: 455.2 [M+H] + .
[0610] 1H NMR (400MHz, MeOD)8.29-8.16(m,1H),7.63-7.51(m,2H),7.34(s,1H),6.90(brd,J=7.1Hz,1H),3.82(br s,1H),2.95(s,3H),2.91-2.83(m,2H),2.45(s,3H),2.07-1.92(m,1H),1.87(s,3H),1.56-1.28(m,7H),1.08-0.93(m,1H).
[0611] Example 24: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-indol-1-yl)methyl)morpholine-4-carboxylate (A23)
[0612]
[0613] Step 1: PPh3 (12.1 g, 46 mmol) and CBr4 (15.3 g, 46 mmol) were added to a DCM (100 mL) solution of (R)-2-(hydroxymethyl)morpholine-4-carboxylic acid tert-butyl ester (5.00 g, 23 mmol) at 0 °C. The reaction mixture was then stirred at 20 °C for 1 h. The product was purified by silica gel chromatography to obtain (R)-2-(bromomethyl)morpholine-4-carboxylic acid tert-butyl ester (5.20 g, 81%). 1 H NMR (400MHz, CDCl3)4.19-3.98(m,1H),3.92(br dd,J=1.8,11.5Hz,1H),3.83(br d,J=7.9Hz,1H),3.67-3.50(m,2H),3.43-3.30(m,2H),2.97(br t,J=11.5Hz,1H),2.75(br s,1H),1.47(s,9H).
[0614] Step 2: To a solution of 4-bromo-2,6-difluoroacetophenone (2.0 g, 8.51 mmol) in EtOH (20 mL), p-tolylhydrazine hydrochloride (1.4 g, 8.94 mmol) and AcOH (50 μL) were added. The mixture was stirred at 80 °C for 4 h. The reaction mixture was concentrated to give product compound 49 (2.9 g), which was used directly without further purification. LCMS (ESI, m / z): 339.0 [M+H] + .
[0615] Step 3: The PPA (30 mL) solution of compound 49 (2.9 g, 8.52 mmol) was stirred at 120 °C for 12 h. The reactants were diluted with water (200 mL) and saturated NH4Cl solution (500 mL), and extracted with EA (300 mL × 3). The combined extracts were dried over Na2SO4, filtered, concentrated, and the crude product was purified by reversed-phase HPLC. The fractions were concentrated to remove MeCN, and the remaining liquid was extracted with EA (50 mL × 3) to give compound 50 (1.3 g, 35% yield) as an oil. LCMS (ESI, m / z): 322.0 [M+H] + . 1 H NMR (400MHz, CDCl3) 8.84 (br s, 1H), 7.46 (d, J = 0.4Hz, 1H), 7.33-7.31 (m, 1H), 7.24-7.21 (m, 2H), 7.10-7.08 (m, 2H), 2.47 (s, 3H).
[0616] Step 4: Add NaH (273 mg, 6.8 mmol, 60% dispersion) and tert-butyl (R)-2-(bromomethyl)morpholine-4-carboxylate (1.9 g, 6.83 mmol) to a DMF (11 mL) solution of compound 50 (1.1 g, 3.41 mmol). Stir the mixture at 25 °C for 14 h. Dilute the reaction mixture with water (50 mL) and extract with EA (20 mL × 3). Wash the combined extracts with brine, dry to Na₂SO₄, filter, and concentrate to obtain the crude product. Purify the crude product by column chromatography to obtain compound 51 (1.3 g, 65%). LCMS (ESI, m / z): 523.2 [M+H] + .
[0617] Step 5: K₂CO₃ (290 mg, 2.10 mmol), diacetoxypalladium (16 mg, 70 μmol), and 1,3-bis(dicyclohexylphosphino)propane bis(tetrafluoroborate) (86 mg, 0.14 mmol) were added to a solution of compound 51 (730 mg, 1.40 mmol) in DMSO (8 mL) and MeOH (1.5 mL). The mixture was stirred at 100 °C under CO₂ (15 psi) for 12 h. The reactants were diluted with water (20 mL) and filtered. The filter cake was washed with EA (20 mL), and the filtrate was extracted with EA (10 mL × 3). The combined organic compounds were dried over Na₂SO₄, filtered, and concentrated. The crude product was purified by reversed-phase HPLC and lyophilized to give compound 52 (450 mg, 59%). LCMS (ESI, m / z): 487.2 [M+H] + . 1 H NMR (400MHz, CDCl3)7.74(br d,J=7.2Hz,2H),7.46(s,1H),7.37(d,J=8.4Hz,1H),7.13(br d,J=42Hz,1H),6.60(s,1H),4.16-4.12(m,2H),3.70-3.55(m,4H),3.32(br s,1H),2.77-2.72(m,1H),2.48(s,3H),2.36-2.30(m,1H),1.40(s,9H).
[0618] Steps 6-8: Compound A23 (88.4 mg) was prepared from compound 52 (230 mg, 0.46 mmol) using the method described in steps 5, 2 and 3 of Example 1. 1H NMR (400MHz, CDCl3)7.74(br d,J=7.2Hz,2H),7.45-7.41(m,3H),7.32(d,J=8.4Hz,1H),7.11(br d,J=8.4Hz,1H),6.56(s,1H),6.28(br d,J=2.0Hz,1H),4.10-4.03(m,2H),3.71-3.64(m,6H),3.53-3.50(m,1H),3.29(br s,1H),3.06(d,J=5.2Hz,3H),2.78(br s,1H),2.47(s,3H),2.40-2.34(m,1H).
[0619] Example 25: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)6-methyl-1H-indol-3-yl)methyl)morpholine-4-carboxylate (A24)
[0620]
[0621] Step 1: Add 15 μL of AcOH to a solution of (S)-2-(3-(2,6-difluoro-4-(methoxycarbonyl)phenyl)-3-oxopropyl)morpholine-4-carboxylate (1 g, 2.69 mmol) and m-tolylhydrazine (395 mg, 3.23 mmol) in EtOH (10 mL). Stir the mixture at 80 °C for 48 h. Concentrate the reaction mixture and purify the residue by preparative HPLC to separate the two peaks. Compound 55A (130 mg, 10% yield) and compound 55B (150 mg, 12% yield) were separated as yellow solids. LCMS (ESI, m / z): 459.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.00(s,1H),7.64-7.60(m,2H),7.53(d,J=8.4Hz,1H),7.12(s,1H),6.93(br d,J=8.0Hz,1H),3.90(s,3H),3.71-3.67(m,3H),3.54-3.49(m,4H),3.3 5-3.29(m,1H),2.98-2.94(m,1H),2.74-2.67(m,2H),2.41-2.35(m,4H).
[0622] Steps 2 and 3: Starting with compound 55B, compound A24 was prepared by the methods described in steps 4 and 5 of Example 1. LCMS (ESI, m / z): 458.1 [M+H] + . 1H NMR (400MHz, CDCl3)8.30(s,1H),7.60(d,J=8.4Hz,1H),7.41(br d,J=7.6Hz,2H),7.19(s,1H),7.01(br d,J=8.0Hz,1H),6.43(br s,1H),3.78(br d,J=11.2Hz,3H),3.61-3.56(m,4H),3.43-3.37(br t,J=10.9Hz,1H),3.04-3.01(m,4H),2.93-2.85(m,1H),2.78-2.75(m,1H),2.48-2.42(m,4H).
[0623] Example 26: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-5-methyl-1H-pyrrolo[2,3-b]pyridin-1-yl)methyl)morpholine-4-carboxylic acid methyl ester (A25)
[0624] Step 1: SOCl2 (138 mmol, 10 mL) was added to a MeOH (60 mL) solution of 4-bromo-3,5-difluorobenzoic acid (5.00 g, 21.1 mmol). The mixture was stirred at 80 °C for 2 h. The mixture was concentrated and the product, methyl 4-bromo-3,5-difluorobenzoate (5.00 g, 93%), was used in the next step without further purification. 1 H NMR (400MHz, CDCl3) 7.62 (d, J=6.6Hz, 2H), 3.95 (s, 3H).
[0625] Step 2: Trimethylsilylacetylene (10 mmol, 1.4 mL), CuI (94.8 mg, 500 μmol), TEA (39.8 mmol, 5.5 mL), and Pd(PPh3)2Cl2 (349 mg, 500 μmol) were added to a THF (30 mL) solution of methyl 4-bromo-3,5-difluorobenzoate (2.50 g, 9.96 mmol). The reaction mixture was then stirred at 60 °C for 3 h. The mixture was diluted with water (100 mL) and extracted with EA (50 mL × 2). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography and dissolved in THF (20 mL). TBAF (1 M, 9 mL) was added at 0 °C, and the reaction mixture was stirred at 20 °C for 1 h. The mixture was diluted with water (100 mL) and extracted with EA (30 mL × 3). The organic layer was washed with brine (90 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give methyl 4-ethynyl-3,5-difluorobenzoate (600 mg, 39%) as a pale yellow solid. 1 H NMR (400MHz, CDCl3)7.59-7.53(m,2H),3.94(s,3H),0.30(s,9H).
[0626] Step 3: CuI (29.1 mg, 153 μmol) and Pd(PPh3)2Cl2 (107 mg, 153 μmol) were added to a solution of methyl 4-ethynyl-3,5-difluorobenzoate (599 mg, 3.06 mmol) and 3-iodo-5-methylpyridin-2-amine (715 mg, 3.06 mmol) in THF (10 mL) and TEA (10 mL). The mixture was stirred in N2 at 60 °C for 2 h. The mixture was diluted with water (100 mL) and extracted with EA (30 mL × 3). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated. The residue was purified by silica gel chromatography to give compound 57 (700 mg, 73%). LCMS (ESI, m / z): 303.0 [M+H] + . 1 H NMR (400MHz, CDCl3) 7.95 (d, J = 1.7 Hz, 1H), 7.67-7.59 (m, 2H), 7.51 (d, J = 2.0 Hz, 1H), 5.02 (brs, 2H), 3.96 (s, 3H), 2.21 (s, 3H).
[0627] Step 4: Indium tribromide (129 mg, 364 μmol) was added to a toluene (35 mL) solution of compound 57 (550 mg, 1.82 mmol). The mixture was then stirred in N2 at 125 °C for 72 h. The mixture was diluted with water (150 mL) and adjusted to pH 8 with aqueous NaHCO3 solution. The mixture was extracted with EA (50 mL × 3). The organic layer was washed with brine (100 mL), dried over Na2SO4, filtered, and concentrated. The residue was dissolved in MeOH (45 mL) and adjusted to pH 4 with aqueous HCl (1 M). Then 30 mL of water was added. The solid precipitate was collected and filtered. The filter cake was washed with PE (10 mL). Compound 58 (250 mg, 41%) was obtained as a pale yellow solid. LCMS (ESI, m / z): 303.1 [M+H] + . 1 H NMR (400MHz, CDCl3) 9.68-9.45 (m, 1H), 8.24 (s, 1H), 7.79 (s, 1H), 7.75-7.69 (m, 2H), 7.16 (d, J = 1.3Hz, 1H), 3.97 (s, 3H), 2.46 (s, 3H).
[0628] Step 5: To a DMF (3.5 mL) solution of compound 58 (110 mg, 364 μmol), tert-butyl (R)-2-(bromomethyl)morpholine-4-carboxylate (204 mg, 728 μmol), Cs₂CO₃ (296 mg, 910 μmol), and NaI (27.3 mg, 182 μmol) were added. The mixture was then stirred at 60 °C for 16 h. The mixture was diluted with water (20 mL) and extracted with EA (10 mL × 3). The organic layer was washed with brine (20 mL), dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography to give compound 59 (130 mg, 69%). LCMS (ESI, m / z): 502.1 [M+H] + . 1 H NMR(400MHz, CDCl3)8.23(s,1H),7.75(s,1H),7.70(br d,J=7.7Hz,2H),6.53(s,1H),4.38-4.23(m,2H),3.99(s,3H),3.89-3.62(m,2H),3.61-3.50(m,2H),3.24(br t,J=11.5Hz,1H),2.77-2.64(m,1H),2.46(s,3H),2.38-2.26(m,1H),1.39(s,9H).
[0629] Steps 6-9: Compound A25 (46 mg) was prepared from compound 59 (130 mg, 259 μmol) using the method described in steps 2-5 of Example 1. LCMS (ESI, m / z): 459.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.22(d,J=1.6Hz,1H),7.75(s,1H),7.47-7.39(m,2H),6.52(s,1H),6.27-6.15(m,1H),4.30(br s,2H),3.92-3.69(m,2H),3.64(s,3H),3.63-3.52(m,2H),3.30-3.19(m,1H ), 3.07 (d, J = 4.9Hz, 3H), 2.84-2.70 (m, 1H), 2.46 (s, 3H), 2.43-2.34 (m, 1H).
[0630] Example 27: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-6-methyl-1H-pyrrolo[3,2-b]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A26)
[0631] Step 1: CuI (1.77 g, 9.3 mmol) and K3PO4 (29.6 g, 140 mmol) and N,N'-dimethylethane-1,2-dicarboxylic acid ditert-butyl ester (10.8 g, 46.5 mmol) were added to a dioxane (80 mL) solution of 3-bromo-5-methylpyridine (8 g, 46.5 mmol) and hydrazine-1,2-dicarboxylic acid ditert-butyl ester (1.64 g, 2.00 mL). The mixture was stirred at 100 °C for 3 h. The reaction mixture was diluted with water (300 mL) and extracted with EA (100 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography and the product was concentrated to give 1-(5-methylpyridin-3-yl)hydrazine-1,2-dicarboxylic acid ditert-butyl ester (9 g, 60%) as a white solid.
[0632] Step 2: A solution of 1-(5-methylpyridin-3-yl)hydrazine-1,2-dicarboxylic acid di-tert-butyl ester (3 g, 9.28 mmol) in 4M HCl MeOH (30 mL) was stirred for 0.5 h at 30 °C. The reaction mixture was concentrated to give 3-hydrazyl-5-methylpyridinium hydrochloride (1.48 g), which was used without further purification. LCMS (ESI, m / z): 124.1 [M+H] + . 1H NMR (400MHz, CDCl3) 8.39 (s, 1H), 8.36 (d, J = 2.4Hz, 1H), 8.00 (m, 1H), 2.58 (s, 3H).
[0633] Step 3: Add 18.5 μL of AcOH to a solution of (S)-2-(3-(2,6-difluoro-4-(methoxycarbonyl)phenyl)-3-oxopropyl)morpholine-4-carboxylate (1.2 g, 3.23 mmol) and 3-hydrazino-5-methylpyridine hydrochloride (1.44 g, 9.05 mmol) in EtOH (13 mL). Stir the mixture at 80 °C for 15 h. Concentrate the reaction mixture to obtain compound 63, which can be used directly without further purification. LCMS (ESI, m / z): 477.1 [M+H] + .
[0634] Step 4: The mixture of compound 63 (1.54 g, 3.23 mmol) and PPA (20 mL) was stirred at 110 °C for 1 h. The reaction mixture was added to saturated Na₂CO₃ (1.5 L) and extracted with EA (500 mL × 3). The combined organic layers were dried over Na₂SO₄, filtered, concentrated, and the residue was purified by reversed-phase chromatography to give compound 64 (300 mg, 20%). LCMS (ESI, m / z): 460.1 [M+H] + . 1 H NMR(400MHz, CDCl3)8.32-8.28(m,3H),7.73-7.66(m,2H),3.99-3.97(m,3H),3.94-3.69( m,4H),3.64(s,3H),3.41-3.27(m,1H),3.04-2.79(m,3H),2.61-2.55(m,1H),2.44(s,3H).
[0635] Steps 5 and 6: Compound A26 (57 mg) was prepared from compound 64 (140 mg) using the methods described in steps 4 and 5 of Example 1. LCMS (ESI, m / z): 459.1 [M+H] + . 1H NMR(400MHz, CDCl3)8.47-8.31(m,1H),7.59(br s,1H),7.46-7.38(m,2H),7.19-7.12(m,1H),3.78-3.66(m,4H),3.62-3.60(m,3H),3.33-3.31(m,1H),3.05(br s,2H),2.99(br d,J=4.0Hz,3H),2.88-2.84(m,2H),2.45(brs,3H).
[0636] Example 28: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-b]pyridazin-3-yl)methyl)morpholine-4-carboxylate (A27)
[0637]
[0638] Step 1: CuBr2 (6 g, 26.9 mmol) was added to a solution of (S)-2-(3-(2,6-difluoro-4-(methoxycarbonyl)phenyl)-3-oxopropyl)morpholine-4-carboxylate (5 g, 13.5 mmol) in CHCl3 (30 mL) and EtOAc (30 mL). The mixture was stirred at 85 °C for 3 h. The mixture was filtered, and the filtrate was concentrated and the residue was purified by column chromatography to give compound 66 (5.6 g, 87%). LCMS (ESI, m / z): 449.1 [M+H] + . 1 H NMR (400MHz, CDCl3)7.69-7.61(m,2H),5.26-5.10(m,1H),4.04-3.83(m,6H),3.76-3.71(m,3H),3.70-3.42(m,2H),2.98(br d,J=11.0Hz,1H),2.87-2.25(m,2H),2.24-2.10(m,1H).
[0639] Step 2: A mixture of compound 66 (1 g, 2.22 mmol) and 3-amino-5-methylpyridazine (727 mg, 6.66 mmol) in dichloromethane (20 mL) was heated to 80 °C for 3 days. The mixture was diluted with H₂O (50 mL) and extracted with EA (50 mL × 3). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated to obtain the residue. The residue was purified by preparative TLC to give compound 67 (96 mg, 9%). LCMS (ESI, m / z): 461.2 [M+H] + . 1H NMR (400MHz, CDCl3)8.48(d,J=2.0Hz,1H),7.82(dd,J=1.2,1.8Hz,1H),7.79-7.72(m,2H),3.99(s,3H),3.85(br d,J=12.3Hz,1H),3.78-3.71(m,2H),3.65(s,4H),3.31-3.17(m,3H),2.94-2.80(m,1H),2.66-2.54(m,1H),2.51(d,J=1.0Hz,3H).
[0640] Steps 3 and 4: Compound A27 (20 mg) was prepared from compound 67 (90 mg) using the methods described in steps 4 and 5 of Example 1. LCMS (ESI, m / z): 460.0 [M+H] + . 1 H NMR (400MHz, CDCl3)8.24(d,J=1.8Hz,1H),7.78-7.63(m,1H),7.42(br d,J=7.4Hz,2H),7.36(br d,J=13.1Hz,1H),3.95-3.65(m,4H),3.63(s,3H),3.37-3.19(m,2H),3.16-3.06(m,1H),2.99(d,J=4.6Hz,3H),2.92-2.78(m,1H),2.54(br dd,J=10.7,12.8Hz,1H),2.45(s,3H).
[0641] Example 29: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyrimidin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A28)
[0642]
[0643] Step 1: 2-Amino-4-methylpyrimidine (727 mg, 6.66 mmol) was added to a solution of compound 66 (1 g, 2.22 mmol) in dichloromethane (10 mL). The mixture was stirred at 80 °C for 3 days. The reaction mixture was concentrated, and the residue was purified by preparative HPLC. The eluent was lyophilized to give a mixture of compounds 69A and 69B (350 mg) as a white solid. LCMS (ESI, m / z): 461.1 [M+H] + ; 461.0 [M+H] + . 1H NMR(400MHz, CDCl3)8.55(d,J=7.2Hz,1H),7.70-7.68(d,J=7.7Hz,2H),6.77(d,J=7.2Hz,1H) ,3.99(s,3H),3.97-3.86(m,1H),3.84-3.75(m,2H),3.69(s,3H),3.59-3.57(m,1H),3.39(br t,J=9.7Hz,1H),3.00-2.80(m,4H),2.65(s,3H).
[0644] Step 2: LiOH·H2O (49 mg, 1.17 mmol) was added to a solution of compounds 69A and 69B (270 mg, 0.59 mmol) in MeOH (3.0 mL) and H2O (0.6 mL). The mixture was stirred at 25 °C for 1 h. The reaction mixture was diluted with water (10 mL) and adjusted to pH 7-8 with HCl (1 M) aqueous solution. The solution was lyophilized to give a mixture of compounds 70A and 70B (261 mg, 99.7%), which was used as is.
[0645] Steps 3 and 4: The mixture of compounds 70A and 70B (260 mg, 0.58 mmol) was treated as described in step 5 of Example 1 to obtain A28 (151 mg, 56%). LCMS (ESI, m / z): 460.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.62-8.57(m,2H),7.43(br d,J=7.6Hz,2H),6.81(d,J=6.8Hz,1H),3.78-3.76(m,3H),3.66(s,3H),3.53(br s,1H),3.39-3.34(m,1H),3.03(br s,3H),2.88(br s,3H),2.66-2.57(m,4H).
[0646] Example 30: Synthesis of (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-c]pyrimidin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A29)
[0647]
[0648] Step 1: A mixture of compound 66 (900 mg, 2.00 mmol) and 4-amino-6-methylpyrimidine (654 mg, 6.00 mmol) in dichloromethane (18 mL) was stirred for 3 days at 80 °C. The mixture was diluted with water (50 mL) and extracted with EA (20 mL × 3). The organic layer was washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was purified by preparative HPLC to give compound 71 (100 mg). LCMS (ESI, m / z): 461.1 [M+H] + .
[0649] Step 2: Compound 72 (75 mg) was prepared from compound 71 (80 mg) using the method described in Step 4 of Example 1.
[0650] Steps 3 and 4: Compound 72 (75 mg, 0.17 mmol) was treated with a solution of DCM (3 mL) containing methylamine hydrochloride (34 mg, 0.50 mmol), EDCI (64 mg, 0.34 mmol), HOBt (45 mg, 0.34 mmol), and DIEA (1.68 mmol, 0.3 mL). The crude product was purified by preparative HPLC and further purified by chiral SFC to give A29 (2.6 mg, 3%). Additionally, isomer A37 (18 mg, 24%) was also obtained. This isomer was formed in the first step but not separated; the mixture was used directly and the isomer was separated in the final step. LCMS (ESI, m / z): 460.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.49(d,J=1.3Hz,1H),7.52(dd,J=1.9,7.8Hz,2H),7.35(s,1H),6.23(brs,1H),4.08-3.93(m,1H),3.91-3.81(m,2H),3.76(dd ,J=2.6,11.6Hz,1H),3.68(s,3H),3.50-3.42(m,1H),3.08(d,J=4.9Hz,3 H),2.99-2.87(m,2H),2.85-2.77(m,1H),2.71-2.60(m,1H),2.57(s,3H).
[0651] Compound A37
[0652]
[0653] LCMS: 460.1 [M+H] + .
[0654] 1H NMR (400MHz, CDCl3)9.21(d,J=1.1Hz,1H),7.48-7.41(m,2H),7.31(s,1H),6.35(br d,J=4.9Hz,1H),4.05-3.78(m,3H),3.70(s,3H),3.62(dt,J=3.2,6.6Hz,1H),3.46-3.34(m,1H),3.06(d,J=4.9Hz,3H),3.03(br d,J=7.4Hz,2H),2.98-2.84(m,1H),2.73-2.61(m,1H),2.56(s,3H).
[0655] Example 31: Synthesis of (S)-2-((2-(3,6-difluoro-2-methoxy-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A30)
[0656]
[0657] Compound A30 was prepared from 2,3,5-trifluorobromobenzene using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 489.3 [M+H] + . 1 H NMR (400MHz, CDCl3)8.16(d,J=7.0Hz,1H),7.61(dd,J=5.8,9.5Hz,1H),7.38(s,1H),6.76(br dd,J=4.6,10.9Hz,1H),6.68(dd,J=1.3,7.1Hz,1H),3.76(d,J=0.8Hz,5H),3.67(s,3H),3.59-3.49(m,1H),3. 44-3.30(m,1H),3.08(d,J=4.5Hz,3H),3.03-2.93(m,2H),2.92-2.81(m,1H),2.64-2.54(m,1H),2.42(s,3H).
[0658] Example 32: Synthesis of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-4-methyl-1H-indol-3-yl)methyl)morpholine-4-carboxylate (A31)
[0659]
[0660] Step 1: Add AcOH (16 μL, 270 μmol) to a solution of (S)-2-(3-(2,6-difluoro-4-(methoxycarbonyl)phenyl)-3-oxopropyl)morpholine-4-carboxylate (1 g, 2.69 mmol) and m-tolylhydrazine (395 mg, 3.23 mmol) in EtOH (10 mL). Stir the mixture at 80 °C for 48 h. Concentrate the reactants and purify the residue by preparative HPLC, obtaining two product peaks, which were then lyophilized and separated. Compound 73A (130 mg, 10%) and compound 73B (150 mg, 12%) were obtained as yellow solids. LCMS (ESI, m / z): 461.1 [M+H] + .
[0661] Compound 73 ALCMS: 459.2 [M+H] + .
[0662] 1H NMR (400MHz, CDCl3)8.14(s,1H),7.71(d,J=8.0Hz,2H),7.16-7.12(m,1H),6.92(br d,J=6.8Hz,1H),3.99(s,3H),3.77-3.71(m,3H),3.61(s,3H),3.48-3.23(m,3H),2.83-2.75(m,5H),2.26-2.21(m,1H).
[0663] Compound 73B
[0664] 1H NMR (400MHz, CDCl3)8.00(s,1H),7.64-7.60(m,2H),7.53(d,J=8.4Hz,1H),7.12(s,1H),6.93(br d,J=8.0Hz,1H),3.90(s,3H),3.71-3.67(m,3H),3.54-3.49(m,4H),3.3 5-3.29(m,1H),2.98-2.94(m,1H),2.74-2.67(m,2H),2.41-2.35(m,4H).
[0665] Step 2: LiOH·H2O (24 mg, 570 μmol) was added to a solution of compound 73A (130 mg, 284 μmol) in MeOH (0.2 mL) and H2O (0.1 mL). The mixture was stirred at 25 °C for 2 h. The reactants were diluted with water (5 mL), the pH was adjusted to 3-4 with HCl (1 M) aqueous solution, and extracted with EA (3 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated to give compound 74 (120 mg, 95%), which was used unchanged for the next step. LCMS (ESI, m / z): 445.1 [M+H] + .
[0666] Step 3: A 2.0 mL solution of compound 74 (80 mg, 180 μmol) and methylamine hydrochloride (37 mg, 540 μmol) in DCM was coupled as described in General Method 5 above to obtain A31 (54 mg, 65%). LCMS (ESI, m / z): 458.1 [M+H] + . 1HNMR (400MHz, CDCl3)8.48(br s,1H),7.42(br d,J=7.6Hz,2H),7.24(s,1H),7.15-7.11(m,1H),6.91(br d,J=6.8Hz,1H),6.41(br s,1H),3.76-3.73(m,3H),3.60(s,3H),3.50-3.48(m,1H),3.41-3.35(m,1H),3 .27-3.23(m,1H),3.05(d,J=4.8Hz,3H),2.82-2.75(m,5H),2.25-2.19(m,1H).
[0667] Example 33: Synthesis of methyl (S)-2-((2-(2-chloro-4-(methylcarbamoyl)phenyl)-7-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A32)
[0668]
[0669] Compound A32 was prepared from N-Boc-(S)-2-ethynylmorpholine, methyl 3-chloro-4-carboxymethylbenzoate, and 2-amino-4-(difluoromethyl)pyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 493.2 [M+H] + . 1HNMR(400MHz, CDCl3)8.38(d,J=6.8Hz,1H),7.92(d,J=1.4Hz,1H),7.81-7.66(m,2H),7.52(d,J=7.8Hz,1H),7.01-6.99(m,1H),6.87-6.55(m,1H), 6.45(d,J=1.4Hz,1H),3.94-3.72(m,3H),3.66(s,3H),3.53-3.52(m,1H), 3.35-3.34(m,1H),3.04(d,J=4.6Hz,5H),2.95-2.75(m,1H),2.56(s,1H).
[0670] Example 34: Synthesis of (S)-2-((3-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyrimidin-2-yl)methyl)morpholine-4-carboxylic acid methyl ester (A33)
[0671]
[0672] Compound A33 was isolated from the synthesis of compound A28 (Example 29). LCMS (ESI, m / z): 460.3 [M+H] + . 1 H NMR(400MHz,CDCl3)7.85(br d,J=7.2Hz,1H),7.52(d,J=8.0Hz,2H),6.79(d,J=7.2Hz,1H),6.45-6.42(m,1H),4.05-4.01(m,2H),3. 77-3.73(m,2H),3.66(s,3H),3.48-3.44(m,1H),3.07(d,J=4.8Hz,3H),2.94-2.84(m,4H),2.66(s,3H).
[0673] Example 35: Synthesis of (2S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A34)
[0674]
[0675] PtO2 (13 mg, 55 μmol) was added to a MeOH (2.5 mL) solution of methyl (S)-2-((2-(2,6-difluoro-4-(methylcarbamoyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (50 mg, 109 μmol) in N2. The suspension was degassed under vacuum and purged several times with H2. The mixture was stirred at 25 °C under an H2 (15 psi) atmosphere for 16 h. The mixture was then filtered and concentrated, and the residue was purified by HPLC to give A34 (16 mg, 30%) as a white solid. LCMS (ESI, m / z): 463.1 [M+H] + . 1 H NMR(400MHz, CDCl3)7.63(br s,1H),7.39-7.29(m,2H),4.26-3.98(m,1H),3.93-3.68(m,4H),3.65(s,3H),3.33(br s,2H),3.12-3.02(m,1H),2.97(d,J=4.6Hz,3H),2.91-2.79(m,1H),2.73-2.57(m,2H),2.54-2.39(m,2H),2.07(br d,J=11.5Hz,2H),1.80-1.61(m,1H),1.17(d,J=6.5Hz,3H)s,1H),7.33(d,J=7.6Hz,2H),4.77(br s,1H),4.69-4.55(m,1H),4.25-3.98(m,1H),3.95-3.68(m,4H),3.65(s,3H),3.33(br s,2H),3.12-3.02(m,1H),2.97(d,J=4.6Hz,3H),2.91-2.78(m,1H),2.74-2.59(m,2H),2.55-2.39(m,2H),2.07(br d,J=11.5Hz,2H),1.81-1.59(m,1H),1.17(d,J=6.5Hz,3H).
[0676] Example 36: Synthesis of (S)-2-((7-chloro-2-(3,6-difluoro-2-methoxy-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A40)
[0677]
[0678] Compound A40 was prepared from 2,3,5-trifluorobromobenzene and 2-amino-4-(difluoromethyl)pyridine as described in Example 31. LCMS (ESI, m / z): 509.4 [M+H] + . 1 H NMR(400MHz,CDCl3)8.27(br d,J=7.4Hz,1H),7.67-7.59(m,2H),6.83(dd,J=1.7,7.4Hz,1H),6.74(td,J=4.0,7.7Hz,1H),3.98-3.73(m,6H), 3.69(s,3H),3.60-3.51(m,1H),3.44-3.31(m,1H),3.09(d,J=4.6Hz,3H),3.00-2.83(m,3H),2.66-2.54(m,1H).
[0679] Example 37: Synthesis of (S)-2-((2-(3,6-difluoro-2-methoxy-4-(methylcarbamoyl)phenyl)-7-(difluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A41)
[0680]
[0681] Compound A41 was prepared from 2-amino-4-(difluoromethyl)pyridine using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 525.3 [M+H] + . 1 H NMR (400MHz, CDCl3)8.41(d,J=7.2Hz,1H),7.75(s,1H),7.64-7.60(m,1H),6.99-6.97(m,1H),6.76-6.75(m,1H),6.83-6.55(t,J=56Hz,1 H), 3.78 (d, J = 1.2Hz, 6H), 3.67 (s, 3H), 3.62-3.51 (m, 1H), 3.43-3.28 (m, 1H), 3.08 (d, J = 4.4Hz, 3H), 3.03-2.79 (m, 3H), 2.63-2.61 (m, 1H).
[0682] Example 38: Synthesis of (S)-2-((7-(difluoromethyl)-2-(2-fluoro-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A42)
[0683]
[0684] Compound A42 was prepared from 2-amino-4-difluoromethylpyridine, N-Boc-(S)-2-ethynylmorpholine, and methyl 3-fluoro-4-carboxymethylbenzoate using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 477.3 [M+H] + . 1 H NMR(400MHz, CDCl3)8.45(d,J=7.0Hz,1H),7.82-7.72(m,2H),7.70-7.55(m,2H),6.98-6.95(m,1H),6.87-6.53(m,1H),6 .35(s,1H),4.09-3.75(m,3H),3.74-3.57(m,4H),3.38-3.37(m,1H),3.16-2.99(m,5H),2.98-2.86(m,1H),2.66(s,1H).
[0685] Example 39: Synthesis of (S)-2-((7-(difluoromethyl)-2-(2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A43)
[0686] Step 1: K₂CO₃ (3.62 g, 26 mmol) was added to a DMSO (10 mL) solution of methyl 4-bromo-3-methylbenzoate (2.00 g, 8.73 mmol) and potassium vinyltrifluoroborate (5.85 g, 43.7 mmol). The mixture was degassed with N₂ and Pd(dppf)Cl₂ (319 mg, 0.44 mmol) was added. The mixture was stirred in N₂ at 80 °C for 16 h, washed with H₂O, extracted with EA (×3), and the combined extracts were dried over Na₂SO₄, filtered, and concentrated. The residue was purified by silica gel chromatography to give methyl 3-methyl-4-vinylbenzoate (1.00 g, 64%). LCMS (ESI, m / z): 177.2 [M+H] + . 1 H NMR (400MHz, CDCl3)7.83-7.82(m,2H),7.52(d,J=8.6Hz,1H),6.97-6.90(m,1H),5.75-5.71(m,1H),5.41-5.38(m,1H),3.90(s,3H),2.38(s,3H).
[0687] Step 2: A solution of t-BuOH OsO4 [2.89 g, 2.5% wt (prepared by dissolving 0.25 g of OsO4 in 9.75 g of t-BuOH)] was added to a mixture of methyl 3-methyl-4-vinylbenzoate (1.00 g, 5.58 mmol) in THF (15 mL) and H2O (15 mL). The mixture was stirred at 25 °C for 0.5 h, then NaIO4 (3.64 g, 17.0 mmol) was added and the mixture was stirred at 25 °C for 16 h. The mixture was added to a saturated Na2S2O3 solution (120 mL) and extracted with EA (50 mL × 3). The combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated. The residue was purified by column chromatography to give methyl 3-methyl-4-formylbenzoate (0.70 g, 67%). LCMS(ESI,m / z):179.0[M+H] + . 1 H NMR (400MHz, CDCl3) 10.33 (s, 1H), 7.98-7.96 (m, 1H), 7.92 (s, 1H), 7.85 (d, J = 8.2Hz, 1H), 3.93 (s, 3H), 2.70 (s, 3H).
[0688] Steps 3-7: Compound A43 was prepared from 2-amino-4-difluoromethylpyridine, N-Boc-(S)-2-ethynylmorpholine, and methyl 3-fluoro-4-carboxymethylbenzoate using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 473.4 [M+H] + . 1 H NMR(400MHz, CDCl3)8.35(br d,J=7.1Hz,1H),7.73(s,2H),7.63(br d,J=7.6Hz,1H),7.35(d,J=7.9Hz,1H),7.00(d,J=7.5Hz,1H),6.86-6.55(t,J= 56.0Hz,1H),6.24(brd,J=4.0Hz,1H),3.97-3.74(m,3H),3.68(s,3H),3.52(br d,J=1.8Hz,1H),3.43-3.31(m,1H),3.05(d,J=4.9Hz,3H),3.03-2.98(m,2H),2.94-2.82(m,1H),2.54(br t,J=11.8Hz,1H),2.31(s,3H).
[0689] Example 40: Synthesis of (S)-2-((7-(difluoromethyl)-2-(5-fluoro-2-methyl-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A44)
[0690] Step 1: SOCl2 (43 mmol, 3.1 mL) was added dropwise to a MeOH (20 mL) solution of 4-bromo-2-fluoro-5-methylbenzoic acid (2.00 g, 8.58 mmol) at 0 °C, and the mixture was stirred at 80 °C for 2 h. The mixture was concentrated, dissolved in EA (10 mL), and added dropwise to H2O (30 mL). The organic layer was separated, dried over Na2SO4, filtered, and concentrated to obtain methyl 4-bromo-2-fluoro-5-methylbenzoate (2.0 g, 94%), which was used directly in the next step. LCMS (ESI, m / z): 246.9 [M+H] + . 1 H NMR (400MHz, CDCl3) 7.86-7.69 (m, 1H), 7.43-7.29 (m, 1H), 4.00-3.81 (m, 3H), 2.38 (d, J = 2.8Hz, 3H).
[0691] Step 2: K₂CO₃ (3.36 g, 24.3 mmol) was added to a DMSO (10 mL) solution of methyl 4-bromo-2-fluoro-5-methylbenzoate (2.00 g, 8.10 mmol) and potassium vinyltrifluoroborate (5.42 g, 40.5 mmol) (2.00 g, 8.10 mmol). The mixture was purged / degassed with N₂ and Pd(dppf)Cl₂ (296 mg, 0.40 mmol) was added. The mixture was stirred in N₂ at 80 °C for 16 h. The mixture was washed with H₂O (100 mL) and extracted with EA (20 mL × 3). The combined extracts were dried over Na₂SO₄, filtered, concentrated, and the residue was purified by silica gel chromatography to give methyl 2-fluoro-5-methyl-4-vinylbenzoate (1.20 g, 76%). LCMS (ESI, m / z): 195.2 [M+H] + . 1 HNMR(400MHz, CDCl3)7.71(d,J=7.4Hz,1H),7.21(d,J=12.0Hz,1H),6.89-6.82( m, 1H), 5.73 (d, J = 17.4Hz, 1H), 5.45 (d, J = 11.0Hz, 1H), 3.91 (s, 3H), 2.32 (s, 3H).
[0692] Step 3: Add a t-BuOH solution of OsO4 [3.14 g, 0.31 mmol, 0.05 equivalence, 2.5% wt (prepared by dissolving 0.25 g of OsO4 in 9.75 g of t-BuOH)] to a mixture of methyl 2-fluoro-5-methyl-4-vinylbenzoate (1.20 g, 6.15 mmol) in THF (15 mL) and H2O (15 mL). Stir the mixture at 25 °C for 0.5 h, then add NaIO4 (3.96 g, 18.5 mmol, 1.0 mL) and stir the mixture at 25 °C for 16 h. Add the mixture to saturated Na2S2O3 (120 mL) and extract with EA (30 mL × 3). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, concentrated, and the residue was purified by silica gel chromatography to give methyl 2-fluoro-4-formyl-5-methylbenzoate (1.00 g, 82%). LCMS (ESI, m / z): 197.2 [M+H] + . 1 ¹H NMR (400MHz, CDCl₃): 10.28 (d, J = 1.6Hz, 1H), 7.82 (d, J = 6.6Hz, 1H), 7.56 (d, J = 10.4Hz, 1H), 3.96 (s, 3H), 2.66 (s, 3H). Steps 4-8: Compound A44 was prepared from 2-amino-4-difluoromethylpyridine, N-Boc-(S)-2-ethynylmorpholine, and methyl 2-fluoro-4-formyl-5-methylbenzoate using the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 491.3 [M+H] + . 1 H NMR(400MHz,CDCl3)8.33(br d,J=7.3Hz,1H),8.05(d,J=8.0Hz,1H),7.74(s,1H),7.12(d,J=12.1Hz,1H),7.01(d,J=6.9Hz,1H),6.83-6.73(m,1H),6.72-6.55(m,J=55.6Hz, 1H),4.00-3.76(m,3H),3.69(s,3H),3.59-3.47(m,1H),3.45-3.31(m,1 H),3.08(d,J=4.6Hz,3H),3.05-2.99(m,2H),2.95-2.84(m,1H),2.57(br t,J=11.9Hz,1H),2.27(s,3H).
[0693] Example 41: Synthesis of (S)-2-((7-ethyl-2-(2-fluoro-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A45)
[0694]
[0695] Compound A45 was prepared from methyl 3-fluoro-4-carboxymethyl benzoate, N-Boc-(S)-2-ethynylmorpholine, and 2-amino-4-ethylpyridine via the method described in steps 1-5 of Example 1. LCMS (ESI, m / z): 455.2 [M+H] + . 1 H NMR (400MHz, CDCl3)8.23(br d,J=6.8Hz,1H),7.77(t,J=7.6Hz,1H),7.69-7.57(m,2H),7.43(s,1H),6.73(dd,J=1.4,7.1Hz,1H),6.51(br d,J=3.9Hz,1H),4.05-3.75(m,3H),3.69(s,3H),3.67-3.58(m,1H),3.46-3.33(m,1H),3.10-2 .99(m,5H),2.98-2.84(m,1H),2.73(q,J=7.5Hz,2H),2.68-2.53(m,1H),1.31(t,J=7.6Hz,3H).
[0696] Example 42: Synthesis of (2S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-(2,2,2-trifluoro-1-hydroxyethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A46)
[0697] Step 1: 2-Amino-4-hydroxymethylpyridine, N-Boc-(S)-2-ethynylmorpholine, and methyl 3-fluoro-4-carboxymethylbenzoate were reacted as described in Step 1 of Example 1. The reaction was preparatively analyzed by HPLC to give compound 83 (300 mg, 28%). LCMS (ESI, m / z): 500.5 [M+H] + .
[0698] Step 2: A mixture of compound 83 (50 mg, 100 μmol) and MnO2 (87 mg, 1.00 mmol) in CHCl3 (1.0 mL) was stirred at 70 °C for 2 h. The mixture was filtered, and the filter cake was washed with CHCl3 (3 mL × 3). The filtrate was concentrated to give compound 84 (200 mg), which was used directly in the next step without further purification. LCMS (ESI, m / z): 498.2 [M+H] + . 1 HNMR(400MHz, CDCl3)10.02(s,1H),8.44(br d,J=7.2Hz,1H),8.11(s,1H),7.97(dd,J=1.5,8.0Hz,1H),7.91-7.78(m,2H),7.35(dd, J=1.5,7.2Hz,1H),3.97(s,3H),3.88-3.73(m,2H),3.66(dt,J=3.7,6.9Hz,1H),3.37(br t,J=11.2Hz,1H),3.19-3.09(m,2H),2.86(brs,1H),2.60(br t,J=11.1Hz,1H),1.44(s,9H).
[0699] Step 3: K₂CO₃ (0.5 mg, 4 μmol) and TMSCF₃ (171 mg, 1.21 mmol) were added to a DMF (2.0 mL) solution of compound 84 (200 mg, 402 μmol). The mixture was stirred at 25 °C for 3 h. The mixture was diluted with H₂O (20 mL) and extracted with EA (5 mL × 3). The combined extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated. The residue was dissolved in HCl / dioxane (2.0 mL), and the mixture was stirred at 25 °C for 16 h. The mixture was concentrated to give compound 85 (200 mg, 99%) as a yellow solid, which was used directly in the next step without further purification. LCMS (ESI, m / z): 468.2 [M+H] + Steps 4-6: Compound 85 (200 mg, 397 μmol) was converted to A46 (13 mg) using the procedure described in steps 3-5 of Example 1. LCMS (ESI, m / z): 525.2 [M+H] + . 1H NMR(400MHz, CDCl3)8.31(br s,1H),7.69-7.53(m,4H),6.97(br t,J=6.0Hz,1H),6.86-6.75(m,1H),6.50-5.89(m,1H),5.09-4.95(m,1H),4.01-3.75(m,3H),3.61(br s,1H),3.36(dt,J=2.4,11.8Hz,1H),3.02(br d,J=4.0Hz,2H),2.98(br d,J=4.6Hz,3H),2.91(br d,J=1.6Hz,1H),2.73-2.57(m,1H).
[0700] Step 7: Compound A46 was separated into two stereoisomers by SFC (column: Daicel Chiralcel OD (250×30mm, 10 μm)) to obtain two products, A46(peak 1) (4.34 mg) and A46(peak 2) (4.28 mg). Stereochemistry did not determine the elution peak order. A single A46 stereoisomer was isolated, but absolute stereochemistry was not determined.
[0701] A46 (Peak 1)
[0702] LCMS: 525.2 [M+H] + .
[0703] 1H NMR (400MHz, CDCl3)8.31(br d,J=5.4Hz,1H),7.70-7.63(m,1H),7.61-7.54(m,3H),6.97(br d,J=6.9Hz,1H),6.77(br d,J=1.4Hz,1H),5.01(q,J=6.7Hz,1H),4.02-3.76(m,3H),3.69(s,3H),3 .60(dt,J=1.5,2.3Hz,1H),3.42-3.30(m,1H),3.11-2.96(m,5H),2.91(br d,J=2.4Hz,1H),2.73-2.56(m,1H).
[0704] A47 (Peak 2)
[0705] LCMS: 525.2 [M+H] + .
[0706] 1H NMR (400MHz, CDCl3)8.32(br dd,J=1.5,3.8Hz,1H),7.70-7.52(m,4H),6.98(br d,J=7.3Hz,1H),6.78(br d,J=1.0Hz,1H),5.07-4.95(m,1H),4.01-3.74(m,3H),3.69(s,3H),3.62(br d,J=2.9Hz,1H),3.37(dt,J=2.6,11.8Hz,1H),3.09-2.96(m,5H),2.95-2.84(m,1H),2.73-2.56(m,1H).
[0707] Example 43: Synthesis of methyl (2S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-(methylsulfinyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A47) and methyl (S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-(methylsulfinyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A48)
[0708]
[0709] Step 1: A mixture of 4-chloro-2-aminopyridine (3.00 g, 23.3 mmol) and NaSMe (4.91 g, 70 mmol) in EtOH (37 mL) and H₂O (9 mL) was stirred in a sealed tube at 140 °C for 18 h. The mixture was diluted with water (150 mL) and adjusted to pH 3 with HCl (1 M) aqueous solution. The mixture was extracted with DCM (30 mL) and the organic layer was discarded. The aqueous layer was adjusted to pH 8 with saturated NaHCO₃. The mixture was extracted with DCM (50 mL × 3). The organic layer was dried over Na₂SO₄, filtered, and concentrated. The residue was ground with 5:1 PE / EA (20 mL) to give 4-(methylthio)-2-aminopyridine (2.8 g, 85%). LCMS (ESI, m / z): 141.3 [M+H] + . 1 H NMR (400MHz, CDCl3) 7.88 (d, J=5.5Hz, 1H), 6.50 (br d, J=4.5Hz, 1H), 6.29 (s, 1H), 4.43 (br s, 2H), 2.43 (s, 3H).
[0710] Step 2: As described in Step 1 of Example 1, methyl 3-fluoro-4-carboxybenzoate (341 mg, 1.87 mmol), 4-(methylthio)-2-aminopyridine (250 mg, 1.78 mmol), and N-Boc-(S)-2-ethynylmorpholine (396 mg, 1.87 mmol) were reacted in a 12 mL solution of 2-Me-THF to give compound 88 (330 mg, 36%). LCMS (ESI, m / z): 516.1 [M+H] + . 1 HNMR(400MHz, CDCl3)8.21(d,J=7.5Hz,1H),7.94(dd,J=1.5,8.0Hz,1H),7.88-7.78(m,2H),7.30(d,J=1.5Hz,1H),6.69(dd,J=1.8,7.3Hz,1H) ,3.97(s,3H),3.91-3.74(m,3H),3.68-3.57(m,1H),3.45-3.33(m,1H) ,3.13-2.98(m,2H),2.94-2.77(m,1H),2.63-2.53(m,4H),1.44(s,9H).
[0711] Steps 3-6: Compound 92 (160 mg) was prepared from compound 88 using the method described in steps 2-5 of Example 1. LCMS (ESI, m / z): 473.2 [M+H] + . 1 H NMR (400MHz, CDCl3) 8.19 (br d,J=7.7Hz,1H),7.79(t,J=7.7Hz,1H),7.70-7.57(m,2H),7.29(d,J=1.5Hz,1H ),6.69(dd,J=1.8,7.3Hz,1H),6.31-6.24(m,1H),4.02-3.77(m,3H),3.70(s,3 H),3.64(dt,J=4.2,6.8Hz,1H),3.46-3.34(m,1H),3.06(d,J=4.9Hz,4H),2.98 -2.84(m,1H),2.71-2.59(m,1H),2.55(s,3H),2.41-2.33(m,2H),2.25(s,5H).
[0712] Step 7: Add a solution of m-CPBA (61.4 mg, 303 μmol, 85% purity) in DCM (0.5 mL) to a solution of compound 92 (110 mg, 233 μmol) in DCM (3.5 mL) at 0 °C. Then stir the reaction mixture at 20 °C for 1 h. Quench the mixture with saturated NaHCO3 (30 mL) and extract with EA (10 mL × 3). Purify the residue by preparative HPLC and freeze-dry the eluted fraction. Two products were separated: product A47 (60 mg, 53%) and compound A48 (6.1 mg, 5%). Compound A47 was further separated into two diastereomers by preparative SFC to give A47(peak 1) (22.4 mg, 37%) and A47(peak 2) (23.3 mg, 39%). A single diastereomer of A47 was isolated, but its absolute stereochemistry was not determined.
[0713] A47 (Peak 1):
[0714] LCMS(ESI,m / z):489.2[M+H] + .
[0715] 1 H NMR: (400MHz, CDCl3)8.55(br d,J=7.2Hz,1H),7.92(d,J=5.6Hz,1H),7.77(t,J=7.6Hz,1H),7.71-7.60(m,2H),7.15-7.07(m,1H),6.37(br d,J=4.6Hz,1H),4.08-3.77(m,3H),3.73-3.63(m,4H),3.40(br t,J=12.1Hz,1H),3.17-3.08(m,2H),3.06(d,J=4.9Hz,3H),3.00-2.87(m,1H),2.82(s,3H),2.76-2.61(m,1H).
[0716] A47 (Peak 2):
[0717] LCMS(ESI,m / z):489.2[M+H] + .
[0718] 1H NMR: (400MHz, CDCl3)8.61-8.46(m,1H),7.91(s,1H),7.78(t,J=7.6Hz,1H),7.71-7.59(m,2H),7.12(dd,J=1.6,7.3Hz,1H),6.30(br d,J=4.6Hz,1H),4.07-3.76(m,3H),3.71(s,3H),3.69-3.64(m,1H),3.46-3.35(m,1H),3.10(br d,J=8.1Hz,2H),3.07(d,J=4.9Hz,3H),3.00-2.89(m,1H),2.82(s,3H),2.77-2.60(m,1H).
[0719] A48:
[0720] LCMS(ESI, m / z): 505.4 [M+H] + .
[0721] 1 H NMR: (400MHz, CDCl3)8.57(br d,J=6.9Hz,1H),8.29(dd,J=0.8,1.8Hz,1H),7.79(t,J=7.6Hz,1H),7.73-7.60(m,2H),7.29(d,J=1.9Hz,1H),6.26-6.18(m,1H),4.1 0-3.77(m,3H),3.75-3.65(m,4H),3.46-3.34(m,1H),3.19-3.10(m,5H),3.07(d,J=4.9Hz,3H),3.01-2.88(m,1H),2.80-2.58(m,1H).
[0722] Example 44: Synthesis of methyl (S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-(fluoromethyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A49)
[0723] Step 1: 4-Hydroxymethyl-2-aminopyridine (600 mg, 4.83 mmol), N-Boc-(S)-2-ethynylmorpholine (1.07 g, 5.07 mmol), and methyl 3-fluoro-4-carboxymethylbenzoate (924 mg, 5.07 mmol) were reacted as described in General Method 1 to give compound 93 (720 mg, 25%). LCMS (ESI, m / z): 500.3 [M+H] + .
[0724] Step 2: DAST (145 mg, 0.90 mmol, 0.1 mL) was added to a DCM (10 mL) solution of compound 93 (300 mg, 0.60 mmol) at 0 °C, and the mixture was stirred at 0 °C for 2 h. The mixture was poured into ice (20 g) and separated. The aqueous phase was extracted with DCM (10 mL × 2). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated, and the residue was purified by column chromatography to give compound 94 (130 mg, 39%). LCMS (ESI, m / z): 502.1 [M+H] + .
[0725] Steps 3-6: Compound A49 (32 mg) was prepared from compound 94 using the method described in steps 2-5 of Example 1. LCMS (ESI, m / z): 459.4 [M+H] + . 1 H NMR(400MHz, CDCl3)8.36(d,J=6.8Hz,1H),7.74-7.71(m,1H),7.67-7.50(m,3H),6.85-6.83(m,1H),6.66(d,J=4.4Hz,1H),5.49(s, 1H), 5.37 (s, 1H), 4.07-3.73 (m, 3H), 3.72-3.55 (m, 4H), 3.37-3.36 (m, 1H), 3.12-2.99 (m, 5H), 2.92 (d, J = 10.8Hz, 1H), 2.64 (s, 1H).
[0726] Example 45: Synthesis of (S)-2-((2-(2-fluoro-4-(methylcarbamoyl)phenyl)-7-(methyl-d3)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A50)
[0727] Step 1: To a degassed (N2 bubbling) solution of compound A11 (20 mg, 43 μmol) in dioxane (1.0 mL), bis-(pinacolyl)diboron (55 mg, 217 μmol), PCy3 (1 mg, 4 μmol), K2CO3 (18 mg, 130 μmol), and Pd(OAc)2 (2 mg, 9 μmol) were added to N2. The mixture was stirred at 110 °C for 12 h. The mixture was filtered, and the filter cake was washed with MeOH (2.0 mL × 3). The combined filtrates were concentrated. The crude product, compound 98 (20 mg), was used directly in the next step without further purification. LCMS (ESI, m / z): 471.4 [M+H] + .
[0728] Step 2: 2M K3PO4 (85μL) and Pd(dppf)Cl2.CH2Cl2 (4mg) were added to a mixture of compound 98 (20mg) and trideuterated (iodo)methane (85μmol, 5.3µL) in DMF (1.0mL) under N2. The mixture was stirred in N2 at 100°C for 12h. The mixture was diluted with H2O (10mL) and extracted with EA (4.0mL × 3). The combined extracts were washed with brine, dried over Na2SO4, filtered, and concentrated to give crude A50 (20mg) as a dark oil. The product was purified by preparative HPLC to give A50 (1.9mg, 8%). LCMS (ESI, m / z): 444.1 [M+H] + . 1 H NMR (400MHz, CDCl3)8.26-8.14(m,1H),7.82-7.75(m,1H),7.68-7.57(m,2H),7.41(s,1H),6.69(dd,J=1.4,7.2Hz,1H),6.36-6.19(m,1H ),3.96-3.78(m,3H),3.71-3.68(m,3H),3.66-3.59(m,1H),3.47-3.36(m,1H),3.10-3.03(m,5H),3.00-2.85(m,1H),2.71-2.61(m,1H).
[0729] Example 46: Synthesis of (S)-2-((7-cyclopropyl-2-(2-fluoro-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A52)
[0730]
[0731] A solution of compound A11 (20 mg, 40 μmol) in toluene (0.9 mL) and H2O (0.1 mL) was added to a Schlenk tube containing Pd(OAc)2 (0.19 mg, 0.9 μmol), XantPhos (1.00 mg, 1.74 μmol), potassium cyclopropyltrifluoroborate (6.49 mg, 44 μmol), and Cs2CO3 (42.4 mg, 130 μmol). The mixture was stirred in N2 at 120 °C for 16 h. The mixture was filtered, and the filtrate was washed with H2O (5.0 mL) and extracted with EA (2.0 mL × 3). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The residue was purified by rapid silica gel chromatography and further purified by preparative HPLC to give A52 (4.87 mg, 23%). LCMS (ESI, m / z): 467.3 [M+H]+ . 1 H NMR (400MHz, CDCl3)8.48-8.24(m,1H),7.91-7.56(m,4H),7.18-6.80(m,1H),6.76(d,J=7.2Hz,1H),4.12-3.83(m,2H),3.83-3.76(m,1H),3.6 9(s,4H),3.38-3.37(m,1H),3.09-2.99(m,5H),2.96-2.86(m,1H),2.73 -2.61(m,1H),2.08-1.96(m,1H),1.22-1.00(m,2H),0.96-0.72(m,2H).
[0732] Example 47: Synthesis of methyl (2S)-2-((2-(2-fluoro-4-(methylsulfinyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A58) and methyl (S)-2-((2-(2-fluoro-4-(methylsulfinyl)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A61)
[0733]
[0734] Step 1: (4-Bromo-3-fluorophenyl)(methyl)thion (700 mg, 3.17 mmol) was reacted according to the method described in Step 1 of Example 6 to give 2-fluoro-4-(methylthio)benzaldehyde (400 mg, 66%). LCMS (ESI, m / z): 171.2 [M+H] + . 1 H NMR (400MHz, CDCl3)10.24(s,1H),7.76-7.73(m,1H),7.07-7.05(m,1H),6.96-6.93(m,1H),2.52(s,3H).
[0735] Step 2: Following the method described in Step 1 of Example 1, N-Boc-(S)-2-ethynylmorpholine, 4-methyl-2-aminopyridine, and 2-fluoro-4-(methylthio)benzaldehyde were reacted to yield compound 99 (300 mg, 35%). LCMS (ESI, m / z): 430.2 [M+H] + . 1H NMR(400MHz, CDCl3)8.17(d,J=7.2Hz,1H),7.61-7.57(m,1H),7.35(s,1H),7.12-7.10(m,1H),7.045-7.04(m,1H),6.63-6.61(m,1H),4.0 5-3.77(m,3H),3.71-3.57(m,4H),3.39-3.36(m,1H),3.07-2.99(m,2H),2.97-2.84(m,1H),2.63-2.60(m,1H),2.53(s,3H),2.40(s,3H).
[0736] Step 3: At 0°C, add a solution of m-CPBA (37 mg, 0.18 mmol, 85% purity) in DCM (0.5 mL) to a solution of compound 99 (100 mg, 0.23 mmol) in DCM (3.5 mL). Stir the reaction mixture at 20°C for 1 h. Wash the mixture with H2O (5 mL) and extract with DCM (3 mL × 3). Dry the combined organic layers with Na2SO4, filter, and concentrate. Purify the crude product by preparative HPLC to give compounds A58 (15.2 mg) and A61 (6.4 mg).
[0737] A58:
[0738] LCMS(ESI,m / z):446.2[M+H] + .
[0739] 1 H NMR: (400MHz, CDCl3)8.62-8.42(m,1H),8.16-7.99(m,2H),7.80-7.63(m,1H),7.61-7.48(m,1H),7.08(d,J=7.0Hz,1H),4.11-3.76(m,3H ),3.75-3.62(m,4H),3.50-3.32(m,1H),3.08(d,J=7.8Hz,2H),3.01-2.87(m,1H),2.83(d,J=1.8Hz,3H),2.78-2.65(m,1H),2.56(s,3H).
[0740] A61:
[0741] LCMS(ESI,m / z):462.2[M+H] + .
[0742] 1H NMR: (400MHz, CDCl3)8.50(s,1H),8.18-8.15(m,1H),8.08(s,1H),7.96(d,J=8.2Hz,1H),7.86-7.84(m,1H),7.10(d,J=6.8Hz,1H),4.10-3.76(m, 3H),3.72(s,3H),3.69-3.66(m,1H),3.46-3.31(m,1H),3.15(s,3H),3.0 7(d,J=4.4Hz,2H),3.00-2.88(m,1H),2.72(d,J=9.2Hz,1H),2.57(s,3H).
[0743] Example 48: Synthesis of methyl (2S)-2-((2-(2-fluoro-4-(S-methylsulfonylimino)phenyl)-7-methylimidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A59)
[0744]
[0745] MeOH (0.3 mL) was added to a mixture of compound A58 (60 mg, 0.13 mmol), PhI(OAc)2 (125 mg, 0.39 mmol), and ammonium carbamate (40 mg, 0.52 mmol). The mixture was stirred at 30 °C for 0.5 h. The reaction mixture was purified by preparative HPLC to give A59 (31.0 mg). LCMS (ESI, m / z): 461.1 [M+H] + . 1 H NMR(400MHz, CDCl3)8.24(d,J=6.8Hz,1H),8.00-7.94(m,1H),7.93-7.87(m,1H),7.85-7.83(m,1H),7.46(s,1H),6.73(d,J=6.8Hz,1H),4.05-3.76 (m,3H),3.69(s,3H),3.66-3.57(m,1H),3.39-3.38(m,1H),3.17(s,3H), 3.06(d,J=5.6Hz,2H),3.00-2.85(m,1H),2.82-2.59(m,2H),2.44(s,3H).
[0746] Example 49: Synthesis of (S)-2-((7-ethyl-2-(2-fluoro-4-(methylcarbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A63)
[0747]
[0748] Compound A63 was prepared from methyl 3-fluoro-4-carboxymethyl benzoate, N-Boc-(S)-2-ethynylmorpholine, and 2-amino-4-methyl-5-fluoropyridine via the method described in steps 1, 4, and 5 of Example 1. LCMS (ESI, m / z): 459.3 [M+H] + . 1 H NMR(400MHz, CDCl3)8.28(d,J=4.6Hz,1H),7.77-7.73(m,1H),7.67-7.55(m,2H),7.41(d,J=7.0Hz,1H),6.31(d,J=4.3Hz,1H) ,4.02-3.76(m,3H),3.69(s,3H),3.65-3.64(m,1H),3.55-3.34(m,1H),3.09-2.90(m,6H),2.65(d,J=3.2Hz,1H),2.39(s,3H).
[0749] Example 50: Synthesis of (S)-2-((7-chloro-2-(4-(dimethylcarbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A65)
[0750]
[0751] Step 1: As described in Step 1 of Example 1, 4-chloro-2-aminopyridine (1.10 g, 8.56 mmol), N-Moc-(S)-2-ethynylmorpholine (1.52 g, 8.98 mmol) and methyl 3-fluoro-4-carboxymethylbenzoate (1.64 g, 8.98 mmol) were reacted to give compound 104 (800 mg, 18%). LCMS (ESI, m / z): 462.4. 1 H NMR (400MHz, CDCl3)8.31(d,J=7.3Hz,1H),7.95-7.92(m,1H),7.86-7.84(m,1H),7.79-7.78(m,1H),7.63-7.59(m,1H),6.82-6.79(m ,1H),3.96(s,3H),3.86-3.76(m,2H),3.72-3.60(m,5H),3.41-3.39(m,1H),3.11-2.98(m,2H),2.97-2.84(m,1H),2.73-2.58(m,1H).
[0752] Step 2 was performed as described in step 4 of Example 1 to obtain compound 105. LCMS (ESI, m / z): 448.2.1 H NMR(400MHz,d6-DMSO)14.05-12.72(m,1H),8.75(d,J=7.6Hz,1H),7.92-7.89(m,2H),7.88-7.79(m,2H),7.30(d,J=7.2H z,1H),3.87(d,J=12.6Hz,1H),3.80-3.74(m,1H),3.71-3.63(m,2H),3.58(s,4H),3.31-3.10(m,3H),2.95-2.70(m,1H).
[0753] Step 3: Compound A65 was prepared from 105 using the method described in Step 5 of Example 1. LCMS (ESI, m / z): 475.3. 1 H NMR(400MHz, CDCl3)8.33(d,J=7.2Hz,1H),7.73-7.71(m,1H),7.64(s,1H),7.36-7.26(m,2H),6.83-6.81(m,1H),4.0 2-3.77(m,3H),3.70(s,3H),3.65(s,1H),3.39-3.36(m,1H),3.14(s,3H),3.06-2.82(m,6H),2.69(d,J=10.8Hz,1H).
[0754] Example 51: Synthesis of (S)-2-((7-chloro-2-(4-(ethyl(methyl)carbamoyl)-2-fluorophenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A66)
[0755]
[0756] Compound A66 was prepared from compound 105 using the method described in Example 50. LCMS (ESI, m / z): 489.3. 1 H NMR (400MHz, CDCl3)8.31(d,J=7.2Hz,1H),7.73-7.69(m,1H),7.59(d,J=1.6Hz,1H),7.29(d,J=7.8Hz,1H),7.23(s,1H),6.81-6.79(m ,1H),4.12-3.77(m,3H),3.70(s,3H),3.68-3.53(m,2H),3.45-3.29(m,2H),3.15-2.86(m,6H),2.75-2.61(m,1H),1.30-1.13(m,3H).
[0757] Example 52: Synthesis of methyl (S)-2-((7-chloro-2-(2-fluoro-4-(pyrrolidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A67)
[0758]
[0759] Compound A67 was prepared from compound 105 using the method described in Example 50. LCMS (ESI, m / z): 501.2. 1 H NMR (400MHz, CDCl3)8.31(d,J=7.2Hz,1H),7.73-7.71(m,1H),7.60(d,J=1.8Hz,1H),7.45-7.34(m,2H),6.81-6.78(m,1H),4.11-3.76( m,3H),3.70(s,3H),3.69-3.65(m,3H),3.49-3.46(m,2H),3.44-3.35(m,1H),3.12-2.84(m,3H),2.75-2.60(m,1H),2.02-1.90(m,4H).
[0760] Example 53: Synthesis of methyl (S)-2-((7-chloro-2-(2-fluoro-4-((S)-3-hydroxypyrrolidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A68)
[0761]
[0762] Compound A68 was prepared from compound 105 using the method described in Example 50. LCMS (ESI, m / z): 517.3. 1 H NMR (400MHz, CDCl3)8.41-8.17(m,1H),7.73-7.69(m,1H),7.60(s,1H),7.48-7.35(m,2H),6.81(d,J=7.4Hz,1H),4.67-4.43(m,1H),3.99-3 .74(m,5H),3.72-3.60(m,5H),3.54-3.33(m,2H),3.17-2.97(m,2H), 2.96-2.81(m,1H),2.78-2.57(m,1H),2.43(s,1H),2.13-1.99(m,2H).
[0763] Example 54: Synthesis of methyl (S)-2-((7-chloro-2-(2-fluoro-4-((R)-3-hydroxypyrrolidine-1-carbonyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylate (A69)
[0764]
[0765] Compound A69 was prepared from compound 105 using the method described in Example 50. LCMS (ESI, m / z): 517.3. 1 H NMR(400MHz, CDCl3)8.34(d,J=6.4Hz,1H),7.75-7.69(m,1H),7.65(s,1H),7.51 -7.34(m,2H),6.83(d,J=7.2Hz,1H),4.67-4.45(m,1H),3.92-3.75(m,5H),3.71 -3.68(m,3H),3.67-3.58(m,2H),3.57-3.47(m,1H),3.43-3.32(m,1H),3.16-3. 00(m,2H),2.95-2.81(m,2H),2.77-2.60(m,1H),2.16-2.05(m,1H),2.01(s,1H).
[0766] Example 55: Synthesis of (S)-2-((7-chloro-2-(2-fluoro-4-((2-methoxyethyl)carbamoyl)phenyl)imidazo[1,2-a]pyridin-3-yl)methyl)morpholine-4-carboxylic acid methyl ester (A73)
[0767]
[0768] Compound A73 was prepared from compound 105 using the method described in Example 50. LCMS (ESI, m / z): 505.2. 1 H NMR(400MHz, CDCl3)8.30(d,J=7.4Hz,1H),7.78-7.74(m,1H),7.70-7.59(m,3H),6.81-6.79(m,1H),6.61-6.60 (m,1H),4.06-3.76(m,3H),3.72-3.62(m,6H),3.61-3.57(m,2H),3.42(s,4H),3.12-2.85(m,3H),2.65(s,1H).
[0769] Example 56: Synthesis of (S)-4-(3-((4-acetylmorpholin-2-yl)methyl)-7-chloroimidazolo[1,2-a]pyridin-2-yl)-3-fluoro-N-methylbenzamide (A88)
[0770]
[0771] Step 1: As described in Step 1 of Example 1, 4-chloro-2-aminopyridine (2.30 g, 17.9 mmol), N-Boc-(S)-2-ethynylmorpholine (3.97 g, 18.8 mmol) and methyl 3-fluoro-4-carboxymethylbenzoate (3.42 g, 18.8 mmol) were reacted to give compound 100 (2.1 g, 22%). LCMS (ESI, m / z): 504.3 [M+H] + . 1 H NMR (400MHz, CDCl3)8.32(d,J=7.2Hz,1H),7.95-7.93(m,1H),7.86-7.78(m,2H),7.61(d,J=1.8Hz,1H),6.82-6.79(m,1H),3.96(s,4H ), 3.79 (d, J = 9.2Hz, 2H), 3.69-3.59 (m, 1H), 3.38-3.37 (m, 1H), 3.14-2.98 (m, 2H), 2.92-2.76 (m, 1H), 2.58-2.57 (m, 1H), 1.44 (s, 9H).
[0772] Step 2: Deprotect compound 100 according to the method described in Step 2 of Example 1 to obtain compound 101, which is used directly in the next step without purification. LCMS (ESI, m / z): 404.3 [M+H] + .
[0773] Step 3: Add EDCI (3.0 equivalents), HOBt (3.0 equivalents), acetic acid (3.0 equivalents), and DIEA (5.0 equivalents) to a DCM (3 mL) solution of compound 101 (1.00 equivalents). Stir the mixture at 30 °C for 16 h. Concentrate the reaction mixture and purify the residue by rapid silica gel chromatography to obtain compound 102. LCMS (ESI, m / z): 446.2 [M+H] + .
[0774] Steps 4 and 5: Compound A88 was prepared from compound 102 using the methods described in steps 4 and 5 of Example 1. LCMS (ESI, m / z): 445.2 [M+H] + . 1H NMR(400MHz, CDCl3)8.46-8.21(m,1H),7.83-7.54(m,4H),6.83-6.89(m,1H),6.37(s,1H),4.44-4.41(m,1H),3.93-3.80(m ,1H),3.72-3.51(m,2H),3.39-3.38(m,1H),3.24-3.12(m,1H),3.09-2.90(m,5H),2.80-2.37(m,1H),2.05(d,J=7.0Hz,3H).
[0775] Example 57: Synthesis of (S)-4-(7-chloro-3-((4-propionylmorpholin-2-yl)methyl)imidazo[1,2-a]pyridin-2-yl)-3-fluoro-N-methylbenzamide (A89)
[0776]
[0777] Compound A89 was prepared from compound 101 using the method described in Example 56. LCMS (ESI, m / z): 459.3 [M+H] + . 1 H NMR(400MHz, CDCl3)8.42-8.22(m,1H),7.82-7.54(m,4H),6.86-6.76(m,1H),6.58-6.57(m,1H),4.44-4.38(m,1H),3.94-3.78(m,1H) ,3.73-3.53(m,2H),3.46-3.32(m,1H),3.15-3.34(m,1H),3.09-2.88(m,5H),2.76-2.39(m,1H),2.37-2.17(m,2H),1.13-1.09(m,3H).
[0778] Example 58: Synthesis of (S)-4-(7-chloro-3-((4-(2-methoxyacetyl)morpholin-2-yl)methyl)imidazo[1,2-a]pyridin-2-yl)-3-fluoro-N-methylbenzamide (A90)
[0779]
[0780] Compound A90 was prepared from compound 101 using the method described in Example 56. LCMS (ESI, m / z): 475.3 [M+H] + . 1H NMR(400MHz, CDCl3)8.40-8.20(m,1H),7.77-7.73(m,1H),7.69-7.53(m,3H),6.83-6.80(m,1H),6.43(s,1H),4. 39-4.36(m,1H),4.15-3.97(m,2H),3.92-3.60(m,3H),3.46-3.33(m,4H),3.19-2.88(m,6H),2.83-2.41(m,1H).
[0781] Example 59: Determination of P2X3 antagonist
[0782] As shown in Part 1, HEK293 cells were transiently or stably transfected with human ion channel cDNA. Stable transfectants were selected by co-expression with an antibiotic resistance gene integrated into the expression plasmid. Selection pressure was maintained by including the selection antibiotic in the culture medium. HEK293 cells were cultured in Dulbecco Modified Eagle Medium / Nutrient Mixture F-12 (D-MEM / F-12) supplemented with 10% fetal bovine serum, 100 U / mL penicillin G sodium, 100 J / mL streptomycin sulfate, and an appropriate selection antibiotic.
[0783] The effects of each test sample as an antagonist were evaluated. Each test sample was evaluated at eight concentrations (0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, and 3 μM, n=3), with each concentration evaluated quadruplicately. Experiments were performed using the FLIPR calcium-sensitive dye kit (Fluo-8 dye, AAT, Bioquest) according to the manufacturer's instructions.
[0784] - Dye loading: Remove the growth medium and add 20 μL of Mg-free dye containing Fluo-8 at 37°C. ++ HBPS, lasting 30 minutes.
[0785] - Pre-incubation (FLIPR step 1): Under room temperature and in the dark, add 5× (5 μL) of Mg-free... ++ The test sample, solvent, or control solution from the HBPS is added to each well and left for 20 minutes. - Stimulation (FLIPR step 2): After pre-incubation, use in a Mg-free environment. ++ Cells were stimulated with 6×(5μL)αβ-meATP at a final concentration of 3μM prepared in HBPS.
[0786] - Nonspecific calcium influx (FLIPR step 3): Five minutes after the addition of the stimulating solution, nonspecific calcium influx was activated by adding 7×(5μL) ionomycin to a final concentration of 5μM. Fluorescence was recorded continuously during FLIPR steps 2 and 3.
[0787] - Positive control antagonist: PPADS (1mM).
[0788] Data was acquired using the FLIPRControl software included with the FLIPR system (MDS-AT), and analyzed using Microsoft Excel 2003 (Microsoft Corp., Redmond, WA). The IC of the tested compounds was [not specified]. 50 The data is shown in the table below.
[0789]
[0790]
[0791] A: <100nM; B: 100–1000nM; C: >1000nM; NT: Not tested.
[0792] The present invention also relates to the following embodiments:
[0793] 1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof:
[0794]
[0795] Formula (I);
[0796] X is C(R) 2 ) or N;
[0797] Y is C(R) 2 ) or N;
[0798] Z represents a bond, CH2, or O;
[0799] R 1 Selected from hydrogen, deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0800] R 2Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0801] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0802] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0803] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0804] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0805] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0806] R 8 Each is independently selected from C1-C6 alkyl groups;
[0807] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0808] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0809] R 14 It is a C1-C6 alkyl group;
[0810] R 15 It is a C1-C6 alkyl group;
[0811] n is 0, 1, 2, or 3;
[0812] p is 1, 2, or 3; and
[0813] q can be 0, 1, 2, 3 or 4.
[0814] 2. The compound according to embodiment 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is a C1-C6 haloalkyl group.
[0815] 3. The compound according to embodiment 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For -OR 7 .
[0816] 4. The compound according to embodiment 3 or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 It is a C1-C6 alkyl group.
[0817] 5. The compound according to any one of embodiments 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a halogen.
[0818] 6. The compound according to any one of embodiments 1-4, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a C1-C6 alkyl group.
[0819] 7. The compound according to any one of embodiments 1-6, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.
[0820] 8. The compound according to any one of embodiments 1-7, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (Ia):
[0821]
[0822] 9. A compound according to any one of embodiments 1-8, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (Ia'):
[0823]
[0824] 10. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-8, having the structure of formula (Ia):
[0825]
[0826] 11. A compound of formula (II) or a pharmaceutically acceptable salt or solvate thereof:
[0827] X is C(R) 2 ) or N;
[0828] Y is C(R) 2 ) or N;
[0829] Z represents a bond, CH2, or O;
[0830] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0831] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0832] R 3Selected from deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -N(R7)2, -CN, -C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0833] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0834] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0835] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0836] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0837] R 8 Each is independently selected from C1-C6 alkyl groups;
[0838] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0839] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0840] R 14 It is a C1-C6 alkyl group;
[0841] R 15 It is a C1-C6 alkyl group;
[0842] n is 0, 1, 2, or 3;
[0843] p is 1, 2, or 3; and
[0844] q can be 0, 1, 2, 3 or 4.
[0845] 12. The compound or a pharmaceutically acceptable salt or solvate thereof according to embodiment 11, having the structure of formula (IIa):
[0846]
[0847] 13. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 11 or 12, having the structure of formula (IIa'):
[0848]
[0849] 14. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 11 or 12, having the structure of formula (IIa):
[0850]
[0851] 15. A compound of formula (III) or a pharmaceutically acceptable salt or solvate thereof:
[0852] X is C(R) 2 ) or N;
[0853] Y is C(R) 2 ) or N;
[0854] Z is CH2 or O;
[0855] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7-C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0856] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0857] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0858] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0859] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0860] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0861] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0862] R 8 Each is independently selected from C1-C6 alkyl groups;
[0863] R 9 and R 10 Independently selected from C1-C6 alkyl groups; or R 9 and R 10 They combine to form a 5- or 6-membered heterocyclic alkyl ring, which may be optionally substituted with 1, 2, 3 or 4 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy and C1-C6 alkoxy groups;
[0864] R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0865] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0866] R 14 It is a C1-C6 alkyl group;
[0867] R 15 It is a C1-C6 alkyl group;
[0868] n is 0, 1, 2, or 3;
[0869] p is 1, 2, or 3; and
[0870] q can be 0, 1, 2, 3 or 4.
[0871] 16. The compound according to embodiment 15, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (IIIa):
[0872]
[0873] 17. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 15 or 16, having the structure of formula (IIIa'):
[0874]
[0875] 18. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 15 or 16, having the structure of formula (IIIa):
[0876]
[0877] 19. The compound according to any one of embodiments 15-18, wherein R 5 -C(O)N(R) 9 (R) 10 ).
[0878] 20. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 15-19, wherein R 9 and R 10 It is independently selected from C1-C6 alkyl groups.
[0879] 21. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 15-19, wherein R 9 and R 10 They combine to form a 5- or 6-membered heterocyclic alkyl ring, which is optionally substituted with 1, 2, 3 or 4 groups selected from halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy and C1-C6 alkoxy groups.
[0880] 22. The compound according to any one of embodiments 15-18, wherein R 5 -C(O)OR 9 .
[0881] 23. The compound according to any one of embodiments 15-22, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a C1-C6 alkyl group.
[0882] 24. The compound according to any one of embodiments 15-22, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a halogen.
[0883] 25. The compound according to any one of embodiments 11-24, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Each is independently selected from halogens, C1-C6 alkyl groups, and C1-C6 alkoxy groups.
[0884] 26. A compound of formula (IV) or a pharmaceutically acceptable salt or solvate thereof:
[0885] X is C(R) 2 ) or N;
[0886] Y is C(R) 2 ) or N;
[0887] Z is CH2 or O;
[0888] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0889] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0890] R 3 Selected from halogens, -CN, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0891] R 4 Each is independently selected from deuterium, -CN, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 Combined to form bridged heterocyclic alkyl rings; R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0892] R 6 Selected from -C(=O)R 11 ;
[0893] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0894] R 8 Each is independently selected from C1-C6 alkyl groups;
[0895] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0896] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0897] R 14 It is a C1-C6 alkyl group;
[0898] R 15 It is a C1-C6 alkyl group;
[0899] n is 0, 1, 2, or 3;
[0900] p is 1, 2, or 3; and
[0901] q can be 0, 1, 2, 3 or 4.
[0902] 27. The compound according to embodiment 26, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (IVa):
[0903]
[0904] 28. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 26 or 27, having the structure of formula (IVa'):
[0905]
[0906] 29. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 26 or 27, having the structure of formula (IVa):
[0907]
[0908] 30. A compound of formula (V) or a pharmaceutically acceptable salt or solvate thereof:
[0909] X is C(R) 2 ) or N;
[0910] Y is C(R) 2 ) or N;
[0911] Z is CH2 or O;
[0912] R 1 Selected from hydrogen, deuterium, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-CN、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8 -S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0913] R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl;
[0914] R 3 Selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 ynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 -N(R) 7 )2、-C(=O)R 8 -C(=O)OR 7 -C(=O)N(R) 7 )2、-NR 7 C(=O)R 8 -NR 10 S(=O)2R 8-S(=O)2R 8 and -S(=O)2N(R 7 )2;
[0915] R 4 Each is independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy, and C3-C6 cycloalkyl; or two R 4 They combine to form bridged heterocyclic alkyl rings;
[0916] R 5 -C(=O)N(R) 9 (R) 10 -C(=O)OR 9 -S(=O)R 15 -S(=O)2R 15 -S(=O)(=NH)R 15 -C2-C9 heterocyclic alkyl-N(R) 9 (R) 10 ) or -C1-C6 haloalkyl-N(R 9 (R) 10 );
[0917] R 6 Selected from -C(=O)OR 11 -C(=O)R 11 and -C(=O)N(R) 12 (R) 13 );
[0918] R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl, and C1-C6 haloalkyl;
[0919] R 8 Each is independently selected from C1-C6 alkyl groups;
[0920] R 9 R 10 R 12 and R 13 Independently selected from hydrogen, deuterium, and C1-C6 alkyl groups;
[0921] R 11 It is a C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl;
[0922] R 14 It is a C1-C6 alkyl group;
[0923] R 15 It is a C1-C6 alkyl group;
[0924] n is 0, 1, 2, or 3;
[0925] p is 2 or 3; and
[0926] q can be 0, 1, 2, 3 or 4.
[0927] 31. The compound according to embodiment 30, or a pharmaceutically acceptable salt or solvate thereof, having the structure of formula (Va):
[0928]
[0929] 32. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 30 or 31, having the structure of formula (Va'):
[0930]
[0931] 33. The compound or its pharmaceutically acceptable salt or solvate according to embodiment 30 or 31, having the structure of formula (Va):
[0932]
[0933] 34. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-29, wherein Z is 0 and p is 1.
[0934] 35. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-33, wherein Z is 0 and p is 2.
[0935] 36. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-29, wherein Z is CH2 and p is 1.
[0936] 37. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-33, wherein Z is CH2 and p is 1.
[0937] 38. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 26-37, wherein R 3 It is a halogen.
[0938] 39. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 11-38, wherein R 1 It is a C1-C6 alkyl group.
[0939] 40. The compound according to any one of embodiments 11-38, or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is a halogen.
[0940] 41. The compound according to any one of embodiments 1-40, or a pharmaceutically acceptable salt or solvate thereof, wherein X is C(R 2 And Y is N.
[0941] 42. The compound according to any one of embodiments 1-40, or a pharmaceutically acceptable salt or solvate thereof, wherein X is N and Y is C(R) 2 ).
[0942] 43. The compound according to any one of embodiments 1-40, or a pharmaceutically acceptable salt or solvation thereof, wherein X is C(R) 2 And Y is C(R) 2 ).
[0943] 44. The compound according to any one of embodiments 1-43, or a pharmaceutically acceptable salt or solvate thereof, wherein R 2 Each is hydrogen.
[0944] 45. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-44, wherein n is 1.
[0945] 46. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-44, wherein n is 2.
[0946] 47. The compound or a pharmaceutically acceptable salt or solvate thereof according to any one of embodiments 1-44, wherein n is 0.
[0947] 48. The compound according to any one of embodiments 1-47, wherein q is 0.
[0948] 49. The compound according to any one of embodiments 1-14 and 26-48, wherein R 5 -C(O)N(R) 9 (R) 10 ).
[0949] 50. The compound according to embodiment 49 or a pharmaceutically acceptable salt or solvate thereof, wherein R 10 It is hydrogen.
[0950] 51. The compound according to any one of embodiments 1-14 and 26-48, wherein R 5 -C(O)OR 9 .
[0951] 52. The compound according to embodiment 51, wherein R 9 It is a C1-C6 alkyl group.
[0952] 53. The compound according to embodiment 51, wherein R 9 It is hydrogen.
[0953] 54. The compound according to any one of embodiments 1-25 and 30-53, wherein R 6 -C(O)OR 11 .
[0954] 55. The compound according to any one of embodiments 1-25 and 30-53, wherein R 6 -C(O)R 11 .
[0955] 56. The compound according to any one of embodiments 1-55, wherein R 11 It is a C1-C6 alkyl group.
[0956] 57. The compound according to any one of embodiments 1-56, wherein R 11 It is -CH3.
[0957] 58. A compound selected from:
[0958]
[0959]
[0960]
[0961]
[0962]
[0963]
[0964] Or its pharmaceutically acceptable salts or solvates.
[0965] 59. A pharmaceutical composition comprising a compound or a pharmaceutically acceptable salt or solvate thereof as described in any one of embodiments 1-58, and at least one inactive ingredient selected from pharmaceutically acceptable carriers, diluents and excipients.
[0966] 60. The pharmaceutical composition according to embodiment 59, wherein the pharmaceutical composition is formulated for administration to mammals by intravenous, subcutaneous, oral, inhalation, nasal, topical, or ocular administration.
[0967] 61. The pharmaceutical composition according to embodiment 59, wherein the pharmaceutical composition is in the form of tablets, pills, capsules, liquids, suspensions, gels, dispersions, solutions, emulsions, ointments, or lotions.
[0968] 62. A method of treating a condition associated with P2X3 activity in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of the compound according to any one of embodiments 1-58.
[0969] 63. A method of treating pain in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound according to any one of embodiments 1-58.
[0970] 64. A method of treating a urinary tract condition in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound according to any one of embodiments 1-58.
[0971] 65. The method according to embodiment 64, wherein the urinary tract condition includes neurogenic overactive bladder, non-neurogenic overactive bladder, interstitial cystitis, prostatitis, prostatodynia, and benign prostatic hyperplasia.
[0972] 66. A method for reducing or preventing uncontrolled urine loss in a mammal in need, comprising administering to the mammal in need a therapeutically effective amount of a compound according to any one of embodiments 1-58.
[0973] 67. The method according to embodiment 66, wherein the uncontrolled urine loss is associated with urge incontinence, cough incontinence, stress incontinence, overflow incontinence, functional incontinence, neurogenic incontinence, postprostatectomy incontinence, urinary urgency, nocturia, and enuresis.
[0974] 68. A method of treating cough in a mammal in need, comprising administering to said mammal a therapeutically effective amount of the compound according to any one of embodiments 1-58.
[0975] 69. The method according to embodiment 68, wherein the cough is an acute cough or a chronic cough.
[0976] 70. The method according to embodiment 68 or 69, wherein the cough is associated with a disease, symptom, or condition selected from: chronic obstructive pulmonary disease, asthma, tuberculosis, bronchitis, bronchiectasis, purulent lung disease, respiratory malignancy, allergic reaction, cystic fibrosis, pulmonary fibrosis, respiratory inflammation, emphysema, pneumonia, lung cancer, lung tumor formation, sore throat, common cold, influenza, respiratory infection, bronchoconstriction, sarcoidosis, viral or bacterial infection of the upper respiratory tract, angiotensin-converting enzyme (ACE) inhibitor therapy, smoker's cough, chronic nonproductive cough, neoplastic cough, cough due to gastroesophageal reflux and inhalation of irritants, smoke, haze, dust, or air pollutants.
[0977] 71. A method of treating pruritus in a mammal in need, comprising administering to said mammal a therapeutically effective amount of a compound according to any one of embodiments 1-58.
[0978] 72. The method according to embodiment 71, wherein the pruritus is associated with an inflammatory skin disease, an infectious skin disease, an autoimmune skin disease, or a pregnancy-related skin disease.
[0979] 73. The method according to embodiment 71, wherein the pruritus is associated with an inflammatory skin disease selected from the following: atopic dermatitis, allergic, irritant contact dermatitis, xerosis, nummular and dyshidrosis dermatitis, lichen planus, lichen sclerosus, polymorphic light psoriasis, Grover's disease, mucinous deposits, mastocytosis, and urticaria.
[0980] 74. The method according to embodiment 71, wherein the pruritus is associated with an infectious skin disease selected from the following: fungal infections, bacterial and viral infections, scabies, lice, insect bites, and folliculitis.
[0981] 75. The method according to embodiment 71, wherein the pruritus is associated with an autoimmune skin disease selected from the following: Duhring's disease, bullous pemphigoid; hereditary skin diseases, Darier's disease, and Hailey-Hailey's disease.
[0982] 76. The method according to embodiment 71, wherein the pruritus is associated with a pregnancy-related skin condition selected from the following: polymorphic eruption of pregnancy (PEP), atopic dermatitis of pregnancy, pemphigoid of pregnancy, tumor formation, and cutaneous T-cell lymphoma.
[0983] 77. The method according to embodiment 71, wherein the pruritus is associated with nodular prurigo.
[0984] 78. The method according to embodiment 71, wherein the pruritus is related to kidney disease or a treatment procedure for kidney disease.
[0985] 79. The method according to embodiment 78, wherein the pruritus is associated with chronic kidney disease.
[0986] 80. The method according to embodiment 78, wherein the pruritus is related to a treatment procedure for kidney disease, wherein the treatment procedure for kidney disease is selected from hemodialysis and peritoneal dialysis.
[0987] 81. The method according to embodiment 71, wherein the pruritus is related to a medical procedure or treatment.
[0988] 82. The method according to embodiment 81, wherein the pruritus is associated with drug treatment using a drug selected from opioids, antimalarial drugs, anticancer therapies, and epidermal growth factor receptor inhibitors.
[0989] 83. A method for treating endometriosis, endometriosis-related pain, and endometriosis-related symptoms in a mammal in need, comprising administering to said mammal a therapeutically effective amount of a compound according to any one of embodiments 1-58.
[0990] 84. The method according to embodiment 83 is used to treat endometriosis in mammals in need.
[0991] 85. The method according to embodiment 83, for treating endometriosis-related pain in mammals in need.
[0992] 86. The method according to embodiment 83 is used to treat endometriosis-related symptoms in mammals in need.
[0993] 87. The method according to embodiment 86, wherein the endometriosis-related symptoms are selected from dysmenorrhea, dyspareunia, dysuria, and dyscontinence.
[0994] 88. The method according to any one of e...
Claims
1. A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof: X is C(R 2 ) or N; Y is C(R 2 ) or N; Z is a bond, CH2 or O; R 1 is selected from hydrogen, deuterium, C3-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 、-N(R 7 )2, -C(=O)R 8 、-C(=O)OR 7 、-C(=O)N(R 7 )2.-NR 7 C(=O)R 8 、-NR 10 S(=O)2R 8 、-S(=O)2R 8 and -S(=O)2N(R 7 )2; R 2 Each is independently selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl; R 3 is selected from hydrogen, deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C3-C6 cycloalkyl, -OR 7 、-N(R 7 )2, -C(=O)R 8 、-C(=O)OR 7 、-C(=O)N(R 7 )2.-NR 7 C(=O)R 8 、-NR 10 S(=O)2R 8 、-S(=O)2R 8 and -S(=O)2N(R 7 )2; R 4 are each independently selected from deuterium, halogen, -CN, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C1-C6 haloalkyl, C1-C6 alkoxy and C3-C6 cycloalkyl; or two R 4 Combined to form a bridged heterocycloalkyl ring; R5 -C(=O)N(R 9 )(R 10 )、-C(=O)OR 9 、-S(=O)R 15 、-S(=O)2R 15 , -S(=O)(=NH)R 15 、-C2-C9 heterocycloalkyl-N(R 9 )(R 10 ) or -C1-C6 haloalkyl -N(R 9 )(R 10 ); R 6 Selected from -C(=O)OR 11 、-C(=O)R 11 and -C(=O)N(R 12 )(R 13 ); R 7 Each is independently selected from hydrogen, deuterium, C1-C6 alkyl and C1-C6 haloalkyl; R 8 Each independently selected from C1-C6 alkyl; R 9 , R 10 , R 12 and R 13 independently selected from hydrogen, deuterium and C1-C6 alkyl; R 11 is C1-C6 alkyl or -C1-C6 alkyl-O-C1-C6 alkyl; R 14 is a C1-C6 alkyl group; R 15 is a C1-C6 alkyl group; n is 0, 1, 2 or 3; p is 1, 2 or 3; and q is 0, 1, 2, 3 or 4.
2. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 It is a C1-C6 haloalkyl group.
3. The compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 For-OR 7 .
4. The compound according to claim 3 or a pharmaceutically acceptable salt or solvate thereof, wherein R 7 It is a C1-C6 alkyl group.
5. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a halogen.
6. The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 It is a C1-C6 alkyl group.
7. A compound according to any one of claims 1 to 6 or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Each is independently selected from halogen, C1-C6 alkyl and C1-C6 alkoxy.
8. The compound according to any one of claims 1 to 7 or a pharmaceutically acceptable salt or solvate thereof, which has the structure of formula (Ia):
9. The compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof, which has the structure of formula (Ia'):
10. The compound according to any one of claims 1 to 8 or a pharmaceutically acceptable salt or solvate thereof, which has a structure of formula (Ia"):
Citation Information
Patent Citations
Imidazopyridine compounds and uses thereof
US9598409B2
